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TARGETED COMPUTATIONAL ANALYSIS OF THE C3HEB/FEJ MOUSE MODEL FOR DRUG 
EFFICACY TESTING 
 
 Efforts to develop effective and safe drugs for the treatment of tuberculosis (TB) require 
preclinical evaluation in animal models. Alongside efficacy testing of novel therapies, effects on 
pulmonary pathology and disease progression are monitored by using histopathology images 
from these infected animals. To compare the severity of disease across treatment cohorts, 
pathologists have historically assigned a semi-quantitative histopathology score that may be 
subjective in terms of their training, experience, and personal bias. Manual histopathology, 
therefore, has limitations regarding reproducibility between studies and pathologists, potentially 
masking successful treatments. This report describes a pathologist-assistive software tool that 
reduces these user limitations while providing a rapid, quantitative scoring system for digital 
histopathology image analysis. The software, called ‘Lesion Image Recognition and Analysis’ 
(LIRA), employs convolutional neural networks to classify seven different pathology features, 
including three different lesion types from pulmonary tissues of the C3HeB/FeJ tuberculosis 
mouse model. LIRA was developed to improve the efficiency of histopathology analysis for mouse 
tuberculosis infection models. The model approach also has broader applications to other 
diseases and tissues. This also includes animals that are undergoing anti-mycobacterial 
treatment and host immune system modulation. A complimentary software package called 
‘Mycobacterial Image Analysis’ (MIA) had also been developed that characterizes the varying 
bacilli characteristics such as density, aggregate/planktonic bacilli size, fluorescent intensity, and 
total counts. This further groups the bacilli characteristic data depending on the seven different 
classifications that are selected by the user. Using this approach allows for an even more targeted 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 – Background 
  Tuberculosis is the leading cause of death by an infectious organism, with an estimated 
1.3 million deaths in 2017 alone [1]. The World Health Organization (WHO) estimates that 23% 
of the world’s population has latent TB, and 10 million new cases of tuberculosis occurred in 2017 
[1]. The burden of new TB infections and TB-related deaths disproportionally affect individuals in 
low-income countries, reflecting the strong connection between this devastating disease and 
conditions associated with poverty (i.e., poor health care, inadequate nutrition, overcrowded living 
conditions) [2]. The current UN Sustainable Development Goals (SDGs) includes a 90% reduction 
in the absolute number of TB deaths and an 80% reduction in new cases by 2030 compared with 
2015 levels.  Progression towards this goal has been made with a 2% annual decrease of 
incidence but falls short of the 4-5% that is needed per year to reach the 2030 milestone [1], [3], 
[4]. To attain the TB SDGs, significant progress needs to be made in multiple areas including: 1) 
the development of new, more effective drug therapies that can shorten treatment duration, 2) 
improved establishment of more predictive animal models that can guide new regimen 
development, 3) more robust and predictive diagnostics and biomarkers that can help guide 
clinical trials and individualized patient therapy, and 4) more protective vaccines.  
  First-line therapy for uncomplicated TB is lengthy, consisting of two months of isoniazid 
(INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA) and an additional 4 to 7 
months of INH and RIF [5]. The first-line regimen is effective, with a success rate exceeding 95% 
[6].  However, poor treatment compliance, resistance to key first-line drugs, and associated co-
morbidities - such as diabetes, human immunodeficiency virus (HIV) infection, alcoholism, 
smoking, cancer, etc – can have a dramatic impact on treatment success and/or lead to 
development and expansion of drug resistance [7], [8]. An additional issue is the increased 
incidence of resistance to first-line TB therapies.  Specifically, resistance to isoniazid and 
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rifampicin is occurring in about 4.1% of the newly infected individuals and in 19% of patients who 
have been previously treated for the disease [9]. Second-line therapy for MDR-TB patients 
involves longer treatment durations appreciably and is associated with increased risk of 
treatment-associated adverse events (i.e., side effects), and significantly higher treatment cost.  
Current second-line therapies may include combinations of newer FDA-approved drugs such as 
bedaquiline (BDQ), nitroimidazoles, including pretomanid and delamanid, or older drugs including 
oxazolidinones such as linezolid, fluoroquinolones, ethionamide, or injectable aminoglycosides 
such as kanamycin, amikacin, or capreomycin.  
Further complicating the challenge of successful treatment of drug-resistant TB is the 
recent emergence of extensively drug-resistant TB (XDR TB) - which is resistant to INH, RIF, any 
fluoroquinolone and at least one injectable second-line drug  and totally drug-resistant TB - which 
shows an even wider array of drug resistance phenotypes. The rise of antibiotic resistance 
underscores the urgent need for the development of new and more effective TB drug regimens, 
which has been the strategic goal for all current TB drug development efforts. Progress towards 
this goal has been made with the approval of three new FDA approved drugs for the treatment of 
TB [10]. These include bedaquiline (brand name Sirturo), a diarylquinoline antibiotic that blocks 
the ability of Mtb to make adenosine 5’-triphosphate and two nitroimidazoles, pretomanid and 
delamanid, both prodrugs, which are thought to exert bactericidal effect by inhibiting bacterial cell 
wall mycolic acid biosynthesis, among other possible targets [11]. All three drugs were approved 
for the treatment of MDR/XDR TB [5], [12]. These recent successes reflect the concerted efforts 
of key stakeholders and funders to entice pharmaceutical companies and their research partners 
back to TB infectious disease research and development. However, the current scheme for TB 
drug development continues to be hampered by a lack of essential tools to predict treatment 
outcomes or identify more effective drug candidates and combinatory drug regimens.   
The causative agent of TB is the bacillus bacterium Mycobacterium tuberculosis (Mtb). 
Typically associated with various disease states of the lungs, Mtb may also spread to other parts 
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of the body, leading to a host of TB-related disease complications, which is the subject of a recent 
review [13] and will not be discussed in detail here. The pathogenesis of pulmonary TB disease 
has been studied for decades, and the key steps and processes are now well described (see 
section 1.2, below; [14], [15]). One distinct feature of human TB patients with active pulmonary 
disease is the appearance of a variety of different pulmonary lesion types (TB-associated 
pathology), whose appearance can have a dramatic impact on treatment effectiveness, disease 
outcome, and the development and expansion of drug-resistance. Georges Canetti first reported 
on the different pathologic states in human TB patients that ultimately succumbed to disease [16]. 
From these early studies to more recent work using modern tools and methodologies, it is now 
abundantly clear, although the exact details are often disputed, that the presence of diverse lung 
pathology has a profound effect on bacterial phenotype [17]–[19]. The key microenvironmental 
differences cited include varying levels of oxygen, or pH, shifts in nutrient availability and carbon 
sources, impact or lack host immune system responses, and altered bacterial location (i.e., 
intracellular versus extracellular in necrotic caseum). From a drug discovery perspective, 
increased knowledge regarding these varying environmental factors has proven valuable in 
evaluating potential TB therapeutics under similar in vitro/ex vivo conditions.  However, 
conventional in vitro assays such as minimum inhibitory concentration (MIC) assay and minimum 
bactericidal concentration (MBC) assay, which is most commonly used in drug discovery of new 
chemical entities [20], fail to recapitulate the pathological and environmental complexity found 
within an infected host or model host in vivo. Additionally, even when new therapeutics are 
discovered, drug efficacy and drug-partitioning are often seen to vary due to lesion-specific 
environmental heterogeneity found in humans and more advanced TB animal efficacy models 
presenting with complex-TB-associated lung pathologies [21]. For example, BDQ distributes 
slowly, and to a lesser extent, into caseum of fibrotic, necrotic granulomas found in TB-infected 
C3HeB/FeJ mice compared to non-encapsulated lymphocyte dominated cellular lesions observed 
in TB-infected BALB/c mice  [22]. Pyrazinamide, in contrast, readily distributes into both necrotic 
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and non-necrotic lesions in mice, but its activity against bacilli is markedly reduced, as a result of 
near-neutral pH of the caseum microenvironment [22], [23].  
Animal models are a fundamental part of both vaccine development, testing novel drug 
therapies, and basic disease research. Common animal models employed in TB research include 
non-human primates, Guinea pigs, mice, and rabbits [24]. Although no one model recapitulates 
all aspects of the human TB disease spectrum [18], all such models aim to recapitulate certain 
aspects of the disease in humans. The most advanced animal models seek to replicate, as much 
as possible, the human disease state includes the pathophysiological lesion conditions described 
in humans with active or latent TB lung disease.  
Although animal models may better represent human situation relative to common in vitro 
models, not all animal models present with the entire range of pathology features and disease 
states observed in human TB patients. The inability to recapitulate these important aspects can 
potentially limit the predictive nature of some animal models and, thus, limit the extrapolation of 
data from in vivo animal models to the human situation. Therefore, the choice of the animal model 
employed during the drug discovery process is key, as is understanding potential limitations of 
the output from the use of these models. Additionally, conducting such experiments and analysis 
of the resultant data can be time-consuming and require highly specialized training and tools. As 
an example, a single histopathological image analysis conducted by our laboratory of 132 
samples, or about 660 individual lung lobes, took nearly four weeks to reduce to a quantifiable 
data set by a dedicated technician (not shown).  Such extensive endeavors lead to user fatigue 
and is subject to variability in data analysis and interpretation when extended over multiple days, 
laboratories, or individual researchers. Therefore, one approach to accelerate and improve TB 
drug development is to employ more predictive animal models that better mimic human disease, 
and concomitantly, to develop and employ faster, more robust methods to analyze and correlate 
resultant data produced in preclinical animal efficacy trials.  
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  Image analysis and artificial intelligence (AI) have seen tremendous research growth 
during the last several years. The capabilities of AI in digital medical image analysis hold the 
potential to not only improve the speed by which large, complex datasets can be analyzed, but 
lead to improved accuracy and can facilitate wholly new analyses that were not possible using 
conventional methods. For example, AI was found to match or outperform qualified health care 
professionals in visually diagnosing human breast cancer and certain skin disease states based 
upon digital pathology images [25], [26]. AI strengths include a reduced level of bias, increased 
reproducibility, faster analysis time, and the ability to collect quantifiable data. Conversely, the 
limiting factor of AI in biological research is the small representative data sets employed for initial 
AI training, and an inability to correctly classify uncommon events that were not present in the 
original training set [27], [28]. A proficient and accurate pathology classification pipeline will not 
rely entirely on either traditional methodology or AI alone, but integrate the two approaches to 
reduce the limitations of either approach while retaining their strengths.  
 
1.2- Human Tuberculosis Disease And Diagnosis 
TB infection begins after a susceptible individual inhales aerosolized droplets (5-10 
microns) of Mtb which travel to the alveolar space within the lung. If the host immune system fails 
to eradicate the pathogen, the disease progresses into primary tuberculosis. During this phase, 
distribution of nearly 40% of pulmonary bacilli in either alveolar macrophages or interstitial 
macrophages occurs, with the majority of replication occurring in alveolar macrophages [29], [30]. 
Upon becoming infected, macrophages produce chemokines and cytokines to attract other 
phagocytic cells such as additional alveolar macrophages, monocytes, and neutrophils. If disease 
progression continues, cells will form a caseating granuloma due to lack of oxygen and blood flow 
into the expanding lesion, which is composed of central caseous necrosis surrounded by 
epithelioid macrophages and lymphocytes [31]. If the host is still unable to control the infection, 
enlargement of the tubercle is proceeded by the dissemination of Mtb into the lymph nodes. The 
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expansion of the pulmonary tubercle and the involvement of the lymph node followed by healing 
is called a Gohn’s complex [32]. The Gohn’s complex includes calcified granulomas in the 
pulmonary tissue and hilar lymph nodes [14]. The bacilli continue to proliferate uninterrupted until 
an effective T-cell mediated immune response develops, which typically happens 2 to 6 weeks 
post-infection.  
The period after the initial infection, in which the host is in a state of a persistent immune 
response to stimulation by the bacilli without overt signs of disease, is called a latent TB infection 
(LTBI). Individuals with LTBI are not infectious and are sputum negative [33]. About five to ten 
percent of LTBI individuals with no underlying medical conditions will experience a reactivation of 
the disease in their lifetime [34]. While a small population of reactivation cases has been observed 
where it took decades, recent studies support the idea that median reactivation time is anywhere 
from a few months to two years [35]. 
 The poles of TB are latenet and active TB, however a dynamic process occurs between 
the latent and active stages of the diseases.  Post-primary tuberculosis, which is the period that 
occurs after a latent infection, is normally restricted to the upper lobes of the lungs with no lymph 
node or other organ involvement. 90% of individuals with reactivated tuberculosis will recover 
without therapeutic intervention [14], [15]. In individuals that proceed to active TB, the disease 
may develop a heterogeneity of different lesion types of varying degrees of pathological severity. 
Post-primary TB pulmonary lesions are more representative of caseous pneumonia in comparison 
to the host tubercle response initially seen in primary tuberculosis. The lipid pneumonia stage 
lesions initially form with the accumulation of foamy macrophages in the alveoli with little edema 
and no leukocytes or fibrin present [15], [36].  A distinguishing feature is the obstruction of bronchi 
by infected cells and debris that shows up as a tree-in-bud structure in radiological imaging [37], 
[38]. Mtb organisms are found extensively in the alveolar macrophages [39], and resolution of the 
disease, or healing, happens in 95% of individuals [14], [40]. Lesions that fail to heal will undergo 
necrosis by fibrin losing its fibrillary structure resulting in the consolidation of the entire alveoli 
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structure and restricting cellular flow. These lesions are termed caseous pneumonia and are 
homogenous in their presentation [41]. Regions of caseous pneumonia will eventually soften, 
followed by fragmentation and expulsion of the fragmented lung via coughing. These areas of 
dislodged tissue form a cavity that is followed by massive amounts of bleeding [42]. Eventually, a 
thin wall of fibrosis and necrotic material forms at the cavity site. Resolution of untreated disease 
at the cavitation phase is infrequent, unlike what is seen previously in the lipid and caseous 
pneumonia phase.  During and after the formation of the cavity, bacilli are present in small 
numbers, and it is only after the maturation of the cavity that the numbers of bacteria substantially 
increase.      
 TB diagnosis based on sputum culturing of bacteria and microscopy was originally 
developed by Robert Koch over 130 years ago and is still the existing method of diagnosing TB. 
Sputum culturing is considered the gold standard for the diagnosis of active TB disease but is 
dependent on the skill of the technician. Sputum culture exhibits a high specificity (98%), but has 
poor sensitivity (45-80%), and takes on average 2 to 8 weeks to provide definitive diagnostic 
results [43]. In response to these limitations, imaging techniques such as plain chest radiography 
and  serial positron emission tomography (PET) combined with computed tomography (CT) 
imaging is used in more affluent areas where cost is not as much of a limitation. On radiographs, 
patients with primary TB Ghon complex, adenopathy, and pleural effusion are visible. In patients 
with reactivated TB, focal patchy opacities, cavitation, fibrosis, nodal calcification, and flecks of 
caseous material can be visualized [43]. In patients with severe immune deficiencies, such as 
patients with HIV, this method of diagnosis is not reliable due to the retardation of lesion 
development [44]. PET/CT imaging provides a more holistic approach by including anatomic 
information of the disease. Active TB readily uptakes 2-[18F]fluoro-2-deoxyglucose (18F-FDG) 
PET/CT (F-FDG PET/CT), which is used to detect active granulomas, and monitor the dynamics 
of activity and the extent of the lesions. Because this technique is not TB specific, it is prone to 
false positives. Besides, PET/CT image analysis does not identify closed ‘cold’ lesions, which can 
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contain viable bacteria. Visualization of lesion dynamics with F-FDG PET/CT has shown that 
treatment affects different lesion types disproportionately [45]. Overall, lung involvement stays 
relatively stable, but individual lesions experience dramatic variations in size and FDG avidity 
during and after effective therapy [46]. F-FDG PET/CT, therefore, represents a studied as an 
alternative approach to assessing treatment efficacy [45].  
 In summary, TB is a dynamic disease that presents with multiple different lesion types. 
Disease progression is rarely static, and heterogeneity in pathology is common, often manifesting 
as multiple different lesion types within a given infected individual. Each lesion presents a unique 
microenvironment in which Mtb must survive and often propagates. Newer methodologies seek 
to understand better how and when these disease manifestations occur and their dynamics with 
treatment over time.  
 
1.3- Animal Models Of Tuberculosis 
Robert Koch initially observed that there was a spectrum of tuberculosis disease that can 
occur both in humans and in experimentally infected animals [47]. Such historical observations 
led to the wider practice of using various experimentally infected animals to study TB disease, 
pathogenesis, and the advent of antimicrobial therapy, drug efficacy, and therapeutic safety. 
While no animal model can perfectly replicate a human TB infection, researchers have capitalized 
on key models that can recapitulate specific aspects of human TB disease. Frequently employed 
animal models for TB research have included non-human primates, marmosets, rabbits, Guinea 
pigs, and mice [18], [24], [48].  These models have been employed to explore specific aspects of 
TB infection and disease progression, including immunity to disease, vaccine efficacy trials, 
bacterial pathogenesis, and drug efficacy. There are many challenges in working with animal 
models.  These include the need for specialized ABLS-3 facilities and approval of key oversight 
committees and agencies (e.g., Institutional Animal Care and Use Committee, Office of 
Laboratory Animal Welfare, etc.). Additionally, because of the complex interactions between the 
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host and pathogen, care should be taken to optimize the experiment to gather relevant, clear, and 
translatable data and to treat the animals as humanely as possible. While many animals respond 
to TB infection similarly to humans from physiological, pathological, and therapeutic perspectives, 
there are also significant species‐by‐species differences. Overall, TB animal models have proven 
invaluable in aiding our understanding of TB biology, pathogenesis and immunology [24], [48]. 
Additionally, animal models, especially the laboratory mouse, have proven essential for the 
advancement of TB therapeutic approaches and the development of new drug regimens.  In the 
following sections, I will briefly describe the most commonly used animal models in TB research 
with an emphasis on the C3HeB/FeJ murine animal model, which is the focus of this dissertation.  
 
1.3.1 - Non-Human Primate 
The non-human primate model (NHP) for TB develops a spectrum of pulmonary lesion 
pathology that appears to be the closest disease representation of human disease. Cynomolgus 
macaques (CM) with a low infectious dose develop a heterogeneity of lesions comparable to 
human disease. In particular, the model can develop both active and latent TB, which is of 
particular importance since there is no other suitable in vivo model of LTBI [49]. Each granuloma 
develops from a single bacterium [50] and can be detected 2 to 4 weeks post-infection in both 
pulmonary and lymph node tissue [51], [52]. Initially, the animals develop a smaller and denser 
cellular granuloma that is typical of human tuberculosis. Additionally, they may develop caseating 
granulomas that will eventually see a reduction of epithelioid macrophages, giant cells, and 
lymphocytes, followed by subsequent mineralization [18]. As seen in humans, PET-CT scan 
analysis revealed that these lesions are dynamic during infection. While CM appears to most 
closely model human disease with their development and heterogeneity of lesion types, it is also 
a weakness of the model. NHP models are expensive to purchase, house, and due to the diversity 
of disease presentations, large numbers of animals are needed to obtain relevant statistical 
information, especially for endpoint necropsy studies. The need for large numbers can be 
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somewhat mitigated by PET-CT technologies, which enables the tracking of lesions of the same 
animal across multiple time points, thus reducing the number of animals needed per study.  
 
1.3.2 - Marmoset 
Marmosets are a commonly used NHP which recapitulates many common aspects of 
human TB disease. After a low-dose aerosol infection, the disease progresses proportionally to 
the virulence of the strain of Mtb used. Common pathological features develop 6 to 8 weeks post-
infection and are composed of cellular, caseating necrotic lesions and Mtb strain-dependent 
cavitation [53]. A pathological difference between marmosets and CM is that marmosets fail to 
develop the calcified lesions seen in human disease. They do offer an advantage over CMs owing 
to their small size, reducing the cost of housing, and the capability of increasing the number of 
animals that can be used in a single study. Another benefit is that marmosets often develop as 
identical twins, which are ideal controls in intervention studies. There is also a wide availability of 
immunological reagents that can be used in contrast to other animal models such as rabbits or 
Guinea pigs.  
 
1.3.3 - Rabbit  
The New Zealand white rabbit TB animal model develops an Mtb strain-dependent 
heterogeneity of pathology presentations reminiscent of the diversity of the human disease. 
Developed pathology includes cellular, caseating, and cavitating lesions, but rabbits do not 
develop the calcified lesion normally associated with healing in human TB patients. Rabbits 
infected with H37Rv generally clear the infection, while animals infected with Erdman develop a 
chronic infection with 53% of the infected animals developing caseous necrotic granulomas [31]. 
When infected with a highly virulent strain of Mtb, such as the clinical Bejing HN878, animals will 
develop granulomas reminiscent of human disease and eventual cavity formation [54]. Mtb 
located in cavitary lesions are associated with phenotypic antibiotic resistance [55]. Resistance in 
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cavitary disease can be somewhat mitigated by treatment with anti-vascular endothelial growth 
factors, which have shown to reduce hypoxia and increase granuloma vasculature with a 
corresponding increase in treatment efficacy [38]. Rabbits are considered excellent models for 
modeling drug penetration, distribution, and cellular accumulation in TB granulomas. Rabbits are 
not more widely used for other aspects of TB biology, vaccine studies, or drug discovery owing to 
the lack of immunological reagents, increase biocontainment requirements due to Mtb shedding 
in their urine, and their overall larger size relative to mice.  
 
1.3.4 - Guinea Pigs 
Guinea pigs are highly susceptible to Mtb infection, and similar to humans exhibit 
pulmonary caseous necrosis, lymphadenopathy, and calcification of resolving lung lesions but 
only infrequently develop lesion cavitation [56]. They are considered the gold standard for vaccine 
efficacy because of the presence of CD1b molecules that responds to glycolipid antigens, also 
present in humans but not in mice [57]. Also, Guinea pigs can be used to replicate latent/dormant 
infection commonly seen in humans or serve as a secondary animal model to measure the 
sterilizing activity of anti-tuberculosis regimens developed using other animal models [58]. Guinea 
pig use is limited due to a requirement to provide daily vitamin C supplements, a limited repertoire 
of immunological reagents, and a higher overall cost relative to that of mice. 
  
1.3.5 - Mouse 
Mice have many practical advantages in comparison to other models such as less space 
requirements, ease of handling, low costs, a wide selection of immunological tools, and diverse 
availability of inbred, outbred, and transgenic strains [59]. C57BL/6 and BALB/c mice have similar 
immune responses as humans after exposure to Mtb but lack the development of lesion 
heterogeneity. They will develop a cellular lesion containing primarily epithelioid macrophages, 
large numbers of lymphocytes, and small amounts of neutrophils. It is uncommon for lesions to 
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develop necrosis, calcification, or cavitation which is considered a limitation in using traditional 
mouse models for TB research. Bacilli reside primarily intracellularly, which is in contrast to other 
animal models and humans that exhibit necrosis where a significant proportion of bacilli reside 
extracellularly.  
While traditional mouse strains do not develop necrosis, several other mouse strains 
present with caseous necrotic pulmonary lesions upon infection with Mtb. These include the 
following mouse strains: CBA/J, I/StSnEgYCit, IL-13tg, and C3HeB/FeJ. The CBA/J mouse strain 
is susceptible to an Mtb infection and has no known immunodeficiency [60]. At approximately 4 
to 6 weeks post aerosol TB infection with Mtb Erdman 50-100 colony forming units (CFU) mice 
will develop caseous necrotic granulomas that may contain fibrosis and bronchiolar intraluminal 
exudate [61]. Only mice that exhibit an outward sign of sickness tend to have necrotic lesions. 
Mortality is relatively low, with most mice surviving 32 to 40 weeks after a high-dose aerosol 
infection.  
Mice from the I/StSnEgYCit (I/St) strain are highly susceptible to an Mtb infection caused 
by the recessive allele Tbc-1s and exhibit disease progression similar to human disease including 
both chronic and reactivated tuberculosis[62], [63]. Lung lesions occur roughly 2 weeks post 
intravenous infection with an infectious dose of 5x105 CFU. It begins with an influx of T 
lymphocytes and neutrophils, and after 3 to 5 weeks post-infection, the formation of necrotic 
granulomas occur rapidly with hypoxic regions [64]. Similar to other murine animal models, there 
are higher levels of bacterial burdens in the lungs relative to the other organs. Mortality in this 
strain is very high, which occurs 3 to 4 weeks after a high-dose infection, but mice generally 
survive 20 to 25 weeks after a low-dose infection.  
The IL-13 -transgenic mouse model overexpresses IL-13 by a transgene containing a 
genomic fragment containing the IL-13 gene and the human CD2 locus control region [65], [66]. 
About 3 weeks post aerosol infection with a low dose of 100CFU Mtb H37Rv small granulomatous 
lesions form, similar to what has been previously observed in BALB/c and C57BL/6 TB-infected 
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mice. At 6 weeks post-infection, organized central necrotic granulomas develop, which by 10 
weeks have matured with a fibrotic capsule with measured levels of hypoxia. At about 14 weeks 
post-infection, mice presenting with these necrotic granulomas begin to be moribund, and by 20 
weeks, most mice have succumbed to the disease [65], [67].  
 
1.3.6 - C3HeB/FeJ Mouse Model 
In contrast to traditional mouse models, the C3HeB/FeJ mouse strain develops a 
heterogeneity of pulmonary lesion types upon an Mtb infection that contains pathology analogous 
to human disease, including caseous necrotic granulomas. The model is often referred to as the 
“Kramnik mouse model” for the pioneering work that Dr. Igor Kramnik did in describing and 
adapting the model to Mtb [68]. C3HeB/FeJ mice are highly susceptible to Mtb infection but have 
no overt immunodeficiencies. Previous work has identified the intracellular pathogen resistance 
1 (IPR1) isoform of the interferon-inducible-75 (Ifi75) gene responsible for this increase in 
susceptibility [69]. Macrophages from IPR1-negative mice will undergo necrosis instead of 
apoptosis even with the major pathways of macrophage responsiveness still intact (such as nitric 







Figure 1.1. The experiment that demonstrates the survival curve and the window of mortality 
(between arrows) of TB infected C3HeB/FeJ mice (n=85) by aerosol infection.   
 
After a low-dose aerosol infection (of approximately 55 CFU Mtb Erdman per mouse), an 
increase in bacillary load and disease progression is observed. By day 40, the bacterial pulmonary 
burden will be around 108 CFU [71], which is substantially higher than 106 CFU observed in 
BALB/c mice [72].  A significant mortality event, ranging from 10-40%, occurs between 28 to 45 
days post-infection (Figure 1.1). The surviving mice will typically stay alive at least an additional 
14 weeks with minimal mortality. Mortality can be predicted based upon the pre-infection weight 
and the development of severe cachexia, hunched posture, and unkempt appearance at about 4 
weeks post-infection. It has also been observed that more virulent strains of Mtb, in general, have 
higher rates of mortality (<80%), while less virulent strains could have no mortality (0%). These 
early mortality rates are influenced by the culturing method for the infective strain used, the 




Figure 1.2. Heterogeneity of lesions that develop in the C3HeB/FeJ mice infected with M. 
tuberculosis Erdman. Type I lesions (A) are highly organized and composed of a caseous necrotic 
center, a band of neutrophils, and encapsulated in a fibrotic rim. Outside the fibrotic rim, the lesion 
is composed of epithelioid and activated macrophages, fibroblasts, and few lymphocytes. Type II 
lesions (B) are composed primarily by neutrophils but lack the fibrosis observed in Type I lesions. 
Type III (C) lesions are composed predominately of epithelioid and activated macrophages with 
a large number of lymphocytes throughout the lesion. (D) A Type I Lesion with bacteria stained 
using SYBR Gold (green) and background tissue stained with DAPI (blue) [73], [74].   
 
After 8 weeks of a low-dose aerosol (LDA) infection with the Mtb Erdman strain, 
C3HeB/FeJ mice may develop three distinct lesion types, now identified as Type I, Type II, and 
Type III. Each lesion type develops independently of each other, and multiple lesion types can 
develop within a single animal. Type I lesions (Figure 1.2A) are fibrous encapsulated caseous 
necrotic lesions that closely resemble the human TB hallmark granuloma. Visible development 
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begins 4 to 5 weeks post-LDA infection with the central accumulation of foamy macrophages and 
neutrophils with margins composed of epithelioid macrophages and lymphocytes. By 7 to 10 
weeks post-infection, the granuloma becomes highly organized in appearance. The environment 
within the core is hypoxic, filled with necrotic debris, and has a neutral pH [74], [75]. The inner 
ring surrounding the core is composed of a dense ring of neutrophils followed by foamy 
macrophages, all encapsulated within a fibrotic collagen rim. Outside the fibrotic rim, the lesion 
tissue is composed of fibroblasts, epithelioid and activated macrophages, and lymphocytes. As 
observed previously, C3HeB/FeJ mice aerosol infected with mouse passaged Mtb H37R or Mtb 
HN878, large Type I lesions may develop cavities in 47% of untreated mice 8 to 14 weeks post-
infection, but the rate of incidence is influenced by infectious dose, and Mtb strain used [76]. 
Bacteria exist both intracellularly in foamy macrophages and extracellularly in the necrotic core 
(Figure 1.2D).  
Type II lesions (Figure 1.2B) are consisting of a fulminant granulocytic pneumonia 
composed predominately of neutrophils, few lymphocytes, and unlike Type I lesions do not 
present with fibrosis. Histopathology analysis of early mortality (4 to 6 weeks) mice showed a 
considerable amount of lung consolidation composed almost entirely by Type II lesions. These 
lesions are rapidly forming and closely resemble polymorphonuclear alveolitis, sometimes seen 
in humans [41]. Visual inspection of Type II lesions shows a considerable number of bacteria that 
appear to be extracellular.  
Type III lesions (Figure 1.2C) are indistinguishable from lesions seen in traditional murine 
models, including BALB/c or C57BL/6. These lesions are composed primarily of epithelioid and 
foamy macrophages with dispersed lymphocyte clusters. These immune controlled lesions are 
commonly associated with low mortality and few bacterial numbers. However, there are some 
exceptional conditions where it had been previously observed with a mouse passaged H37Rv 
strain that developed a considerable amount of lung consolidation composed of predominately 
Type III lesions with a corresponding high mortality rate (Unpublished Data).  
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 For my thesis, I have opted to use the C3HeB/FeJ mouse model for a variety of reasons. 
The first is because it is a murine model we can house a larger number of animals per cohort than 
we could with other animal models such as Guinea pigs or NHPs. The larger numbers will allow 
us to have data that is more representative of the population. The second is that we have a large 
database of historical data, which includes pathology tissue blocks, images, bacterial burden data, 
and time points. The third is that the animal model develops complex pathology that mimics many 
aspects of human disease, especially the Type I granuloma. Machine learning requires large 
amounts of data, which is why the first two reasons were of such importance. Creating a predictive 
model would not have been feasible otherwise, especially with such complex data classifications. 
This complexity also allowed us to demonstrate that machine learning is a viable tool to perform 
targeted histopathology analysis, which currently is not available in the TB field. Lastly, the 
C3HeB/FeJ mouse model is becoming more widely used, especially in drug efficacy and 
determining Mtb virulence, which is why we wanted to develop tools to help research laboratories 
in their analysis.   
 
1.4- Scoring Histology On Microscopy Slides 
In clinical diagnosing and monitoring disease, a nominal classification may be sufficient in 
determining patient treatment options or disease progression. For example, cutaneous basal cell 
carcinoma does not require additional information because it is the clinical diagnosis. In other 
cases, having a simple classification may not provide enough information to determine the specific 
treatment option or disease prognosis. For example, breast carcinoma histology samples are 
assigned a histology grade based on cell morphology. The grade will determine the 
aggressiveness of cancer present and the corresponding treatment options [77]. For research 
purposes, histological scores are given as a way to perform quantifiable analysis across 
individuals, cohorts, and across independent studies.  
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A robust scoring system should have three defining characteristics, as suggested by 
Crissman and colleagues: (1) definable, (2) reproducible, and (3) produce meaningful results [78]. 
When performing analysis using a predetermined scoring system, several steps need to be taken 
to generate a useful score [79]. The first is to mask the samples of any identifiers to reduce any 
preformed biases that may result in the examination of the tissues. Failure to properly mask the 
samples may inadvertently create an observational bias that may distort the severity of disease 
or the effects of treatment [80]. The second is to perform a thorough examination of the samples 
and record all the information that may seem pertinent to the study. Important information may 
include severity, frequency, and type of lesions that may provide value in a larger scope than the 
specific study in which the data was collected [81]. The third is following the lesion parameters by 
defining the type of lesions that can be studied in the study. Defined parameters should 
encompass what applies to the specific use of the animal models, organ/tissue, and disease 
under the conditions of the experiment.  The fourth is having clear scoring definitions and avoiding 
collection methods that collect ordinal data such as scoring language that includes terminology 
such as “mild” or “severe” [81], [82]. A more appropriate reporting methodology is the quantitative 
reporting of percent involvement, which enhances the reproducibility and sensitivity of an 
experiment. The fifth and last step is the reduction of diagnostic drift, which is the variation of 
values consistently during analysis [77]. Bias can happen if there are large numbers of samples, 
examination occurs over an extended period, category definitions are poorly defined, or multiple 
pathologists are examining the same cohort of samples. It is common practice in research to have 
one pathologist score all the microscopy slides in a practical timeframe to increase the 
consistency of results and limit the amount of variability that occurs between classifiers [77], [78].  
When designed correctly, scoring systems should be reproducible and provide data that 
is impactful for the experiment. There are two commonly used approaches in the validation of a 
scoring system. The first is the repeatability of the observer in scoring consistently amongst a 
single experiment. A recent study by Begley and Ellis has demonstrated that when using current 
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standard methodology, it is difficult to achieve reproducibility. They repeated the experiments of 
53 published high impact oncology studies to determine if they were reproducible, with only a 
shocking 11% (6/53) success rate [83]. While there has been an unspoken acknowledgment of 
issues with irreproducible data, the scientific community, for the most part, has taken the validity 
of published work as fact. With the rise of drug development costs, late-stage clinical trial failures, 
and lack of new therapeutics as discussed previously, this lack of reproducibility has begun 
receiving more attention [84], [85].  
The second approach is to validate the relationship between the relevant parameters of 
disease severity and the corresponding scores. The relationship is, at times, calculated using a 
statistical correlation approach (e.g., Spearmans correlation for nonparametric data) to measure 
the strength and direction of the association between the two variables. The approach would 
provide a value between -1 and 1, and as the value approaches zero the lower the correlation. If 
the scoring system has a value close to 1, it is considered positively correlated, while a negative 
value indicates a negative correlation depending on the definition [86]. The context associated 
with the different aspects of the disease severity is important as individual factors may not 
contribute equally. An example is presented by using the C3HeB/FeJ mouse model development 
of the three lesion types. In this case, two mice display with 20% lung involvement, but one mouse 
presents with predominately Type II lesions associated with high mortality, whereas the other 
mouse has predominately Type III associated with low mortality, a score of 20% lung involvement 
would not be sufficient to classify these animals. Instead, each lesion type context needs to be 
taken into consideration with more weight for the Type II lesion classification and a less weighted 
value for the Type III lesions in the analysis.  
 
1.4.1 - Histology Scoring Of Tuberculosis-Infected Tissues On Microscopic Slides 
Histological scoring in tuberculosis research primarily focuses on pulmonary pathology 
and is highly dependent on the animal model in question. Different scoring methodologies are 
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being used in the field for the multiple TB animal models. In NHPs, the pathology focus is on 
pulmonary lesion characteristics such as the lesion architecture appearance, type, distribution 
patterns, and cellular composition. Based on the listed criteria, a score of 0-3 is applied for each 
characteristic, and an overall score is calculated [87]. In the rabbit model, the focus is primarily 
on pulmonary lesion characteristics but also includes the general condition of the animal. 
Parameters include the animal’s weight, lesion type, lesion location (which lung lobe), pleural 
involvement, number of lesions, and granuloma presence on the mediastinal lymph node, 
kidneys, and appendix. Disease severity is calculated by the summation of individual pathology 
scores, with a maximum score of 50 that can be attained for the most severe cases [88]. In 
classical mouse models, such as BALB/c, each histological parameter of peribronchiolitis, 
perivasculitis, alveolitis, and granuloma formation is scored. The score ranges from 0-5, with 5 
being the most severe form for that particular parameter. The lesion frequency and general lung 
involvement determine overall disease severity. A maximum score of 20 is what can be achieved 
using this system [89]. In the scoring of pathology of the C3HeB/FeJ mouse model in our 
laboratory by board-certified pathologist collaborators, each lesion type (I, II, III) is scored from 0-
4. A score of 0 is defined as 0% lung involvement, a score of 1 is defined as 0-10% lung 
involvement, a score of 2 is defined as 10-25% involvement, a score of 3 means 25-50% 
involvement, and a score of 4 means greater than 50% involvement. Each lesion is also weighted 
differently with the Type I lesion score multiplied by 3, Type II lesion score multiplied by 4, and 
Type III multiplied by 2. Therefore, an animal can have a maximum score of 36, but most severe 
cases receive a score of around 20.  
As demonstrated above, within the tuberculosis field, there is no standardized method to 
score histopathology in determining the efficacy of treatments or disease severity. It is subject to 
what has been previously done in the specific animal models, laboratories, and individual's 
preferences. This makes comparisons across different studies or laboratories difficult unless the 
same pathologist reviews the studies, following the same scoring criteria, with a short time period 
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between analyses.  A more reproducible and informative methodology would be to provide exact 
measurements for each parameter that is of interest to the disease. An example using the TB 
C3HeB/FeJ mouse model would be to report the percent involvement for each specific lesion 
type. This will move the data from being nominal or ordinal to a ratio data type that can be used 
for statistical measurements and data analysis. The unbiased quantitive data decreases the user 
variability and increases the reproducibility of the results regardless of the time or individual 
performing the analysis. With the widespread availability of digital image analysis and machine 
learning scoring automation of analysis, not only the variability but the amount of time required by 
a human user has been significantly reduced.  
 
1.5 - Image Analysis 
1.5.1 - Introduction 
Computer vision (CV) is an interdisciplinary field that aims to mimic human vision through 
the detection and/or classification of objects from visual media such as images, videos, or 
sensors. It has allowed digital optical analysis to be automated, to be faster, and more reliable 
than human operators [90]. Human visual analysis, while highly complex, is plagued with 
‘perceived’ rather than ‘factual’ information when making decisions. This is because we have 
evolved to make quick decisions based upon visual stimuli that may be lacking key information or 
the ability to process large amounts of stimuli. After light hits an object, it takes about a tenth of a 
second for our brains to process this information, but during that tenth of a second, we are missing 
information that is still being provided and haven’t yet been processed [91]. Our brains will fill in 
these blind spots with information from its surroundings and contextual clues, which is 
indistinguishable from the real information [92]. This approach is called ‘top-down’ visual 
processing, which is more computationally efficient than ‘bottom-up’ visual processing [93]. Our 
visual processing method impacts areas of intra and inter-observer variability, and the perception 
of dimension, color, and size [94], [95]. We can identify our visual shortcomings in the form of 
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optical illusions. While these neural shortcuts may have provided a competitive advantage for 
avoiding predators to our ancestors, in today’s context, it delivers many unperceived 
disadvantages when performing manual visual tasks that require precision and reproducibility. In 
contrast, the biggest advantage humans currently have over computer vision is the flexibility, or 
the ease of transitioning between crystallized and fluid intelligence, when encountering deviating 
or previously unseen scenarios [96]. With a simplistic example, this means that if you had created 
a CV algorithm to classify images of cats and dogs and you gave it an image of a bird, it would 
try to classify it as either a dog or cat. Humans do not have this limitation because even if we had 
never seen a bird before, we would recognize it as neither a cat nor a dog and give it its own 
classification. With current technology limitations, there is still a need in research and clinical 
settings to not remove the human element in their analysis but complement the strengths of each 
approach by implementing a hybrid solution [97], [98].  
 
1.5.2 - Techniques In Computer Vision And Image Processing  
CV works by implementing an optical sensor (e.g., camera) and an algorithm to extract 
information about an image object. Most CV solutions utilize similar steps as listed: (1) digital 
image formation or capture using the optical sensor, (2) image preprocessing to improve or 
enhance desired qualities or features, (3) image segmentation in which objects of possible interest 
are separated from background noise, (4) quantification of object features, and (5) image 







Figure 1.3. The steps used in image analysis: (1) digital image formation, (2) image 
preprocessing, (3) image segmentation, (4) image quantification, and (5) image interpretation 
 
Image preprocessing aims to either correct the image quality or enhance for features that 
are of interest. Most images are subject to changes in illumination, atmospheric conditions, 
viewing angle, and/or instrument errors [100], [101]. In biomedical research, most digital image 
quality limitations are not the result of poor external conditions around the sensor, but of the 
sample itself. This is because the optical sensor (microscope, MRI, CT/PET, etc.) is in very 
controlled environments that have little deviation in angles, lighting, and exposure. Specifically, in 
microscopy, sample complexity and deviations in the preparation and staining of microscopic 
sections have the greatest influence on the degree of image pre-processing that may be required 
[102]. Common techniques used, include but are not limited to image blurring, sharpening, 
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normalization (color, size), distortion, erosion and dilation, morphological processing, and 
outlining [103] (Figure 1.4).  
 
Figure 1.4. A comparison of the commonly used image analysis techniques: (A) Original image, 
(B) normalization, (C) erosion, (D) edge detection, (E) blurring, and (F) threshold segmentation. 
Image (A) taken from the NIAID website under the creative common license [104]   
 
Image segmentation is the method of partitioning an image into separate, distinct objects. 
Each pixel within an image is assigned a label, and pixels that receive the same label are 
determined to be part of the same object. This is a common approach to focus on areas of 
significance, determine the location within the image as well as boundaries, and to reduce the 
amount of processing that may need to be performed for additional tasks. Image segmentation 
can be roughly divided into two different types; sematic and instance segmentation. Sematic 
segmentation assigns each pixel as either background or object. Instance segmentation assigns 





Figure 1.5. An example of cluster-based image segmentation for pedestrian detection. (A) An 
image is uploaded, clusters of pixels with similar characteristics are identified, and (B) objects of 
interest (green and red) are separated from the background (blue). Images were taken from the 
Penn-Fudan Database for Pedestrian Detection and Segmentation [105].    
 
A common segmentation technique is “threshold segmentation” (Figure 1.4F), which partitions 
each area of an image-based upon pixel values. Calculations for this technique are simple, fast, 
and perform well with high contrast (e.g., fluorescence imaging). The method performs poorly if 
there is not a substantial amount of contrast or if there is an overlap in pixel values. Another 
approach is “edge detection segmentation,” which looks for discontinuous local features within an 
image. Also, in this case, this technique suffers if there is not a substantial amount of contrast 
between adjacent discontinuous pixels and if there is a high degree of complexity. The last 
approach for segmentation is clustering-based image segmentation. Clustering techniques divide 
pixel populations into a specified number of groups or ‘clusters.’ Pixels within a particular cluster 
have increased similarity of characteristics than those of other clusters. This approach is simple 
to implement but is computationally expensive to use, which limits it to only small datasets. A 
common example of image segmentation is detecting pedestrians. The algorithm determines 
which objects are of interest (the pedestrians) and subtracts the background (Figure 1.5). By 
implementing a segmentation approach, you can determine where the pedestrian is in the image.  
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Quantification of image objects measures specific characteristics of the segmented 
objects. This can include but is not limited to the number of objects, region of interest (ROI) 
intensities, ROI hues, ROI saturation, areas, shapes, and locations. While this information on its 
own is valuable, it may also be used in providing a classification (interpretation). For example, 
when providing grades for breast carcinoma, the information required includes each cell’s shape, 
color, and the number of carcinoma cells relative to healthy cells. The interpretation step can 
either be automated to give a recommendation based upon the parameters or left up to a 
specialist who is trained to look for specific features from the quantification step. This approach 
is commonly used in microbiology settings to distinguish between the differently labeled cells 
using multiplex fluorescent imaging.  
 
1.5.3 - Machine Learning 
Arguably one of the biggest advances in CV is the implementation of machine learning 
(ML) to perform trivial and highly complicated CV tasks. ML can be defined as the implementation 
of computer algorithms and statistical models to perform specified tasks without having to 
program in explicit instructions. ML can be broken down into two main categories, ‘supervised’ 
and ‘unsupervised’ learning. Supervised learning uses a ground truth that ‘learns’ by using 
examples of the desired output. An example would be developing a classification algorithm that 
distinguishes between dogs and cats. Common supervised learning algorithms include methods 
such as logistic regression, naïve Bayes, support vector machines, and neural networks. 
Unsupervised learning does not have labeled outputs, so it is up to the algorithm to determine the 
output structure present within a given dataset. This approach is popular in data exploration when 
the researcher is in the process of discovering new information on data. Common unsupervised 
algorithms include k-means clustering, principal component analysis, autoencoders, and neural 
networks. Because of the flexibility of approaches developed for neural networks, they are utilized 
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in both supervised and unsupervised learning but are considered very computationally expensive 
[106], [107].  
Supervised ML models are developed using representative data called ‘training sets’ to 
discover patterns through inference. Below is an illustrative example of the difference between 
traditional CV and ML in solving an image analysis problem. If a researcher wanted to enumerate 
fluorescently labeled bacteria within an image using traditional CV, they would calculate the hue, 
saturation, and lightness of representative pixel values of the bacteria versus the background. A 
range of values for each metric listed above will be collected, and objects of interest (bacteria) 
will be masked out. Masking is the process in which portions of the image are hidden, leaving 
only the specified pixels of interest. Segmentation will follow and further masking based upon cell 
size to eliminate objects that are considered false positives. The last step would be to implement 
a shape-specific contour algorithm, followed by enumerating the objects that are present. 
Traditional CV requires the user to program explicit instructions on how to detect the object in 
question, which can get complicated and can be non-specific depending on the circumstance. 
The benefit is that supervised ML only requires a small amount of training data and in some 
instances, can be fast to implement. A researcher can create a training set of representative 
images of bacteria and train an ML algorithm. There would be no need to perform preprocessing, 
determine pixel value ranges, or object sizes as the ML algorithm could infer these patterns on its 
own. The main advantage is that there is no prior information needed to train the algorithm, which 
is important when one is unsure about what the critical parameters are. The disadvantage is that 
depending on the complexity of the problem, the ML algorithm may require thousands if not 
millions of training set image data points to achieve a level of accuracy that would be acceptable. 
In the biological sciences field, acquiring a thousand separate images of multiple classifications 
may not be realistic, especially for digital histological data. This is why both approaches are still 
relevant in creating algorithms to analyze digital images.    
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 In CV, there are a number of algorithms used in ML, which include convolutional neural 
networks (CNN), deep belief networks and deep Boltzmann machines, and stacked 
autoencoders. For the purpose of this thesis, we will focus on CNNs and their applications in 
object classification. The conception for CNN was inspired by the visual mechanisms and neural 
processing that takes place in biological organisms [108]. Just like a human brain works by the 
firing of highly connected neurons in response to a stimulus to create an output, CNNs follow a 
similar framework. An input value is passed to a neuron, which is either turned off or on. This 
continues for multiple connected neurons until an output is generated.  Early implementations of 
neural connectivity, hierarchical organized transformations of images, and later additions of error 
gradient proved very successful [109]–[111]. This field is highly evolving, and over the last couple 
of years, more efficient algorithms and alternative CNN approaches have become available. In 
comparison to other image classification algorithms, little pre-processing is needed.  
 
Figure 1.6. A visual representation of the architecture of a common CNN. This includes multiple 
convolutional and pooling layers before being processed by a fully connected layer. Adapted from 




 At its core, a CNN is comprised of three main types of neural layers: (1) convolutional 
layers, (2) pooling layers, and (3) fully connected layers (Figure 1.6). Convolutional layers utilize 
various kernels to convolute an entire image and its intermediate feature maps into multiple 
feature maps. The purpose of a kernel is to take data as an input and transform it into a 
predetermined form. From a biology perspective, this step mimics human vision, where specific 
identifying features of an image such as color, shapes, and size are identified in the image. 
Pooling layers reduce the spatial dimensionality of the input image for the next convolutional layer. 
The reduction in size leads to a loss of information but is actually beneficial due to a decrease in 
computational cost and prevents overfitting of the network. Average pooling and max pooling are 
the two most common pooling algorithms used in this step [113]. The last step takes the feature 
maps that were created in the convolutional and pooling steps and passes the flattened image 
through a fully connected neural network. From a practical standpoint, this is when the learning 
takes place in distinguishing between the different images. Within a fully connected layer, there 
are multiple neurons, and each neuron is connected to the activation of the previous layer. Each 
neuron activation is computed by matrix multiplication and the bias offset. Eventually, the fully 
connected layers will convert the two dimension feature map into a one dimension feature vector. 
The derived vector will then be fed forward into the specified number of classification categories 
to produce the final classification result [114].  
 
1.5.4 - Human Bias In Research 
Historically, pathologists have been using a manual histopathology scoring system to 
analyze pathology images which are considered to be semi-quantitative at best. Manual scoring 
produces qualitative or semi-quantitative scores that are rich in detail about the disease but even 
with experienced pathologists can be subjective to user bias and interpretation [115]. Bias, or 
systemic error, could alter the results or diminish the validity of a study [80], [116]. As mentioned 
previously, with the rising cost of drug development and the difficulty for the science community 
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to generate reproducible work, this has increasingly become a larger concern. There are many 
potential sources of bias that may unintentionally arise when scoring pathology and these are 
often referred to as visual traps.  
 
Figure 1.7. Examples of known visual biases, or optical illusions that can impact the ability of 
human researchers to make judgments and the corresponding pathology equivalent. Both (A) and 
(B) demonstrate how contextual clues influence our perception of size. This is also seen in 
pathology of a cell whose membrane is shown stained and unstained (C). The checkerboard 
illusion (D) demonstrates our inability to discern color gradients properly. Both checkers labeled 
A and B are of the exact same color. The pathology equivalent is shown where two images (E & 
F) have the same amount of staining (Brown) present. Adapted from Aeffner et al. [117].   
 
Several potential visual trap scenarios have been described, such as the Ebbinghaus 
illusion of size, which demonstrates that our perception of size is influenced by the context in 
which it is presented [118], [119]. In Figure 1.7A, B, the inner circles are of the same size but 
contextually appear different due to the surrounding outer circles. Illusions of size is influenced 
by preconceived concepts and memory of the observer. This can be conceptualized in 
histopathology analysis of a perceived size difference for instance, by the addition of a labeled 
membrane to a nucleus (Figure 1.7C) [117]. The Checker Shadow Illusion (Figure 1.7D) is a visual 
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trap that demonstrates the faulty perception of brightness, contrast, and surrounding 
variation[120], [121]. Throughout our lives, we have visualized countless instances of objects that 
appear darker in shadows than in light. We have seen so many that our brains automatically 
assume that it is the same as we have previously experienced and make these compensations, 
whether they are real or not. Combined with our perception of ignoring soft edges of shadows and 
visualizing the sharp edges of the squares makes this illusion possible. Lastly, the distinction 
between hues and gradients of colors can also vary tremendously between individuals. It is 
estimated that the average human can distinguish between 30,000 to 10 million colors [122] that 
can be impacted by several factors such as the environment, age, health, and lifestyle choices. 
Color is perceived by not only the light refracted by a specific color but also by the light nearby, 
which is called color induction [123], [124]. For example, a dark yellow surrounded by red will 
appear as a greenish tint. In contrast, a 12-bit camera can distinguish 68 billion different shades 
of color, and a 14-bit camera can store up to 4 trillion shades [125]. Digital systems are far more 
superior to the human visual system in capturing hue and color gradient differences. A pathology 
example that illustrates the checker shadow illusion and color induction is demonstrated in Figure 
1.7E, F. This example shows that two different levels of cytoplasmic staining in the context of 
adjacent membrane staining clearly influence the assigned scores. Using digital analysis, it is 
determined that both images would actually receive equivalent scores.  
In addition to visual traps, human objectivity is also hampered by cognitive biases. This 
includes confirmation bias, which is defined as unknowingly interpreting new information as 
confirmation of previously held beliefs [126], [127]. An example would be the belief that left-
handed people are more creative than right-handed people. The next time you run into a left-
handed artist, regardless of reality, it will only confirm that bias. This is evident when an 
investigator will inadvertently seek and interpret data that support their given hypothesis. 
Confirmation bias is often reduced by blinding the data and implementing the scientific method 
when acquiring data. Another cognitive bias is diagnostic drift, which is the variation of score 
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values in a consistent manner throughout a study. Even experienced pathologists and clinicians 
are subject to diagnostic drift, especially during long studies with multiple time points [128], [129]. 
While this section is not an exhaustive review of potential human bias in research, it helps 
underscore the need for integration of an unbiased automated digital analysis in the pathology 
scoring system.  
 
1.5.5 - Computer Vision (CV) In Clinical And Biomedical Research 
Computer-aided analysis and diagnosis combine the flexibility and training of a human 
specialist with the reproducibility and accuracy of a machine. ML became feasible for biological 
laboratories with the development of graphical processing units (GPUs) in the early 2000s. GPUs 
are composed of hundreds of simple cores that perform thousands of concurrent hardware 
threads. Central processing units (CPU), in comparison, have a couple of complex cores with 
single-thread performance optimization. What this means is that GPUs can perform thousands of 
simple tasks simultaneously while a CPU can perform a few complex tasks at a time.   The viability 
of CNN became apparent in 2012 when training with the ImageNet dataset had an error rate 10.8 
percentage points lower than the next runner up which used more standard methodology [114]. 
Since 2019 it has been referenced over 40,000 times and is considered one of the most influence 
events in computer vision.     
In the early 2000s, the threshold for entry in ML implementation was reduced thanks to 
advances in GPU in both cost and performance. In 2008, the utility of computational pathology 
had been clearly demonstrated by Thomas Fuchs with predictive analytical modeling of renal cell 
carcinoma in patients [130]. In 2012, the introduction of CNN in ML showed a significant 
improvement over the previous methodology for image analysis [131]. And in 2014, the 
development of generative adversarial nets have lowered the amount of training data required 
which has been a limitation for biological research [132]. 
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AI has expanded into applications of biomedical diagnostic systems from previously other 
human domains such as facial recognition and self-driving cars. This includes oncology, 
pathology, radiology, and infectious diseases, which have seen rapid advancements in their 
respective fields [133]. Digital image analysis has allowed the high throughput of data at a 
relatively low cost while increasing the efficiency of the analyzing specialists. The TB field has 
seen a relatively slow expansion of ML compared to fields such as oncology; nonetheless, the TB 
field has begun utilizing these new methodologies to improve their analysis [134]–[136].  
 
1.6 – Rationale 
 The objective of this dissertation was to develop computational analysis tools that take a 
targeted approach on acquiring data on specific host disease states and bacilli populations. These 
are metrics that are potentially important in evaluating the efficacy of novel and existing therapies 
for TB. Current targeted approaches can be time-consuming and require multiple steps, which 
introduce additional steps where errors can occur. They are also subject to multiple forms of user 
bias and rely on specialized knowledge to be able to accomplish accurately. These problems are 
further compounded when analyzing complex pathology, such as what is developed by the TB 
C3HeB/FeJ mouse model. To accurately analyze this murine model, the classifier needs to look 
at what pathology structures are formed and what the cellular makeup is for each lesion. With 
recent advancements in ML and CV, we were able to develop specialized analysis tools, which 
are called Lesion Image Recognition Analysis (LIRA) and Mycobacterial Image Analysis (MIA).  
Each tool required algorithm development, analysis verification using existing methodologies, and 
determining the limitations of employing these tools in future analysis. We propose that analysis 
done with these tools will result in faster analysis, an increased agreement among human 




Specific Aim 1: To develop software utilizing deep convolutional neural networks that will assist 
in the identification and quantification of pulmonary lesions using digital microscopic images from 
the lungs of M. tuberculosis-infected C3HeB/FeJ mice. Hypothesis: Pathologists that are aided 
by a computational tool, such as LIRA, in their analysis will show a reduction in the amount of 
time needed to perform the analysis and more agreement between different pathologists than 
pathologists who use standard methodology.   
 
Specific Aim 2: Compare pathologist results using LIRA or those made by a certified pathologist 
using actual tissue slides from a previous drug-efficacy trial. Analysis will include a review of the 
original study conclusions. Hypothesis: Histology, from a drug efficacy trial, when analyzed with 
the assistance of LIRA, will generate scores that are in agreement with a board-certified 
pathologist. In addition, using a more targeted analysis approach will expand upon the initial 
conclusions that were made.  
 
Specific Aim 3: To generate software for the enumeration of fluorescently stained bacteria in 
pulmonary tissues of C3HeB/FeJ mice infected with M. tuberculosis. Hypothesis: Analysis of 
Mycobacterium tuberculosis located in infected C3HeB/FeJ mice tissue using MIA will identify 
differences in bacterial enumeration metrics (density, % involvement, size) among treatment 
cohorts and lesion types.  
 
The development of computational tools to provide quantifiable data for analysis is an 
important tool for drug development. For histopathology analysis, these computational tools will 
allow the reduction in variability found between pathologist scoring while reducing the analysis 
time and scoring errors seen previously. It also allows researchers to collect metrics that 
previously were not available, which may lead to new discoveries. The metrics that are being 
generated using the novel software for histopathology include the percent lung involvement for 
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each lesion type, as well as metrics on bacterial density, shapes, and fluorescent intensities for 
bacterial populations found within each lesion microenvironment. In conjunction with fluorescent 
labeling for specific cells, this will allow researchers to quantify the effects of therapies on both 
the host and bacteria in targeted microenvironments within the host. This targeted data analysis 
approach will help expand our knowledge used in the development of new therapies and speed 






















CHAPTER 2: DEVELOP LESION IDENTIFICATION AND AREA CALCULATION SOFTWARE 
(LIRA) FOR THE C3HEB/FEJ MOUSE MODEL1 
 
2.1- Introduction 
Tuberculosis (TB) is a communicable disease that continues to affect modern society with 
a quarter of the world believed to have active or latent TB, primarily in low and middle-income 
countries [4], [137]. TB is transmitted by aerosol inhalation of the bacterium Mycobacterium 
tuberculosis (Mtb) from an infected individual. During the course of infection, a wide variety of 
pulmonary disease lesion presentations may concurrently present within the same host [16], 
[138], [139] . This pulmonary pathology includes, but is not limited to, inflammatory lesions, 
interstitial pneumonia, necrotic caseating granulomas encapsulated within a fibrotic rim, non-
cavitary necrotic lesions, non-necrotic cellular lesions, and cavitary lesions [14], [41]. The 
heterogeneity of lesions within a single individual represent a myriad of microenvironments for 
Mtb that range from hypoxic regions, where bacteria are extracellular in caseum, to vascularized 
and more aerated regions, where Mtb is intracellular within various macrophage populations 
[140],[141]. Because of the complex environments that develop in the lung throughout infection, 
Mtb has developed adaptive strategies to alter its metabolism and replicative state to increase 
survival [22], [73], [142], [143]. The adaptation of Mtb to its environment results in bacterial 
populations exhibiting multiple distinct phenotypes [19], [140]. A critical component in 
understanding disease outcome and, importantly, treatment success is our understanding of 
 
1 Authors: Bryce C. Asay, Blake Blue Edwards, Jenna Andrews, Brendan K. Podell, Juan F. Muñoz Gutiérrez, 
Chad B. Frank, Forgivemore Magunda, Michael Lyons, Asa Ben-Hur and Anne J. Lenaerts. Bryce C. Asay 
conceptualized the project/software, created the training set, contributed to the coding, pipeline 
development, design of the validation testing, and performed the validation analysis. Paper under review 




these varying lesion microenvironments and bacterial phenotypes  [144]–[146]. Two important 
clinical implications emerge from the lesion heterogeneity observed in the lungs of TB patients in 
terms of the effectiveness of drug treatment in the various lesion types and lesion compartments. 
Lesion characteristics differentially affect (1) drug penetration and distribution of TB drugs inside 
the lung lesions where the bacteria are located [147], and (2) the relative drug susceptibility of the 
bacilli contained within these lesions due to metabolic adaptation that could induce phenotypic 
drug tolerance and bacterial persistence [140], [148]. These combined factors result in marked 
inter- and intra-lesional variability of drug-mediated killing. We have reported previously on the 
C3HeB/FeJ mouse model, which after Mtb aerosol infection, develops a heterogeneity of 
pulmonary lesion types more reflective of the lung pathology seen in TB patients, and which has 
proven useful to further our understanding of disease progression as well as studying treatment 
responses for emerging therapies [22], [71], [74], [149], [150]. 
Murine models are employed in TB research due to their small size and low cost, and in 
addition, their physiology and genetics are well understood. Standard laboratory mouse strains 
such as C57BL/6 and BALB/c have been used most widely for TB research. However, these 
mouse strains show limitations by solely developing a single lesion type after Mtb infection, and 
they lack the lesion heterogeneity seen in TB patients. The C3HeB/FeJ TB infection model 
presents with a heterogeneity of lesion types more reflective of human disease [71], [74]. This 
mouse model was first described for tuberculosis by Igor Kramnik et al. (and is therefore also 
more commonly referred to as “the Kramnik mouse model”) [68].  These mice developed a de 
novo recessive allele, identified in a region at the 54.0-cM location of chromosome 1, termed the 
‘super susceptibility to tuberculosis -1’ locus (sst1) [69]. The susceptible sst1 allele was reported 
to control the formation of caseous necrosis of pulmonary lesions. In C3HeB/FeJ mice after an 
Mtb infection with a low inoculum, the bacterial load increases to high bacterial numbers in lungs, 
and mice develop a chronic disease state with a dramatic progression of the lung pathology over 
time. After 8 weeks post-infection, three pulmonary lesion types can be identified which we 
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classified earlier [71], [74], as: (i) a highly organized encapsulated caseous necrotic granuloma 
defined as a Type I lesion, (ii) a neutrophil dominated lesion with cellular necrosis defined as a 
Type II lesion, and (iii) cellular lesions with distinct clusters of lymphocytes defined as a Type III 
lesion type. Both the Type I and II lesion types contain high bacterial numbers (approximately 106-
7 per lesion), whereas the smaller Type III lesions only show few bacteria (approximately 102-3 per 
lesion).  All three lesions types can be present at the same time within a single mouse, and even 
in a single lung lobe [74]. Occasionally cavities have been observed, although this has been an 
infrequent event in the C3HeB/FeJ mouse model infected with Mtb H37Rv or Erdman [38], [71].  
The efficacy of tuberculosis vaccines [151], [152] or drugs [20], [153] is primarily measured 
by determining the reduction in bacterial load in target organs. The quantification of lung 
involvement in disease has proven to be informative as a secondary readout. A thorough 
pathology assessment can be informative to assess the effect of the therapeutic intervention on 
the disease itself, by studying improvement or worsening of inflammation or measures of tissue 
repair, such as fibrosis, as well as revealing potential immunotoxicity. Serial PET/CT scans of M. 
tuberculosis-infected animals, and TB patients have been used to monitor disease progression 
and response to treatment [53], [154], [155], allowing precise quantitation of the extent of disease 
and inflammatory response of the host. Parallel studies of CM and humans have shown 
comparable rates of radiological response to linezolid [156], and based on these initial studies, 
radiographic surrogate markers are being actively explored for use in human clinical trials of new 
agents and TB regimens [45], [157], [158]. For mouse models used in preclinical testing for TB, 
the treatment effect on pulmonary pathology is generally examined on microscopic images using 
a histological grading system by a veterinary pathologist specialized in TB [159]. The pathologist 
then assesses both macroscopic recognition of larger pathologic structures such as lesion types, 
as well as microscopic identification of predominant immune cell types. Because of the complex 
nature of the classification process, quantification of the lesions and their lung involvement for 
research purposes is not only a specialized task but highly time-consuming and variable upon the 
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individual performing the analysis. The person-to-person variability and subject nature of the 
method can lead to differing results, and this will, in addition, make inter-experiment comparisons 
of the histopathology results difficult. The time-consuming manual analysis can lead to increased 




While histopathology analysis of TB lung lesions is complex, recent advances in machine 
learning can provide for certain aspects of such analyses to be automated. Areas such as digital 
image analysis in cancer research [25], [26], [160], magnetic resonance imaging / computed 
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tomography [161],[162], and clinical and anatomical pathology [163],[164] have seen an increase 
of analysis tools being developed using machine learning approaches. Many of the algorithms 
currently employed in the medical digital imaging field include CNNs [165]–[168], and support 
vector machines (SVM) [169],[170]. CNNs are neural networks designed specifically for images 
and address the issue of achieving classification invariance for object recognition using local 
feature extractors or filters. These feature extractors or filters are applied at increasing levels of 
granularity, thereby allowing the system to recognize features at increasing levels of abstraction 
similarly to how the brain processes visual stimuli [171], [172]. CNNs also have a demonstrated 
history of success in image classification, and a plethora of open-source tools and packages are 
widely  available for use [27].  
Figure 2.2. Graphical representation of the workflow required to analyze images. 1) Original 
image is uploaded , 2) CNN1 detects Type I lesions and is verified by a user, 3) Window location 
is cropped based upon classification, 4) Image broken up in 80 x 145 windows to generate our 
predictions, 5) Classification predictions generated using 1 of two CNNs, 6) User is allowed to 
edit the results one last time. 
 
In this work, we propose a TB lesion machine learning classifier that follows established 
classification criteria developed in our laboratory, which distinguishes three different lesion types 
that develop in the C3HeB/FeJ mouse TB infection model [71], [74]. This digital image analysis 
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software package was developed as a modular neural network [173]–[176], consisting of three 
CNNs, each optimized for a specific sub-task, together with two human intervention checkpoints 
to limit the probability of misclassification (Figure 2.1, 2.2). This digital image analysis pipeline is 
named ‘Lesion Image Recognition and Analysis’, or LIRA. From its inception, LIRA was designed 
to work in conjunction with pathologists with the goal to improve the analysis of pulmonary 
pathology to be more efficient, accurate, and reproducible regardless of the individual analyzing 
the digital image slides.  
 
2.2 - Materials And Methods 
2.2.1 - Sample Collection From Archived Animal Studies 
The digital images from pulmonary samples used for the development of the image 
analysis software package were derived from archived C3HeB/FeJ mouse studies conducted for 
the development of the mouse model [71], [74], for drug efficacy trials using existing and novel 
drugs for tuberculosis [22], [149], and studies focusing on virulence of various Mtb strains 
(unpublished results). Lung samples were collected from 14 previous independent mouse studies, 
conducted over several years (from 2012-2018), and samples were obtained from two different 
research laboratories at CSU. Mtb strains used for the mouse infection studies included M. 
tuberculosis Erdman (TMC 107, purchased from ATCC), HN878 (Clinical Isolate W210, CSU, 
Fort Collins, CO, available at BEI resources), or H37Rv (Trudeau Institute, Saranac Lake, New 
York). Bacteria for mouse infections were initially grown as a pellicle and further propagated in 
Proskauer-Beck (PB) medium containing 0.05% Tween 80 (Sigma Chemical Co., St. Louis, MO), 
never extending past mid-log phase [177]. Female C3HeB/FeJ mice, 6-8 weeks of age (Jackson 
Laboratories, Bar Harbor, ME) were housed in a bio-safety level III animal facility and exposed to 
an Mtb aerosol infection using a Glas-Col inhalation exposure system [178].  Mice were 
euthanized by CO2 inhalation, between 4 to 10 weeks post aerosol exposure. Whole lungs were 
fixed by inflation with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) in 
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phosphate-buffered saline solution (PBS) via cardiac perfusion before subsequently being 




2.2.2 - Processing Of Samples To Generate The Digital Image Dataset 
 Fixed lung samples were further processed at either Premier Laboratory (Boulder, CO), 
the Experimental Pathology Facility at CSU (Fort Collins, CO), or at the Microbiology, 
Immunology, and Pathology (MIP) Department. Pulmonary tissue samples were placed in a single 
cassette per mouse, then paraffin-embedded and sectioned. Tissue sections (5µm) with the 
largest surface area were used for further histopathology analysis and mounted on glass slides. 
Paraffin sections processed for Haemotoxylin and Eosin (H&E) staining underwent a Xylene bath 
for 10 min before undergoing gradient hydration. Samples were stained using a Leica ST5020 
instrument with an initial staining step using Hematoxylin 560 (Leica Selectech, Buffalo Grove, IL) 
for 5 min and rinsed in tap water. Next, the slides were washed using a Define wash step (Leica 
Selectech, Buffalo Grove, IL) for 10 sec before being placed in a Blue Buffer Solution (Leica 
Selectech, Buffalo Grove, IL) for 1 min. The slides were then rinsed with Eosin for 1 min before 
being transferred to 96 Eosin Y 515 (Leica Selectech, Buffalo Grove, IL) for 3 min. The final step 
included a washing step with 96% EtOH for 6 min before being mounted using a LEICA CV5030 
Mounting instrument (Leica Selectech, Buffalo Grove, IL), thereby using the Coverseal-X Xylene 
Mounting Media (Cancer Diagnostic Inc., Durham, NC). Slides were generated and stained at 
three facilities using similar, however not the exact same, protocols over a time span of several 
years (2012-2018). Digital image scans from microscopic slides containing C3HeB/FeJ lungs 
were generated from one of three microscopes. Image scans from Premier Laboratories 
(Longmont, CO) were generated on an Aperio Scanscope XT microscope (Nikon, Melville, NY) 
at 20x magnification. At the Experimental Pathology Core (CSU), the images were acquired using 
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an Olympus VS120 microscope (Olympus, Center Valley, PA) using the Olympus VS-ASW 
software (v.2.9; Olympus, Center Valley, PA) at 20x magnification. Images acquired within the 
MIP Department were generated on a Nikon Eclipse Ti microscope  (Nikon, Melville, NY) at 20x 
magnification, using the Nikon NIS Elements AR software (v. 4.51.00; Nikon, Melville, NY). In 
total, for the training and subsequent validation of LIRA, lung sections from 176 mice were 
scanned digitally to generate 176 digital image scans (containing all five lung lobes for every 
mouse per microscopic slide and per digital image scan). Because of the heavy computational 
load that occurs from the large size of pathology scans, digital image files were generated 
separately for every individual lung lobe (resulting in five digital image files per mouse).  
 
2.2.3 - Lesion And Histopathology Classification Scheme 
The histopathology classifications used for the creation of the training, test, and validation 
sets included the original classifications of pulmonary lesion types in the C3HeB/FeJ mouse 
model, as previously described by Lenaerts et al. [71], [74]. Briefly, C3HeB/FeJ mice present with 
three distinct pulmonary lesion types after an Mtb aerosol infection. Type I lesions show well 
organized, caseous, necrotic lesions with a layer of foamy macrophages around a core composed 
of neutrophilic debris, which is surrounded by a collagen rim with interstitial macrophages 
admixed within the rim. Type I lesions contain high bacterial numbers, which are either 
extracellularly located in the lesion core, or intracellular in foamy macrophages. The Type II 
lesions are less organized with a massive recruitment of neutrophils, resulting in large areas of 
alveolar wall necrosis throughout the lung parenchyma. Type II lesions also contain high bacterial 
numbers, both intra- and extracellularly. Type III lesions develop as a result of the accumulation 
of lymphocytes, epithelioid, and foamy macrophages as well as small pockets of neutrophils. The 
latter is similar to the main lesion type described for other immunocompetent mouse strains, such 
as the BALB/c and C57BL/6 [72], [179], [180].  
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In addition to the lesion classifications, other histopathology categories were added for the 
machine learning approach to ensure the inclusion of healthy tissue, non-Mtb specific lung 
pathology, artifacts, and an empty slide feature. In total, seven classification categories were 
identified, which were as follows: Type I Rim, Type I Core, Type II, Type III, Healthy, 
Miscellaneous (Misc.), and Empty slide. Each classification is characterized by certain 
macroscopic pathology features, as well as microscopic features based on multiple different cell 
types. Each of the seven classifications is described in detail below and are presented in Figure 
1. 
The Type I (caseous necrotic) pulmonary lesion type is characterized by two distinct 
pathology features, which include a collagen rim and a caseous necrotic core. For this reason, 
the Type I lesion was categorized into two distinct classifications for the analysis, defined here as 
the ‘Type I Rim’ and ‘Type I Core’ categories. The Type I Core is composed of central necrosis 
surrounded by a dense neutrophilic debris layer, and a foamy macrophage layer which lies within 
the collagen rim. The Type I Rim composition includes the collagen rim and the outside layer 
composed of fibroblasts, epithelioid, and activated macrophages, and clusters of lymphocytic 
cells. The ‘Type II’ pulmonary lesion consists primarily of large numbers of neutrophils at times 
visible as a honeycomb-like structure of lung parenchyma. Along the periphery of the Type II 
lesion, the presence of aggregates of extracellular DNA, pockets of lymphocytes, and 
compressed tissue can be present. These pathology features are mostly found in close proximity 
and, therefore, also classified as Type II. The ‘Type III’ pulmonary lesions are cellular 
inflammatory lesions composed primarily of epithelioid, foamy and activated macrophages, large 
numbers of lymphocytes, and small pockets of neutrophils. The ‘Healthy’ classification is here 
reserved for tissue features, such as healthy lung parenchyma, bronchiole epithelium, blood 
vessels, compressed tissue, and any other pulmonary tissues that are present in healthy 
individuals. The ‘miscellaneous’ classification encompasses a broad array of tissue pathology 
features that are not found in healthy tissue, that are not part of the specified TB lesions, and are 
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not associated with healthy pulmonary tissue. The miscellaneous classification includes pleural 
pneumonia, adipose tissue, non-TB specific inflammation, as well as staining and processing 
artifacts. Lastly, the ‘empty slide’ classification was included as a separate category, although this 
classification was ultimately not included in the final performance and accuracy analysis of the 
results.  
 
2.2.4 - The LIRA Pipeline  
LIRA was developed as a modular neural network. This implementation of multiple neural 
networks working together follows the natural logic employed by trained researchers to classify 
lesions by intuitively first investigating on a more general, macroscopic level (for Type I lesion 
recognition), followed by a more detailed analysis on a microscopic level to identify other 
pathological features on a cellular level. In preliminary work, we used a single CNN to identify all 
seven classifications. However, due to similarities between multiple lesion types at a microscopic 
scale (such as the necrosis encountered in a Type I Core and a Type II lesion), multiple neural 
networks operating at different visual scales (macro and micro) were used to limit misclassification 
of lesion types. The final approach, illustrated in Figure 2.2, employs a modular architecture [173]–
[176] with three CNNs and two human intervention checkpoints. After a digital image is uploaded, 
in a first step, the macro-classifier (CNN1) identifies the Type I physiological structure with its 
characteristic caseous necrotic center and collagen rim. Human feedback is required after this 
initial step to reduce the false positive rate of Type II lesions misclassified as Type I lesions (see 
also in result section 1). The macro-classifier CNN1 will then identify the individual image areas 
either positively or negatively for the Type I pathology features. Based upon the macro-classifier 
CNN1 prediction, the digital image areas are partitioned into two separate data sets, classified as 
‘Type I’ or ‘not Type I’ lesion. Subsequently,  both the positively or negatively identified image 
areas are further analyzed at a microscopic level based on cell types, by either the CNN2 or the 
CNN3 micro-classifiers. Both CNN2 and CNN3 require that the digital image sections are tiled 
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into individual image patches that are 80x145 pixels in size. In case a Type I lesion is detected 
after CNN1, then CNN2 analyzes these image patches further and classifies each image patch 
as either Type I Rim, Type I Core, Healthy Tissue, Miscellaneous, or Empty. The remaining image 
patches (not identified by CNN1) are in parallel further classified with CNN3 as either Type II, 
Type III, Healthy, Miscellaneous, or Empty.   
The output of the implementation of the three CNNs uses raw image patch counts (RIPC) 
per classification category, which are the sum of the tiled image patches for each classification. 
RPIC are classified, classification locations recorded, and subsequently visualized as colored 
overlays on the digital image. Every classification category is represented by a different color for 
easy visualization, qualitative analysis and result verification (See Figure 2.1). The classifications 
with unique colors for the seven pathology classifications are then overlaid and smoothed with a 
node labeling algorithm [181], with each image patch classification being considered an individual 
node, onto the original H&E stained scanned digital image. The digital image of the lung lobe with 
colored overlay is then inspected and verified by the user at a second human intervention 
checkpoint, and at this point, the user can make changes before the final classification 
calculations are performed (Figure 2.2). Ultimately, the final output of LIRA using the two human 
intervention checkpoints includes the enumeration of the various lesion types and the calculation 
of area of lung involvement per classification category (presented as % lung involvement).  
 
2.2.5 - Neural Network Training 
All CNNs in the LIRA pipeline were trained using the Keras 2.0 machine learning 
framework in Python 3.5, on an NVIDIA Titan X GPU. Using a built-in human-in-the-loop 
classification tool for LIRA, trained research technicians assisted in creating the training set for 
CNN1 by collecting 791,000 individual image patches with a patch size of 128x128 pixels. The 
purpose of these patches was solely to identify the Type I lesion structure at a macroscopic level. 
Additionally, 1.2 and 1.3 million image patches with a patch size of 80x145 pixels were collected 
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in a similar manner for further classification at a microscopic level for both the Type I (CNN2) and 
Non-Type I lesion classification (CNN3), respectively. 
Each CNN model was subsequently trained on the provided training set of image patches, 
with the following parameters as implemented in Keras 2.0. Values for training and validation 
were initially chosen using a Bayesian Optimization Algorithm, and values were further adjusted 
by hand. The composition of each of the neural networks is presented in Table 2.1.  
 
Table 2.1. Tables explaining the specific details on the creation of our model. The top table is the 
makeup of the Type I detector (CNN1), and the bottom table contains the information for the other 
two CNN (CNN2&3).   
 
2.2.6 Validation Of Software  
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After training the CNNs, a validation step was included using a separate digital image set. 
Validation of the entire LIRA pipeline was performed by comparing results to a classical manual 
pathology readout. First, the performance of the LIRA software was assessed to recognize the 
various lesion types, i.e., calculation of the percent error per lesion type by LIRA when compared 
to the analysis by the experienced TB researcher (as baseline). Second, the percent agreement 
between four board-certified veterinary pathologists (American College of Veterinary 
Pathologists) was calculated by comparing the results after classifying image patches with and 
without LIRA assistance. Lastly, the histopathology readout was measured more robustly by 
calculating a reliability coefficient developed to measure the agreement among observers, using 
the Krippendorff’s alpha coefficient [182]. The coefficient was calculated and based on data 
generated by four board-certified veterinary pathologists with and without the use of LIRA, as well 
as four research technicians with the use of LIRA.  
To assess the agreement in the analysis by the pathologists with and without the use of 
LIRA, seven randomly selected scanned images of single lung lobes were selected for the 
software validation step. In a first step, the pathologists hand labeled each 80x145 pixel image 
patch using one out of seven classifications (same as described for LIRA). Data on every 80x145 
pixel-sized image patch classification was collected as RIPC. The hand-labeled result by the 
pathologists and technicians generated a seven-color classification overlay for every digital 
image. The result also included the calculated RIPC for each of the seven classification categories 
for every digital image of a single lung lobe. In a second step, seven days later, the pathologists 
and research technicians were presented with the same seven digital images of lung lobes to 
review, this time with the assistance of LIRA predictions for both the macroscopic (CNN1) and 
microscopic classifications (CNN2, CNN3). Both the pathologists and technicians were requested 
to review the LIRA predictions, and to intervene and potentially modify the Type I lesion detection 
at the first intervention step (CNN1 LIRA prediction) and/or the individual image patch 
classifications at the second intervention step (CNN2, CNN3 LIRA prediction) if needed.  
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The analysis of the validation results included the calculation of the percent agreement in 
prediction results between the four pathologists[183]. Using percent agreement does not take into 
account that classifications may have been selected by chance; it is, however, still a commonly 
used metric and useful as a first measurement in the context of this work [184], [185]. The formula 
is PA=NxANyA+ND×100 where PA is percent agreement, NA is the number of agreed upon 
ratings divided by the total sum of cases, and ND is the total cases of disagreements.  
 As mentioned before, the classical histopathology readout is only semi-quantitative and in 
some cases subjective, which makes comparisons of the LIRA prediction results to a gold 
standard unreliable.  To study the variance in readouts between the different pathologists after 
manually reviewing the digital images, we opted for an inter-annotator comparison approach to 
calculate the agreement among the pathologists with and without LIRA. The Krippendorff’s alpha 
coefficient calculation using nominal data and any number of observers was implemented here 
as an analysis tool to quantify the agreement between the prediction results of multiple observers 
with or without assistance with LIRA. The formula is provided below, where nuc = the number of 
values c assigned to unit u. nuc  m observers, nuk by analogy nu. =cnuc = the number of values 
assigned to unit u, n.c =u|nu.2nuc = the number of pairable values c occurring in the reliability data 
(omitting all units with lone or no values: nu.1) n.. =u|nu.2nu. = the total number of all pairable 
values in the reliability data (omitting all units with lone or no values: nu.1); n.. mN. 
 
The Krippendorff’s alpha approach takes into account chance classifications, can be used with 
nominal data, using more than two raters, with multiple categories, plus the approach can be used 
with large datasets [186]. Each image patch was considered as a separate observation, and the 
classifications from all four pathologists were used for calculations. The Krippendorff’s alpha 
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approach provides a coefficient between 0 and 1, with α < 0.667 being rejected, α ≥ 0.667 being 
the lowest acceptable limit, and α≥ 0.800 being considered to have good agreement [187].    
 
2.2.7 - Evaluation Metrics For Performance And Accuracy Of The Neural Networks  
For CNN1 the sensitivity was calculated by 
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒(𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒+𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒) ∗ 100 and specificity 
was calculated using  𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒(𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒+𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒) ∗ 100. These numbers were acquired by counting 
the number of true positives, true negatives, false positives, and false negatives within 70 digital 
images of lung lobes that had been classified by the CNN1 detector. This approach did not 
stipulate that the entire lesion was detected, but any area of the lesion be correctly or incorrectly 
identified.  
In order to determine the accuracy of CNN2 and CNN3, a standard or ground truth 
classification was established on 12 digital images by a researcher with substantial experience 
analyzing C3HeB/FeJ mouse pathology (author Bryce C. Asay). The researcher manually labeled 
each image patch using one of the seven different classifications described earlier. The 
researcher was also the main individual training LIRA, and therefore this analysis was mainly 
aimed to investigate whether LIRA performed adequately and met expectations. The 12 digital 
images containing a lung lobe consisted of three images primarily composed of Healthy Tissue, 
three images primarily composed of Type I lesions, three images composed of Type II images, 
and three images composed primarily of Type III lesions. Total image patch counts for only the 
classification of interest were then used to calculate the percent error for each individual 
classification for LIRA compared to the manual labeling result by the researcher.  
 
2.2.8 - Computer Code Availability 
 At publication, the computer code will be made open source to the research community 
(Github), and we will include a statement in the Methods section, under the heading "Code 
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availability", indicating where and how the code can be accessed without any restrictions. This 
will be made publicly available through the Lenaerts lab Github repository.  
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2.3 - RESULTS 
2.3.1 - Ability Of CNN1 To Identify Caseous Necrotic (Type I) Lesions 
  After training CNN1 with the digital image training set, a validation step was introduced to 
evaluate the sensitivity, specificity, and false-positive rate of classifying Type I lesion cores. After 
an image is uploaded, the Type I object detector (CNN1) is used to macroscopically detect the 
caseous necrotic center of Type I lesions (Figure 2.1, 2.2). LIRAs CNN1, the Type I object 
detector, showed to be consistent in identifying and delineating Type I lesion structures, with a 
sensitivity of 86.36%. CNN1, however, shows a high false-positive rate by misclassifying other 
lesion types for a Type I with the specificity of 55.11%. Most misclassifications occurred when 
large areas of cellular necrosis were visible in the center of Type II lesions, which on a single 
image patch shows a similar cellular composition as the Type I cores. The high recall rate is likely 
the result of the training set for the creation of CNN1, having an insufficient number of images 
needed for training. To decrease the false positive rate for CNN1, continued training with a larger 
training set might be an area of improvement for future iterations. Despite the high recall rate, we 
opted to retain CNN1 as it facilitated the rapid identification of Type I lesions for the user, and it 
provided an accurate demarcation of its margins from surrounding lesions or tissue. For instance, 
the validation results showed that the inclusion of CNN1 decreased the inconsistencies seen after 
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hand labeling among multiple pathologists in identifying and demarcation of the Type I Rim. 
Overall, the addition of CNN1 proved to be a substantial time saver as more time is allocated to 
accurately identify the margins of the Type I lesions than in the removal of potential 
misclassifications.  
 
2.3.2 - The Accuracy For LIRA In Comparison To An Experienced TB Researcher  
Table 2.2. LIRAs accuracy measured by percent error, which measures the precision of each of 
the predicted classifications. 
  
 
After the initial positive or negative classification by the macroscopic object detector 
CNN1, the areas designated as Type I were further classified by CNN2, and the remaining image 
patches were classified in parallel by CNN3 (Figure 2.1, 2.2). To determine the accuracy of the 
overall pipeline (Figure 2.2), a ground truth was established on 12 digital images by a researcher 
with substantial experience analyzing C3HeB/FeJ mouse pathology. These 12 images consisted 
of lung lobes composed of three Type I dominated tissues, three Type II dominated tissues, three 
Type III dominated tissues, and three predominately Healthy tissues. Total image patch counts 
for only the classification of interest were used to calculate the percent error per individual 
classification. The results for LIRA without human intervention were then compared to the manual 
labeling results by the researcher. As seen in Table 2.2, the overall percent error for all seven 
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classifications was 12.11% across all 12 digital images. Healthy Tissue and Type III had the 
lowest percent error, while Type II had the highest percent error at 38.37%.  
 The high percent error observed for the Type II lesions for LIRA compared to the 
experienced researcher was the result of poor demarcation by LIRA of the surrounding lesion 
tissue, which is often composed of compressed tissue and in some cases, aggregates of 
extracellular DNA (potentially NETs). Compressed tissue is the result of lesions pressing into 
healthy lung parenchyma, which changes the morphological structure. The aggregates of 
extracellular DNA are considered part of a Type II lesion, whereas compressed tissue, as defined 
here, is considered “Healthy Tissue”. Another area contributing to the decrease in accuracy by 
LIRA was from processing artifacts to generate the microscope slides. This included areas of high 
red blood cell number, which were incorrectly classified by LIRA as Type III. Also, minor 
differences in the staining procedure of the microscope slide affected the intensity and colors of 
the tissue and its images, which resulted in slight differences in classification by LIRA. Lastly, 
sectioning artifacts such as microtome occasional knife chatter, lines, or fragment holes were also 














2.3.3 - Improved Agreement Of Histopathology Classifications Among Pathologists Using LIRA 
  
Figure 2.3. Line graph representation of each cohort: LIRA, Pathologist, Pathologist+LIRA. Left 
Y-axis is the Raw Image Counts generated during classifications, Right Y-axis is each of the 
classifications, and the bottom X-axis is the image number. Each colored line represents an 
individual pathologist or LIRA. As visualized, there is a smaller range of raw image patch counts 
when the pathologists are assisted by LIRA (Pathologist+LIRA) than when the pathologists are 
unassisted (Pathologists). Many of the values that the Pathologists+LIRA gave are only 








To evaluate the performance of LIRA in terms of reproducibility and concordance between 
users, a second validation step was included using a previously unseen digital image set. Seven 
randomly-selected scanned images of single lung lobes were used for this validation step. The 
goal for this validation step was to compare the pathology classification results from the classical  
 
Figure 2.4. Image 3, which consists of Type I Core (Red), Type I Rim (Blue), Type II lesions 
(Green), Type III (Yellow), and Healthy Tissue (Pink). The top row consists of pathologists hand 
labeling the tissue, the middle row consists of pathologists with the assistance of LIRA, and the 
bottom row is the labeling by the research associates with the assistance of LIRA.  Black arrows 





pathology analysis approach of four pathologists or four research technicians, to the prediction 
results of LIRA with pathologist assistance (Figure 2.3). The comparison focused on three criteria: 
1) the accuracy of both approaches in identifying the correct pathology classification; 2) the 
accuracy of demarcation of lesion margins that affect the area of lung involvement, and 3) the  
 
Figure  2.5. Color overlay results of 4 images from our validation set with (a) Image 3, (b) Image 
5, (c) Image 6, and (d) Image 7. The far-left images are  the best-labeled Pathologist image, the 
middle images are the poorly labeled Pathologist images, and the far-right are the poorly labeled 
Pathologist image but with LIRA assistance. When a pathologist who labels poorly has assistance 
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from LIRA, the final result is in more in accordance with the best-labeled pathologist example. 
This allows studies to be comparable across multiple pathologists, limiting the amount of error 
that might have been introduced.  
 
variability between users. For this purpose, the pathologists were first given seven images to 
classify each image patch by hand.  After one week, the pathologists used the same seven digital 
images in a random order to classify each image patch now with the assistance of LIRA. Using 
the classical pathology approach, the results of the four pathologists showed a consensus on the 
specific lesion classification in general, but not always on the extent of the percent lung 
involvement (Figure 2.4). The disease classification categories with the most variability in results 
were Type I Rim and Type II lesion types, which subsequently also impacted the Healthy tissue 
classification indirectly. The variation in results within these categories was mostly the result of 
inaccurate demarcation of lesion margins after manual labeling by the pathologists. Specific 
examples detailing the high variability for each of these classifications are presented in Figure 2.5 
and Supplemental Figures 2.3 & 2.4.  
As LIRA makes classification predictions per image patch at a microscopic level, it became 
clear in the validation step that both CNN2 and CNN3 can identify certain areas of a single lesion 
as one classification whereas another area of the same lesion could be identified as a different 
classification. An example of this can be observed in Figure 2.4 (Image 3), which consists of one 
Type I and multiple Type III lesions. In this example, for the pathologist-only readout, an observed 
disagreement was seen for the demarcation of the Type I Rim and the start of the Type III lesion 
that is adjacent to it.  Only one of the four pathologists (pathologist 2) had accurately identified 
neutrophil-rich regions of the Type III lesion (in green), which is an unusual event for a Type III 
lesion. For the pathologist-assisted LIRA results (Figure 2.4), three out of four pathologists 
decided to reduce the lung area for the Type I lesion after being prompted by LIRA. In addition, 
all four pathologists recognized regions of neutrophil infiltration only after the assistance of LIRA 
(in green). Another disagreement between pathologists was observed regarding the classification 
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of bronchial airways and artifacts. For the pathologist-only readout, two out of four pathologists 
classified the bronchial airways as Healthy tissue, and the two remaining pathologists classified 
these regions as Empty slide. The same was observed for a tissue processing artifact visible on 
the image scan (a fragment hole artifact), which was classified by two pathologists as Healthy 
tissue and by the other two as Empty slide. With the assistance of LIRA, the results for all four 
pathologists were now in agreement, and both the bronchial airways and the artifact were 
classified correctly as empty slide. The change in the classification that occurred at the 
pathologists’ checkpoints after CNN2 and CNN3 showed to have a significant impact on the 
output data in terms of reducing the variability and increasing reproducibility of the results.    
 
Table 2.3. For each image, the percent agreement and Krippendorfs alpha were calculated to 




Reproducibility of histopathology analysis regardless of the pathologist analyzing the data 
or the variation that can occur over time is important when comparing data across preclinical 
studies or laboratories. To measure whether the agreement between pathologists increased with 
the assistance of LIRA, multi-rater percent agreement, and the Nominal Krippendorff’s alpha 
approach were used. Each image patch was considered a separate observation for the analysis, 
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and the percent agreement was calculated per image. The multi-rater average percent agreement 
without LIRA for the four pathologists across all images was 87%. Images showing the lowest 
agreement consisted of primarily Type I (Images 1&3) and the Misc. classification (Image 7) 
(Table 2.3 and Figure 2.5D). With the assistance of LIRA, the percent agreement for the four 
pathologists increased across all images, and there was a 53% decrease in disagreement overall 
to achieve an overall agreement of 94%. The most prominent increase in percent agreement was 
observed for the images containing Type I lesions and the Misc. classification.   
Using a more refined additional metric of analysis, the Krippendorff’s statistical analysis 
approach was used for calculating the nominal alpha coefficient. Again, each image patch 
classification by the four pathologists was seen as a separate observation. Manual labeling of 
seven pathology features for seven images by the four pathologists showed an average alpha of 
0.796 (Table 2.3), which is interpreted as tentative. Four of the seven classified images were 
below the 0.80 threshold, which means the pathologists failed to achieve good agreement on the 
classification of those images. In contrast, when performing the Krippendorff’s analysis on the 
data generated by the four pathologists with the assistance of LIRA, the calculated average alpha 
was 0.91 (Table 2.3). The Krippendorff’s analysis results for all seven images were above the 
0.80 threshold, and results for all seven images were above the 0.8 threshold, which is considered 
good. These results confirmed our observations using percent error, providing further evidence 
of the benefits of LIRA assistance.  
The increase in agreement among pathologists with the assistance of LIRA was the result 
of two main beneficial factors. First, the use of the LIRA software increased the accuracy of the 
demarcation of lesion margins, which affected the percent lung involvement in various categories 
indirectly. In addition, LIRA prompted the pathologist to revisit and re-analyze specific areas in 
the lungs, often small in size, which were often overlooked using the classical histopathology 
approach. Examples are shown in Figure 3 (Pathologist 1, Pathologist 1 + LIRA) and Figure 4 
(Images 6 & 7), which show the improvement of lesion margin demarcation with LIRA assistance. 
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With the use of LIRA, the classification of the pathological features not only improved the 
agreement between pathologists, but the results tended to be closer to the predictions made by 
the most experienced TB pathologist (Pathologist 4) (Figure 2.3). An example where LIRA 
prompted the user to re-analyze their initial prediction is shown in Figure 3D. Here, a large area 
of fibrotic tissue is observed, which should have been classified as miscellaneous as it does not 
fit any other definition. With the assistance of LIRA, the pathologist changed the classification to 
miscellaneous, which was in agreement with the other three pathologists. The accuracy of 
classifying image features in the miscellaneous category is mostly dependent on the background 
and level of expertise of the user, and therefore this category will always be the most difficult to 
standardize across multiple users. The assistance of LIRA in the miscellaneous category, 
however, did minimize the misclassifications in this category and was an added benefit.  
In summary, the results of the validation tests showed a clear benefit of using LIRA 
assistance in the pathology readings by board-certified pathologists, and this by improving the 
accuracy in the demarcation of lesion margins as well as prompting the user to re-analyze certain 
areas thereby increasing conformity and reproducibility of an otherwise subjective readout. 
Additionally, compared to previous manual pathology analysis methods employed by the four 
pathologists taking about 15-30 min manual effort per lung lobe, an average decrease in manual 
analysis time of 82% was observed, now reducing the histopathology manual analysis to 3-10 
min semi-automated effort per lung lobe (with 5 minutes on average per lung lobe).  
 
2.3.4 - Trained Research Technicians + LIRA 
In a final validation assessment, we investigated whether LIRA could be easily employed 
by research technicians, and how their prediction results would compare to those made by 
specialized pathologists. For this purpose, four research technicians were first trained in the 
identification of lesion types of the C3HeB/FeJ animal model (Trained Research Technician + 
LIRA). The technicians were then asked to analyze the same seven digital images of a single 
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lung lobe, in that same manner as performed by the pathologists for the validation step. The 
results showed that for the research technicians with the assistance of LIRA, similar classification 
predictions were obtained as described earlier for the pathologists. Most notable was again the 
accurate demarcation of the lesions with LIRA assistance (Figure 2.4). The results by research 
technicians assisted by LIRA exhibited a slightly higher variability when compared to the results 
of the pathologists assisted by LIRA. One area where the research technicians using LIRA 
showed less accurate results was in the identification of the Miscellaneous Tissue category. For 
example, in Image 7, a large area of fibrotic inflammation was not identified by the research 
technicians, whereas this was correctly classified by the pathologists using LIRA (Figure 2.4, 
Misc., Image 7). Two out of four research technicians correctly identified fibrotic inflammation 
(Figure 2.4, Image 5), which was also observed by the pathologists.  
In summary, the output of the research technicians with LIRA was remarkably similar to 
that of the experienced pathologists using LIRA, except when uncommon or infrequent tissue 
types were present.  Taken together, the data of the validation study indicates that even with the 
implementation of AI, a certain level of pathology expertise is still preferred to quantify certain 
unique lesion pathology accurately.  
 
2.4 - Discussion 
 Traditional histopathological analysis generally involves an experienced board-certified 
pathologist, often using a semi-quantitative scoring system to identify and quantify unique 
disease-specific pathology features [79], [188]. Specific scoring criteria are developed which can 
distinguish between various disease states, thereby informing about disease progression or on 
effects of treatment intervention. These scoring criteria are then applied in double-blind 
histopathology analysis to reduce bias and variability. However, issues such as reproducibility 
between studies and variability in readouts by different pathologists still exist, and this continues 
to be an area of active research [116], [189]. In non-clinical TB animal studies used in drug and 
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vaccine development, studies are often long term, require multiple time points, and generally 
occur in more than one laboratory to confirm that novel treatments or interventions are 
reproducibly efficacious. To evaluate the progression of pulmonary lesions in TB animal models, 
a histological grading system was developed years ago, based on grading granulomatous lesions 
for inflammatory cell numbers and their infiltrative distribution pattern [159]. The pathologist would 
then calculate a mean total lesion score for individual tissues; as normal (score of 1), mild (score: 
1–3), moderate (score: 3–6), severe (score: 6–8) to reflect the disease state per animal. The 
variability in histopathology analysis between studies, time points, and individual pathologists, 
owing to the subjective nature of this method, was often substantial thereby making it difficult to 
interpret results. In addition, studies would be time-consuming, and results over time will be 
affected by user fatigue. In this report, we describe the development of novel software for a rapid 
automated and unbiased digital image analysis using a machine learning approach based on 
convolutional neural networks to evaluate the histopathology of mouse models for tuberculosis in 
a quantitative manner. The goal was to make the software intuitive for its user, as well as facilitate 
and accelerate histopathology analysis for the non-expert.  
 We report here on the training and validation of a model for the accurate classification of 
seven pathology features using histopathology images. The model uses human classifications to 
learn robust features from a large number of H&E stained image patches. The model is currently 
suitable for quantitative lesion identification of the C3HeB/FeJ mouse model for tuberculosis. 
Initial attempts tried to implement a single convolutional neural network to identify all seven 
histopathology classifications. However, significant misclassification was observed caused by 
similar cell compositions in more than one lesion type. Therefore, LIRA was created using three 
individual neural networks to create a single modular network to generate more accurate 
predictions based on both macroscopic- and microscopic histopathology events. Currently, the 
accuracy of the model is not sufficient to rely solely on the implementation of the LIRA software 
without any human intervention. Two human intervention checkpoints for the user are still 
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required: first, to confirm and potentially modify the Type I lesion prediction (CNN1) and second, 
to confirm the individual image patch classifications made by LIRA (CNN2, CNN3). Moreover, 
human intervention can help prevent the misclassification of infrequent pathology events and 
artifacts on which the specific CNN had not previously been trained. Of note, certain 
misclassifications by LIRA may ultimately be beneficial to the process as they can bring a 
particular pathology feature to the attention of the user, and can prompt the researcher for closer 
analysis. Future iterations will focus on improving the model by including additional datasets for 
training when more studies become available to increase LIRA’s performance under all 
circumstances.  
 There were multiple advantages to using assistive software in identifying and quantifying 
disease states with digital image analysis. First, we observed a significant reduction in analysis 
time and user-fatigue, whereby an 82% decrease in time was achieved for quantitative analysis 
in comparison to the standard histopathology scoring methodology. Second, with the assistance 
of the software, the variability of the predicted classifications among different pathologists was 
greatly reduced. Of importance, with the assistance of LIRA, a more accurate pathology 
comparison will be possible across multiple animal studies, different longitudinally time points, 
and studies performed at multiple laboratories. Where LIRA outperforms the individual pathologist 
is the consistent and accurate demarcation of lesion margins, as well as the detection of small 
regions on a microscopic level, which both substantially affects the quantitative analysis of the 
lesion area involvement. Pathologists and LIRA, in most instances, both correctly classify the 
lesion type, but the variability in the results from classical pathologist readouts is derived from the 
imprecise or inconsistent demarcation of lesion margins. Where pathologist expertise and 
intervention is still needed and preferred is for the identification of infrequent pathology events or 
unusual artifacts.  As also described for other applications in medical image analysis, diagnostic 
confidence never reaches 100%, and combining machine learning and physician or pathologist 
experience will enhance system performance [190].  
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 During the development of the LIRA software, it became apparent that the quality of tissue 
sample preparation can impact the accuracy of the results of the software. LIRA is affected by 
features such as the presence of high red blood cell numbers and processing artifacts, which led 
to the software incorrectly classifying these regions as pulmonary lesions instead of healthy 
tissue. Deviation from the sample preparation protocol presented in our methods section, 
including using frozen sections or changes in section thickness, will also result in a decrease in 
accuracy. When sample preparation varies, it is recommended that a new model be trained on 
image patches generated with these new protocols. In addition, the current iteration of LIRA is 
designed to identify lesion types for C3HeB/FeJ pulmonary tissue collected between 6 to 10 
weeks post-infection. We have tested LIRA on more commonly used BALB/c or C57BL/6 
pulmonary tissues infected with Mtb, and results showed these models are suitable for LIRA use.  
A future direction to improve the current LIRA pipeline are to generate a new classification 
for the surrounding Type II tissue and to increase the sensitivity of CNN1. LIRA predictions for 
Type II lesions could be significantly improved by creating a separate class for the surrounding 
tissue, primarily composed of aggregates of extracellular DNA and compressed tissue. And an 
increase of the Type I detector (CNN1) sensitivity might allow omission of the first human 
intervention checkpoint. The current false-positive rate for the Type I Core is the result of the 
limited sample numbers that were available at the time of training CNN1. With an increase in the 
data available for training and the utilization of generative adversarial networks (GANs) [132] and 
pre-trained neural networks [191] represent possible future solutions.  
A potential adaptation of LIRA’s architecture for use in TB preclinical models could be an 
enhancement beyond just classification and quantification of infection in tissues. Researchers can 
combine lesion classification features with additional quantifiable measurements. Of particular 
interest in TB drug and vaccine development is to include the mycobacterial quantification metrics 
of each individual lesion. The goal would be to integrate precise measurements on bacterial 
numbers after fluorescent staining [74], [192], as well as bacterial aggregation sizes, level of 
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fluorescence, and the average number of bacteria as a metric of area. With the availability of 
matrix-assisted laser desorption ionization (MALDI) imaging to assess drug levels across 
pulmonary lesions [18], [193], one can envision the development of a model that would integrate 
data sets from digital lesion pathology with bacterial metrics as well as drug exposure. 
 In conclusion, LIRA does not replace the histopathology analysis by pathologists but 
instead intends to improve the accuracy, speed, and reproducibility of the analysis. While there 
are certain limitations with the current model, these can easily be corrected and adjusted. The 
ability to more quickly and more accurately assess the effect of treatment interventions on 
histopathology of target organs will improve the evaluation of the efficacy of novel antibiotics and 
vaccines. Our demonstrated approach is not limited to TB and can be modified to include 
additional diseases and animal models, by creating new training sets and modifying the original 




CHAPTER 3: IMPLEMENTATION OF LIRA TO ASSESS TREATMENT RESPONSES USING 
THE C3HEB/FEJ MOUSE EFFICACY MODEL. 
 
3.1 - Introduction 
Not everyone who becomes infected with Mtb will develop active tuberculosis. In 90% of 
cases, the infected individual will exhibit latent disease, which is when a person is infected with 
Mtb but does not have overt signs of an active TB infection. They are not infectious, and the only 
sign of infection is a positive reaction to the tuberculin skin test or TB blood test. The risk of 
developing active disease is higher for individuals with an impaired immune system, especially 
those with a co-HIV infection or diabetes.  Even though symptoms are benign in latent TB, 
treatment is essential to reduce the risk that the infection will progress to active TB disease. 
Depending on the state of the disease (active or latent), age of the patient, overall health, if 
antibiotic resistance is confirmed, and location of the infection within the host, the duration and 
specific drug regimen will vary. For latent disease, the treatment consists of Isoniazid (INH) and 
Rifapentine (RPT) for 3 months [194]. For active disease, there are treatment regimen guidelines 
for drug-susceptible TB, drug-resistant TB, multidrug-resistant TB (MDR TB), and the uncommon 
extensively resistant tuberculosis (XDR TB) [195]. There are two different phases in treatment 
regimens in patients for drug-susceptible TB disease, using first-line therapies, called the 
intensive phase and the continuation stage. The intensive phase includes a combination of INH, 
RIF, PZA, and EMB taken 7 days/week for 8 weeks. This is followed by the continuation phase 
which consists of additional treatment of INH and RIF for 7 days/week for an additional 4-7 months 
[5]. For the purposes of the aim analysis, I will only be providing a condensed background 
synopsis on the antibiotic INH. INH is bactericidal to actively dividing extracellular and intracellular 
bacilli, and bacteriostatic to slow-growing bacilli. It is a prodrug that must be activated by the Mtb 
catalase-peroxidase enzyme KatG which later forms a covalent adduct with the NAD cofactor. 
The INH-NAD adduct acts as a binding competitive inhibitor for InhA in the FAS II fatty acid 
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biosynthesis pathway[196]. In the presence of INH, actively growing Mtb will undergo cell lysis, 
but after removal of the drug the surviving bacilli will resume rapid growth and division[197]. Drug 
resistant TB relies on second-line therapies which entail longer treatment times of 18+ months, 
increased negative side effects, and consist of a combination of thioamides, diarylquinoline, 
nitroimidazole, fluoroquinolones, and aminoglycosides. XDR TB treatment is completely 
dependent on the drugs that are still effective and currently relies heavily on the newly developed 
drugs such as BDQ or delamanid [198].  
Because treatment is at a minimum 6 months in duration, non-adherence to TB treatment 
is of major concern. In a recent study, it was reported that 33% of patients missed either one or 
two doses within a 2 week period [199]. Failure to properly adhere to treatment schedules can 
result in an increased risk of the spread of TB and may lead to the development of drug resistance.  
While resistance is considered an uncommon event, it is increasing to an annual rate of more 
than 20% [200]. This is a disturbing statistic since, according to the European Centre for Disease 
Prevention and Control (ECDC) 2015 report, MDR TB in Europe had a success rate of 46% and 
only 23.2% for XDR TB [201]. The WHO observed slightly higher rates with 56% of patients with 
MDR TB having a successful outcome [202].  Drug resistance is an increasing problem, but with 
the discovery of novel therapies, such as delamanid, pretomanid, and BDQ, we can increase the 
success rate of therapy.  
When a potential new drug candidate is identified, it goes through iterative phases of 
testing. This process is costly, with only a 13.8% probability of success that the proposed 
compound will be approved [203]. The percentage of success is important in prioritizing research 
funds and time. Having models that more accurately represent human outcomes is critical to help 
mitigate the risks involved. Compounds are initially tested in vitro, commonly with cell assays, and 
if positive results are seen, compounds are further tested in vivo using animal models. Animals 
are commonly used in TB pharmaceutical research because they offer the complexities of a host 
environment not available in vitro and help predict the efficacy, safety, and the optimal regimen 
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for human patients [204], [205]. There are many metrics measured in animal models used to 
determine the efficacy of TB drugs such as animal morbidity (weight, posture, and physical 
appearance), mortality, pathology, and bacterial burden (culturable and visual). Some aspects, 
such as monitoring the animal's weight, are quantitative with little room for user interpretation, 
while other metrics such as pathology currently rely on a mixture of qualitative and quantitative 
results to accurately describe the disease. Different types of data types collected during an 
experiment provide various benefits and limitations that need to be considered in their relation to 
proving or disproving the hypothesis.   
In our laboratory, the C3HeB/FeJ mouse model has been developed to be used as a tool 
in preclinical development of novel drugs and regimens. Throughout a drug efficacy trial one of 
the most important metrics that is measured is the severity of pulmonary lesion development. 
Untreated C3HeB/FeJ mice aerosol infected with a moderately virulent strain of Mtb consistently 
develop three independent lesions types termed Type I, Type II, and Type III (Figure 1.2) [74], 
[206], [207]. Type I lesion can be broken down into two separate classifications, the Type I Core 
and the Type I Rim. The Type I Core is everything from the caseous necrotic center to the fibrotic 
rim, and the Type I Rim is from the rim outward comprised mostly of fibroblasts, epithelioid, and 
activated macrophages, and occasional lymphocytes. Type II lesions are composed of a rapidly 
expanding caseous necrotic center comprised primarily of neutrophils but lacking the 
encapsulation of Type I lesions. Type III lesions are cellular, inflammatory lesions containing 
macrophages, lymphocytes, and small pockets of activated neutrophils. 5 weeks post aerosol 
infection lesions become distinguishable [74], and historically our laboratory has collected 
pathology within the 8 to 10 weeks window after aerosol. This is to allow for sufficient 
advancement of the pathology of Type I lesions, as well as the enrichment of mice that have Type 
I lesions. 10 weeks past the aerosol infection, the Type I lesions continue to grow in size which 
makes histology processing, especially sectioning, difficult to perform. Drug treatment in this 
mouse model and others have altered lung pathology development, generally by improving lung 
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pathology over time. This is demonstrated by previous studies that during treatment, lesion 
progression will either begin to resolve or halt lesion progression [208], [209]. However, it has 
been observed that efficacious antimicrobial drugs can also result in a substantial increase in the 
inflammatory response and lesion development. This immunopathologic event caused by 
treatment can result in a spike in morbidity and increased lung consolidation. In our experience, 
we found treatment with a new experimental drug being tested in our laboratory resulted in Type 
I lesions, which progressed to cavitary disease (personal communication, Dr. A. Lenaerts). In 
scoring pulmonary pathology, signs such as healing of lung pathology and decrease in lesion 
involvement are usually implying a drug is efficacious, but it is important to take into account that 
drug treatment could initially worsen lung pathology  
Treatment efficacy is also influenced by multiple factors, including the lesion-specific 
properties that influence drug penetration and access [210], [211]. Humans and the C3HeB/FeJ 
TB animal model both display a heterogeneity of lesion types that have varying 
microenvironments and physical lesion structures. Another similarity is that multiple different 
lesion types can exist within a single host independent of each other which can hinder attempts 
for successful treatment [22], [149]. The fibrotic rim within the C3HeB/FeJ mouse model Type I 
lesions is densely vascularized meaning the pharmacotherapy is often successful in these 
regions. In contrast, the Type I caseous center has had most of its vascular architecture destroyed 
causing a failure to properly mount an adequate immune response and little drug availability from 
the blood. This means the drug needs to diffuse across the cellular rim to the necrotic center 
without the aid of active or facilitated transport mechanisms. If an adjunct treatment strategy were 
available that would improve drug delivery into the encapsulated lesions (by, for instance, 
decreasing the integrity of the Type I in C3HeB/FeJ mice), it might shorten the length of treatment. 
Potential adjunct therapies include inhibition of the eicosanoid pathway [212], statins [213], [214], 
and vitamin D[215]. One adjunct therapy that had been explored in our laboratory was the use of 
losartan (LK) in an attempt to inhibit the formation of the fibrotic capsule in the Type I lesion [206]. 
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The hypothesis was that C3HeB/FeJ TB infected mice treated with LK will have inhibited 
progression of the collagen rim in the Type I lesion allowing for greater penetration of drugs 
resulting in reduced bacterial burdens. Adjunct therapies, such as LK, will need to be combined 
with current clinical therapies to see an increase of efficacy or a decrease in therapy duration. 
LK is an antihypertension drug that is commonly used to treat high blood pressure and 
provide protection to kidneys from damage resulting from diabetes. It works by inhibiting the 
vasoconstriction of blood vessels and increase blood flow[216]. This inhibition by LK specifically 
results in the reduction of fibrinogen, collagen I, collagen II, fibronectin, and TGF-β1[217]. There 
has been a reported secondary effect of LK in the reduction of fibrosis in multiple diseases such 
as skeletal muscle injuries [218], ovarian cancer[86], and bleomycin-induced lung fibrosis[219]. 
An earlier study in our laboratory evaluated the addition of LK to existing drug treatments in the 
TB C3HeB/FeJ animal model with the aim of using this anti-fibrolitic chemotherapy to manipulate 
the collagen rim of the Type I granuloma (study by Dr. Emily Driver, a Ph.D. student at the 
time)[206]. The goal of the previous study was primarily aimed at determining the effect of adjunct 
combination regimen on bacterial loads in the lungs and used a manual scoring system for the 
lung histopathology analysis.  
Current histopathology scoring metrics utilized a semi-quantitative methodology that is 
non-standardized and highly susceptible to user bias [78], [220]. To reduce bias and errors, 
common pathology parameters and guidelines are often used, such as standardized diagnosis 
metrics, grading, staging, and biomarker scoring. In the case of TB, no set scoring standards have 
been developed, which requires the researchers to develop their own. This makes comparing 
results across laboratories, studies, or even time points difficult. Even if the scoring systems are 
similar, they can result in varying interpretations. It also can mask results because the scoring 
parameters are not sensitive enough to distinguish differences. This is exemplified in TB scoring, 
where an ordinal score is given based upon arbitrary boundaries of the disease percent 
involvement. For instance, if a particular treatment cohort averages 12% lung involvement but 
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another cohort averages 23% lung involvement, with the current scoring system, they can both 
receive the same pathology score, even though biologically, the differences might be significant. 
With the recent advancements in ML and CV, a more targeted analysis with less human bias can 
be accomplished. This allows the reporting of quantitative assessments that are reproducible, 
less prone to human bias, and can be standardized across multiple laboratories and time points.  
 As described in Chapter 2, we demonstrated that LIRA increases the user agreement 
across multiple pathologists scoring the same microscopy slides. This analysis was performed on 
mice following their natural disease progression without any form of treatment or host 
manipulation. Next, LIRA’s performance needed to be tested on lung lesions from the C3HeB/FeJ 
mouse model that had been treated, therapies included immunotherapy and anti-mycobacterial 
drug treatments. ML classification models can be sensitive to changes in the image input, and the 
introduction of drug treatment can be a potential source of noise that may impact the proficiency 
of the model. It is important that the model is verified using standard pathology scoring 
methodology as a control, using C3HeB/FeJ histopathology images that have additional image 
noise from drug treatment, which may influence overall performance. We are hereby using a past 
C3HeB/FeJ study with a combination treatment of LK with classical TB drug treatment as an 
example of how to use the LIRA software in a TB drug treatment study. With the improved 
approach for histopathology analysis using LIRA, we hope in addition to investigate: 1) the effects 
of standard TB drugs on lungs pathology, 2) assess the potential of LK as adjunct therapy for TB, 
and 3) assess how using a targeted computational analysis can alter the interpretation of the final 
results.  
 Of most interest to my thesis was investigating how implementing a targeted data analysis 
approach can change the final interpretation of the data. By comparing historical data analysis 
interpretations using techniques that take a less targeted approach with data generated using 
LIRA, we have shown that there is a difference in the study outcomes. Masking of potentially 
efficacious drugs or major biological events not only makes drug efficacy more costly but also 
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impedes the development of other potential new therapies. With cost, reproducibility, and time 
becoming major hindrances in the development of new therapies, it is imperative that tools are 
developed that overcome these obstacles. LIRA represents a new tool for TB drug development 
that addresses many of the obstacles associated with human pathology scoring while also 
providing additional quantifiable data that was not available previously. LIRA is not only applicable 
to normal disease progression analysis as demonstrated in Aim 1 (chapter 2) but also can 
determine the severity of disease compared to a board-certified pathologist while quantifying 
additional data metrics for further analysis.  
 
3.2- Materials and Methods 
All methodologies for the animals, bacteria, chemotherapies, aerosol infection, and 
stereology were performed previously within the Lenaerts laboratory. Inclusion of this information 
for my dissertation is for convenience purposes but more detailed information can be found in 
Driver et al. [206]. The histology preparation, staining, microscopy, pathology scoring, and 
analysis were planned and executed by Bryce Asay for the purpose of this dissertation.  
 
3.2.1 Animals 
Female C3HeB/FeJ mice aged 6 to 8 weeks were purchased from Jackson Laboratories, 
Bar Harbor ME. Animals were housed in a bio-safety level III animal facility and were routinely 
monitored. Mice were specific pathogen-free which was verified by testing sentinel mice housed 
within each colony.  
 
3.2.2 Bacteria  
M. tuberculosis Erdman strain (TMCC 107) was used for aerosol infections and was 
prepared as previously described [221], [222]. In summary, Mtb bacilli were grown as a pellicle to 
generate seed lots. Working stocks were cultured by growing individual seed lots to mid-log phase 
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in PB medium containing 0.05% Tween 80 (Sigma Chemical Co., St. Louis, MO) in three 
passages. Before storage at -70֯C titers will be calculated by colony counting on 7H11 agar plates 
and divided into 1.5 ml aliquots.  
 
3.2.3 Chemotherapies 
3 weeks post aerosol infection mice were treated with one of 3 drug combinations: INH 
(25mg/kg), LK(50 mg/kg), and INH+LK (25+50 mg/kg) for 6 weeks. Due to the high acute 
mortality, the dose for LK was reduced to 20 mg/kg at week 2 of treatment for both the single and 
combination therapy.  
 
3.2.4 Aerosol Infection and Sample Collection 
C3HeB/FeJ mice were inoculated with a low-dose aerosol infection of Mtb Erdman strain 
in a Glas-Col inhalation exposure system resulting in an average of 15 bacteria in the lungs. To 
determine the infectious dose, five mice were sacrificed the next day[222]. At 3 and 6 weeks of 
treatment, mice were euthanized by carbon dioxide inhalation, the right caudal lung was collected 
for histology, and whole lungs were homogenized, and the bacterial burden was calculated by 
serial dilution on 7H11 agar plates.   
 
3.2.5 Pathology, Slide Preparation, and Imaging 
At the time of necropsy, the right caudal lobe is collected and fixed in 10% neutral buffered 
formalin in phosphate-buffered saline. Samples were embedded in paraffin wax and sectioned to 
a thickness of 5µm using a microtome before being mounted on a slide. Before further processing, 
the paraffin is dissolved using either Histoclear (Electron Microscopy Sciences, Hartfield, PA) or 
xylene and gradually rehydrated using multiple baths with a systematic decrease in alcoholic 
concentration. Each slide is then stained with Hematoxylin and Eosin and imaged using an 
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Olympus BX41 with Olympus DP70 camera controlled by Olympus DP Software (Olympus, 
Melville, NY).  
 
3.2.6 Stereology  
Lung, lesion, and collagen deposition was originally analyzed using Stereo Investigator 
8.2 (MBF Biosciences, Williston, VT) [223]. The workstation was composed of a Nikon 80i 
Research Microscope equipped with a bright field CFU objective (2x/0.01 Plan Apo, 4x/0.2 Plan 
Apo, 100x/1.4 Plan Apo), 2-z-axis computer-controlled stepping stage with linear grid encoders, 
Z-axis motorized specimen stage, color digital camera, and virtual slice Zoomify software. Lung 
and lesion areas were determined by using the area fraction fractionator module at the 40x 
objective. The data was presented as the mean ratio of lesion area to lung area from randomly 
selected image patches.  Investigators were blinded to the cohorts before analysis to reduce bias.  
 
3.2.7 Scoring Of Pathology for LIRA Comparison 
Standard pathologist methodology used lesion area approximations with its corresponding 
scores as follows:  <1% lung receives a score of 0, 1-10% receives a score of 1, 10-25% receives 
a score of 2, 25-50% receives a score of 3, and >50% receives a score of 4. To further 
characterize the severity of disease, scores would be weighted: Type I lesions being multiplied 
by three, Type II lesions being multiplied by four, and Type III lesions multiplied by two. The 
weighted scores would be summed and the mean calculated for each cohort with a minimum 
score of 0 for no visible disease involvement and a high of 28 for a mix of both Type II and Type 
III lesions. This scoring methodologies major drawback is that a lung tissue that has 100% Type 
II lung involvement would receive a score of 16 while a mixture of 50% Type II and 50%Type III 
would have a high of 28. This makes scores above 16 unreliable because Type II lesions are 
more severe than Type III.  
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Analysis with LIRA provides results that are a quantitative score that is less prone to user 
bias. Percent involvement is calculated and provides exact values that can be used in statistical 
analysis. In order to compare the two methodologies the scores generated by LIRA needed to be 
converted to the same scoring methodologies employed by the pathologist. This was 
accomplished by summing each lung lobe total image patch counts for each individual lesion, 
calculating the percent involvement for each, and translating it using the criteria outlined by the 
pathologist.  
 
3.2.8 LIRA Analysis 
Data was generated using LIRA by a graduate research assistant (GRA) highly 
experienced in C3HeB/FeJ pathology analysis and a research associate (RA) with training in the 
analysis but as much experience. The agreement of scores generated by the pathologist, GRA, 
and RA was measured using Krippendorff’s alpha as previously described in Aim 1 (See Chapter 
2 for more detailed explanation). 
 
3.3- Results  
3.3.1. Design And Past Results Of The C3HeB/FeJ Efficacy Study (Study Performed By Dr. Emily 
Driver, [206]) 
The main advantages of using a prioir study for MIAs verification is that we can reuse 
preiouvsly collected samples, and the original analysis had been done with methodologies 
commonly used in histology analysis to help reduce bias in the analysis. The original aim of the 
study performed previously was to use an anti-fibrolitic chemotherapy to manipulate the collagen 
rim of the Type I granuloma in an attempt to increase drug penetration [206]. The study consisted 
of TB infected animals either being treated with INH, LK, or INH+LK with pathology collected at 3 
and 6 weeks post-treatment. Samples were collected at both 3 and 6 weeks from the initial time 
of treatment. Samples were either fixed in PFA before H&E stained or homogenized and serially 
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diluted to determine bacterial burdens. The CFU, percent lung involvement, lesion classification, 
and percent collagen involvement were measured. It was predicted that the combination of INH 
and LK would have reduced bacterial burden and reduced disease lung involvement. The original 
conclusion from the study stated that there was no difference in the percentage of lesion 
involvement and collagen deposition between any of the cohorts at both time points [206] (Figure 
3.1). Despite this finding, the researchers noted that animals treated with INH and INH+LK 
appeared to have more Type I lesion involvement but did not have any quantifiable data to support 
their claims. Additionally, there was no other significant observation about the pathology severity 
of the LK and control cohorts except that the LK cohort had less collagen deposition. Analysis 
tools during the original study were limited in the scope and granularity that could be applied to 
the samples. Most notably, the stereology technique used randomized sections of tissue to 
extrapolate percent lesion involvement. LIRA, in comparison, achieves absolute percent 
involvement of the slide section while also providing the percent involvement of each 
classification.  It is prudent to determine if having a more targeted approach, such as LIRA, would 
altar the original final conclusions that had been made.  
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Figure 3.1.  It was determined in the original LK study that there was no substantial difference in 
lesion development between the different cohorts over 6 weeks of treatment. Tissue 
measurements were performed using stereology. Adapted from Driver dissertation [206].    
 
3.3.2 LIRA Histopathology Analysis 
There were two aims in reanalyzing the histopathology of the original drug treatment study.  
The first aim was to discern if using a targeted analysis tool, such as LIRA, can give additional 
information in drug treatment studies. The second aim was to assess whether the values that 
were derived from LIRA were in agreement with the pathology scores given by a board-certified 
pathologist. Again, this was the first time LIRA was used on a TB drug treatment study using 
C3HeB/FeJ mice. For both aims, H&E stained slides of lungs from each of the treatment cohorts 
were given to a board-certified pathologist who was blinded of any identifier information.  Using 
standardized methodology for scoring lung pathology [88], [224], each sample was given a 
pathology score based upon each lesion classification’s percent lung involvement from 0-4, with 
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0 being no disease present and 4 being the most severe for each lesion type. Single scores were 
weighted based upon the severity of the lesion type, and all the scores across all the lesion types 
were summed to provide an end score used for comparison. These scores were compared to the 
converted values produced by a graduate research assistant (GRA) with extensive experience 
analyzing pathology from the TB C3HeB/FeJ mouse model and a research associate (RA) with a 
moderate amount of experience.  
 
Figure 3.2. Using LIRA there was a substantial difference in overall disease severity between the 
INH 6wk and LK 6wk. This was in contrast to the original study that had been performed which 
had determined there was no difference between the different cohorts (Figure 3.1).  
 
For the prior studies in this section, the analysis performed using the stereology had 
determined that there was no significant difference between the different cohorts and time points. 
With the ability of LIRA to quantify percent lung involvement for each lesion type, trends for each 
cohort were observed that were not discovered previously. All groups showed similar pathology 







Pre RX Control 3wk INH 3wk LK 3wk INH LK 3wk Control 6wk INH 6wk LK 6wk INH LK 6wk
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lesion severity and type was observed between the INH and LK cohorts (Figure 3.2). The INH 
cohort showed a substantial increase in lesion severity, particularly for Type I lung involvement, 




Figure 3.3. Histology analysis performed using LIRA by quantifying the three different lesion types 
separately. Unlike previously, differences were seen between three and 6 week time points of 




The untreated control developed moderate amounts of both Type I and III and a slight 
increase in Type III lesion involvement as expected.  The INH treatment cohort after 3 weeks of 
treatment showed a slightly increased Type I lesion involvement (score=1.6), which was 
somewhat increased compared to the untreated control group (score=1.2). This becomes even 
more pronounced after 6 weeks of treatment with INH, where lung involvement of Type I lesions 
is considerably higher (score = 3.2) in comparison to the control (score = 1.3) (Figure 3.3). There 
were fewer Type II lesions (score = 0.1) and Type III (score = 0.8) involvement at 6 weeks with 
INH treatment. The LK cohort at 6 week treatment showed almost no Type I (score=0.2) or Type 
II (score=0.0) lesion involvement and some Type III (score = 1.5). Dual treatment (LK+INH) 
showed mixed results with Type I lesions having the most lung involvement (score=1.8), followed 
by Type III (score=1.25), and Type II (score=0) lesion involvement. The dramatic increase in Type 
I pathology with the INH cohort was unexpected since previous drug efficacy trials demonstrated 
reduced lesion involvement or halted the severity of lesions.  Yet it had a reduction in culturable 
pulmonary CFU and the lowest mortality out of the other cohorts. In contrast, the LK cohort had 
the lowest level of lesion severity and a reduction in culturable CFU comparable to INH but had 
the highest mortality out of all the cohorts. The results demonstrate that by utilizing a more 
targeted approach, such as LIRA, the interpretation of the collected data provides additional 
insights not identified earlier.  
 
3.3.3 Cohort Overall Score Agreement Between LIRA And The Classical Pathology Approach 
When comparing the overall severity and classification generated during the analysis by 
the board-certified pathologist versus the RA, there was no substantial difference between the 
users. The agreement of pathology scoring was calculated using Krippendorff’s alpha with a score 
of 0.843, which can be interpreted as a good agreement between the GRA, RA, and pathologist. 
The only exception was for the INH treatment group after 3 weeks of treatment, whereby the 
‘expert’ scored a 0, and the GRA had a score of 1 for Type II lesions. Post analysis revealed it 
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stemmed from the disagreement of atypical lesions that were still in the process of formation. The 
atypical lesion was the outcome of the early collection time point of the lung tissue when the Type 
I lesions are still being formed with a partial fibrotic rim on one side and high numbers of 
neutrophils on the other side of the immature Type I lesion (Figure 3.4). The early-stage Type I 
lesions are difficult to identify, and classification is largely based on expertise and information 
given prior to the analysis. This particular example highlights the need for both AI and human 
classifiers working together to achieve optimal results. In summary, there was a good agreement 
in the summary scores given for overall lesion severity at the cohort level when measuring the 
agreement between the board-certified pathologist and trained researchers.  
 
Figure 3.4. Example of a partially formed Type I lesion. Portions of the lesion have the early 
stages of fibrosis and collagen development (blue arrow), while other portions have no fibrosis 







3.3.4 Individual Lesions (Type I, II, & III) Score Agreement Between LIRA And The Classical 
Pathology Approach 
For Aim 2, the objective was to determine if the specific lesion scores (e.g., Type I, II, or 
III) that were derived from LIRA were in agreement with the pathology scores given by a board-
certified pathologist. This was measured using Krippendorff's alpha, which measures the 
agreement between the individual user's score.  Type I lesion scores were mostly in agreement 
with the Krippendorff’s alpha value of 0.879 which would be considered ‘good agreement’. The 6 
week LK group had a noteworthy observation showing no Type I lesion classifications by the RA. 
The reason for this failure of recognizing the Type I lesions was the atypical structure which 
required previous experience to correctly discern these forms of abnormal events, as 
demonstrated by the pathologist and GRA (Figure 3.5). Type II lesion scores showed to have a 
‘tentative agreement’ with a Krippendorff's alpha value of 0.690. The tentative agreement resulted 
from the improved recognition of LIRA at a microscopic level of small pockets of neutrophils. The 
small clusters of neutrophils are generally not noticed by manual scoring of lesions, as this would 
be far too time-consuming and are easily overlooked.  As a result, the GRA and RA reported very 
low levels of Type II involvement, and the pathologist indicated no involvement. Type III lesion 
scores were on the limit between ‘good and tentative agreement’ with a Krippendorff’s alpha score 
of 0.796. There were no significant outliers in the scoring agreement between the pathologists 
with scores showing a consensus among the users. It is important to note that when each 
classification agreement is measured separately, all alpha scores are above the minimum 0.667 
which is the lowest conceivable limit. In summary, agreement for each lesion classification was 
all above the acceptable limit, with Type I scores demonstrating the highest agreement for severity 






3.4 Discussion And Conclusions   
In this chapter, the objective was to assess LIRA’s performance using a past drug trial in 
comparison to scores generated by a pathologist and evaluate whether we would be able to gain 
more information with reduced bias and is quantitative for our histopathology analysis. For this 
purpose, we were able to use a previous C3HeB/FeJ mouse study with animals treated with both 
LK and INH to investigate how a more target analysis using computational tools, such as LIRA, 
can enhance the end result interpretation.  
One major limitation of traditional pathology analysis is bias variation that occurs between 
researchers and laboratories, as previously discussed. To reduce the impact of these limitations, 
LIRA has been developed as a software tool to assist in digital image analysis for the TB 
C3HeB/FeJ animal model, with a specific emphasis on TB drug development purposes. In Aim 1, 
we had previously demonstrated that assistive analysis with LIRA on lung pathology images of 
infected but untreated C3HeB/FeJ mice showed a more rapid and quantitative readout compared 
to traditional methodologies, which are only semi-quantitative. One of the limitations of current 
CNN methodologies is that most models only classify what the model has been trained for. A 
simple example would be a classifier trained in classifying cats and dogs when given an image of 
a bird would try to classify the image as a cat or dog, not a bird. Therefore, it was important to 
investigate whether any changes in the experimental design of the mouse study, such as 
antimicrobial treatment or host immune response manipulation, would alter the histopathology to 
the extent that LIRA’s performance would decline.  
 To perform the experiment, LIRA’s scores were converted using the score rubric provided 
by the pathologist, which has been previously outlined. The analysis between the different users 
(Pathologist, GRA, RA) in which disease involvement for each lesion type was given a score from 
0-4 and weighted to reflect each lesion's disease severity. The overall disease severity had almost 
unanimous agreement except for one cohort, the 3 week INH. The reason for this was the result 
of the misclassification of an immature Type I lesion (Figure 3.4). These partially-formed lesions 
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take on the appearance of atypical Type II lesions with small isolated pockets of fibrosis. For 
future analysis, it has become apparent that disclosure of time points is essential to prevent any 
misclassification that could potentially occur.  
Another important observation in the study was the disagreement between scores for the 
6 week LK cohort for the individual Type I scores. Both the pathologist and GRA were able to 
identify poorly formed Type I lesions (Figure 3.5) due to the fibrotic inhibitory effects of the LK 
treatment. The RA was not able to identify these lesions, most likely due to LIRA not being trained 
on atypical Type I lesions. This highlights that LIRA is not a replacement for expertise but merely 
augments the current classification ability of the user. This limitation may be overcome by 
expanding the training dataset used in training the CNN to predict atypical Type I lesions more 
accurately or limiting the usage of LIRA to users experienced in the C3HeB/FeJ pathology.   
Figure 3.5. Visual comparison of the development of Type I lesions with treatment with either LK 
(A) or INH (B). Type I lesions from the LK cohort was not as developed as Type I lesions seen 
within the Control and INH treated mice.   
  
Individual Type III lesion scores showed little variation between the different groups, but 
the individual Type II lesion scores showed several discrepancies between the classifiers. Most 
notably, when Type II lesions were the predominant lesion type, the three classifiers were 
generally in agreement. The discrepancy occurs when predominantly Type I and Type III lesions 
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have small pockets of neutrophils that are identified by LIRA. When the pathologist is making their 
classification, they do so at a macroscopic level. In contrast, LIRA performs the majority of its 
analysis at a microscopic level identifying each individual image patch as one of seven 
classifications. By following the traditional scoring rubric used even if the pulmonary tissue has 
only 2% involvement, which would have been deemed inconsequential, it will receive a score of 
1. This highlights one of the major limitations with converting ratio data values into a form of 
ordinal data, which is that there is a substantial loss of information that was previously present in 
the prior data format. As highlighted earlier, a score of 12%, 24%, and 25% would receive the 
scores 2, 2, and 3 respectively masking potentially significant differences or similarities. 
Converting the pathologist scores would be the ideal option but is not possible since no direct 
measurements are done but are subjective to the pathologist’s interpretation of lesion 
involvement.  
 The second aim was to determine how using a targeted analysis using computational tools 
may enhance the result interpretation compared to using traditional methodology. The original 
study relied on stereological techniques that required a randomized sample selection of different 
lung areas to represent the population. Based upon this approach, it was concluded that there 
was no significant difference in the lesion involvement between the different cohorts, except for a 







 Table 3.1. Mouse mortality separated by treatment cohorts. Adapted from Driver dissertation 
[206].  
 
Using LIRA, we have observed substantial differences between the different cohorts that 
warrant attention. The first is that there was substantially more total lesion involvement for the 
INH group than previously reported. This consisted primarily of an increase of Type I lesion 
involvement and received an average score of 3 out of 4, implying considerable lung 
consolidation. The second observation was that the LK cohort showed considerably less lung 
consolidation when compared to any other treatment group, consisting of Type I lesions with an 
average score of 1.4, implying a low degree of lung consolidation. It has been observed previously 
within the laboratory that lesion severity will, at times, get initially worse with successful treatment 
due to increased inflammation by dead bacteria. This study marks one of the first times that this 
effect has been quantified. Both the results from the LK and INH are counterintuitive of the 
paradigm that effective treatment results in the decrease in lung involvement.  
When comparing mortality, the LK group within the study showed significant mortality 
(50%), followed by the untreated controls and INH+LK cohort (29%), and no mortality for the INH 
group (0%) (Table 3.1). The mortality in the LK treatment group was of particular interest because 
the LK group showed a considerable reduction in bacterial burden from 8.57 ± 0.58 log10 CFU 
at 3 weeks to 6.01 ± 0.45 log10 CFU at 6 weeks. A similar reduction in bacterial load was also 
seen in the INH group, which at 3 weeks had 8.01 ± 0.38 log 10 and was reduced down to 6.29 ± 0.34 log10 at 6 weeks. However, INH treatment as expected resulted in increased survival. 
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This indicates that bacterial burden and lesion severity alone cannot be used as an indication of 
increased survivability in mice, but additional quantifiable metrics are needed.  
Future studies will be using time points that extend past the 10 week post aerosol infection 
for which LIRA had been originally trained. While we have successfully demonstrated here that 
animals treated and images collected 6 to 10 weeks post aerosol infection will achieve 
comparable scores given by a board-certified pathologist, no analysis has been done for cohorts 
analyzed past this time point. A future direction would be as soon as data becomes available to 
perform a similar experiment using treated animals at later time points (10 to 20 weeks post 
aerosol infection) to find the limit of LIRAs accuracy. If the model fails to classify the pulmonary 
lesions correctly, there can be two approaches to correct these inconsistencies. The first would 
be to create a new CNN model that specializes in animals 13 to 20 weeks post aerosol infection. 
This means that based on the time of collection of the tissue samples, they will have to go to one 
of two different models that either is trained for samples 6 to 10 weeks or 10 to 20 weeks. The 
second approach would be to have one classification algorithm that can handle any time point. 
This will require continuing the training of the original CNN classification algorithm with additional 
data that had been collected past the 13 week time point. The second approach is not 
recommended since it would require substantially more data than the first approach. Collecting 
additional data is difficult and is the limiting factor with biology-based ML.  In summary, users 
using LIRA generate scores comparable to a board-certified pathologist and provide additional 
data that aids in coming to a correct study conclusion.  
In summation, LIRA achieves comparable results to a pathologist, is quantitative, and can 
thereby provide additional insights that may influence the interpretation of the experiment 
outcome. LIRA’s major advantage is that the calculated disease severity includes the targeted 
percent involvement for each lesion type, how many Type I lesions are present, and does so in a 
timely and reproducible manner.  As data acquisition and analysis becomes more complex, the 
development of computational tools will be required to more accurately represent what is actually 
89 
 
occurring in the animal models during infection. As shown without these tools, conclusions that 
do not accurately depict the experiments results may unintentionally overlook successful 

























CHAPTER 4: DEVELOPMENT OF MYCOBACTERIAL IMAGE ANALYSIS (MIA) SOFTWARE 
TO QUANTIFY LESION SPECIFIC POPULATIONS OF MYCOBACTERIUM TUBERCULOSIS 
 
4.1 - Introduction 
Human TB is a dynamic disease that develops a variety of pathological and immunological 
features in the lung, thereby creating a complex niche of pulmonary microenvironments for Mtb 
to occupy. For that reason, phenotypic analysis needs to be done in the context of the TB lesion. 
Lesion microenvironments in the lung that develop as the result of infection include varying levels 
of iron (Fe) [225], vascularization [226], hypoxia [227], pH [18], [19], carbon and energy availability 
[228], and immunological pressures. Mtb is present either intra or extracellularly in the lung. Over 
the course of months and even years, TB lesions are constantly fluctuating in both size and 
metabolic activity, as demonstrated using PET/CT imaging in human patients [46], [158].  Mtb has 
multiple mechanisms to successfully adapt to the myriad of environments and stresses that it will 
encounter. For example, within macrophages, Mtb will increase its lipid metabolism through 
isocitrate (icl), siderophore production to scavenge iron, and sigma factor production[229]. Within 
the necrotic granuloma, Mtb has been shown to elevate host lipid and cholesterol production[230], 
increase rates of replication [139], and induction of the dosR and devR transcription 
regulators[231]. Understanding exactly how TB responds to its environments and the different 
heterogenic bacterial populations that compose each specific lesion type is essential in designing 
targeted therapies to increase the chances for a successful treatment.  
TB treatment is highly effective in the first weeks of treatment but is generally slowed by 
the occurrence of drug tolerance. Two types of drug tolerance have been described: the first is 
stochastic and seen as persistence after drug treatment of actively replicating bacilli (Class I), and 
the second is caused by the specific environmental locations where residing Mtb bacteria are 
non-replicating (Class II), [232]. TB drug development tries to overcome both types of drug 
tolerance to cure the infection and shorten treatment.  
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The first type of drug tolerance, or Class I, addresses the observation that multiple 
phenotypic populations can exist concurrently within a single lesion after drug treatment.  The 
surviving Mtb populations are reversibly tolerant to one or more standard therapies but not always 
to therapy combinations[232]. Previous dogma had assumed that there were only two distinct 
populations of Mtb: dormant and active [233], [234]. Active bacteria were defined as replicating 
and metabolically active. This population of bacteria are susceptible to both antimicrobial 
treatment and host immune responses. Dormancy was defined as non-replicating bacteria that 
are in a quiescent metabolic state. Bacilli in this dormant state were considered to be resistant to 
both antimicrobial therapies and host immune responses [235]. This had previously explained 
how difficult it was to achieve sterilization during treatment and why some hosts seemed to stay 
in the latent phase of the TB infection. It has been observed that the transcriptional profile of drug-
resistant Mtb is in a slow-growing, metabolically, and synthetically downregulated state [236].  
Recent studies have expanded upon this hypothesis by showing that within a single uniform 
environment, multiple phenotypic populations can exist concurrently [237], [238]. McKinney et al. 
demonstrated in vitro that the surviving bacterial population under treatment with isoniazid 
showed three distinct populations;  the first was a subpopulation that quickly resumed growing 
and remained metabolically active, the second was non-replicating but remained metabolically 
active, and the third population was both non-replicating and was in a quiescent metabolic state 
[140]. In vivo, they are represented by a biphasic reduction in the Mtb burden that continues 
before failing to reduce the burden below a certain level of detection. More importantly, Class I 
phenotypic resistance has been observed in human patients that are receiving the standard drug 
therapies[239] and within murine [71] and Guinea pig animal models [240].  
The second type of drug tolerance is reflected by a bacterial population located within 
specific lesion compartments that do not behave uniformly across the various lesion types (Class 
II) [232]. Each compartment microenvironment can present with different challenges that need to 
be addressed to design therapies that target a variety of phenotypic bacterial populations, 
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successful delivery, and environmental conditions (e.g., pH) to clear an infection. Stressful 
environmental conditions can induce phenotypic drug tolerance that can halt net Mtb replication. 
Non-replication can be the result of transcriptional responses to the environment or  an altered 
cell wall [241]. Host microenvironments are further complicated by the fact that within a human 
host, multiple different lung lesion types can exist simultaneously during infection [14]. Lesions 
are also highly dynamic and are consistently changing throughout the lifetime of the patient. 
Similar to pulmonary TB in patients, the C3HeB/FeJ animal model also develops a variety of 
different lesion types in the lungs displaying various levels of hypoxia, intra and extracellular 
bacteria, diversity of carbon and energy sources, and immunological pressures [74]. By utilizing 
the C3Heb/FeJ TB mouse model, we can better understand phenotypic antibiotic resistance that 
can arise as the result of environmental stimuli.  
Utilizing an animal model that develops a heterogeneity of lesions types allows for the 
targeted visual analysis of specified bacterial populations within specific lesion compartments.  In 
the C3HeB/FeJ mouse model, there are five main pulmonary environmental niches where Mtb 
can be visualized (also detailed in Chapter 2). The first and second environmental niches are the 
Type I lesion that can be further divided into the Type I Core and the Type I Rim. The Type I Core 
is hereby defined as the caseous necrotic center enclosed within the fibrotic rim where the 
bacteria are extracellular, in a lipid-rich environment, neutral pH [75], and are under hypoxic 
conditions due to a lack of vascularization [74]. The Type I Rim consists of the collagen rim as 
well as the consolidated region just outside the fibrotic rim. It is neovascularization, and bacilli are 
generally intracellular within the surrounding macrophages. Type II lesions are not highly 
vascularized, have large areas of cellular necrosis, karyorrhectic debris, and bacilli are 
intracellular within neutrophils. Type III lesions are the result of a host cellular immune response, 
and a limited number of bacteria are intracellular within interstitial macrophages. The last 
environment is the uninvolved lung parenchyma, where very few to no bacteria are located, here 
defined as Healthy tissue. The optimal animal model will attempt to mimic the complexity 
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observed in human TB disease since a treatment that would be effective in one particular lesion 
may not be efficacious in another lesion.  
By microscopic analysis, the heterogeneity in bacterial populations has been reported on 
by acid-fast staining of either in vitro cultures or in tissues [73], [192]. The stress of the host 
immune response can affect the bacterial transcription thereby modulating the composition of the 
mycobacterial cell wall.  Mimicking intracellular conditions in vitro, using low oxygen, nutrient 
deprivation, and acidic pH, the bacilli can lose its acid-fastness and accumulate triacylglycerol 
and wax ester [242], [243]. In macrophages, a subgroup of Mtb mycolic acids are substantially 
altered [244]. Bacilli in standard laboratory mouse strains have also been documented to lose 
their ability to retain the Ziehl Nielsen acid-fast stain over time [245]. Even though these studies 
highlight the ability of Mtb to alter their cell wall in vitro, this was also demonstrated previously in 
vivo in our laboratory. Ryan et al. visualized the cell wall heterogeneity of Mtb lesion populations 
in Guinea pigs and mice by using two separate staining techniques: Auramine-Rhodamine (AR) 
and fluorescent in situ hybridization (IF). These stains identified three separate bacterial 
subpopulations in equal proportions that either stained with AR, IF, or a combination of both stains 
and whose populations were homogenous throughout the tissue. This included tissues that were 
hypoxic and/or necrotic, which always had at least three distinct populations [73]. Both Ryan et 
al. and McKinney et al. establish that antibiotic targeting of a single Mtb population will not be 
efficacious in successful treatment and prevention of relapse.  
Aim 3 of my dissertation proposes the development of novel quantitative software that will 
enumerate bacteria at the various locations in the lungs of the C3HeB/FeJ mouse model. This 
software will measure the number of visual CFU in a specified area (density), percentage of the 
visual field composed of bacteria (% bacteria), and individual bacterial CFU area. The software 
will be referred to as the Mycobacterial Image Analysis or MIA for the remainder of this paper. 
The goal for this initial study was to test the MIA software and to use MIA for the first time on a 
drug efficacy trial by quantifying the different bacterial metrics for each lesion type found within 
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drug-treated C3HeB/FeJ mice. For this purpose, microscopic slides from an earlier mouse study 
were used to optimize and validate the MIA software. The C3HeB/FeJ mouse study was 
described in this dissertation in Aim 2 (see Chapter 3), and detailed the treatment with either 
isoniazid (INH) with or without losartan (LK). This mouse study was chosen as comprehensive 
data was already available, by having both lung CFU data from plating on 7H11 plates, pathology 
data after manual histopathology, as well as analysis by LIRA.   
For this Aim, the bacterial enumeration for every lung lesion compartment of the 
C3HeB/FeJ mice was quantified for every treatment group. The same pathology classifications 
for the diverse lung lesion compartments were used as detailed in Aim 1 (Chapter 2): Type I Core, 
Type I Rim, Type II, Type III, Healthy, and Miscellaneous. The same classifications were again 
used for the quantification with MIA, except for the addition of the Type I Core Outside. Tissue 
samples collected previously were stained using SYBR Gold, which is a DNA/RNA nucleic acid 
stain that is selective for Mtb [192]. SYBR Gold has a >1000 fold fluorescent enhancement when 
binding to both double or single-stranded DNA or RNA and has low levels of fluorescent 
background noise. This makes it ideal for image analysis by providing a stark contrast between 
the object of interest and the background noise. Using the SYBR Gold staining method, we 
optimized the MIA software to this stain and showed the utility of MIA in a preliminary study to 
accurately identify bacterial clusters and distinguish changes that occur between time points and 
treatment cohorts.  
 
4.2 – Methods 
4.2.1 Mouse Infection  
C3HeB/FeJ mice infected with Mtb Erdman strain via aerosol infection (See Chapter 3 
Methods) 
 
4.2.2 Staining and Imaging 
95 
 
Histology slide samples were stained with a diluted 1:1000 SYBR dye (Invitrogen, Eugene, 
Oregon)  that was diluted with a solution composed of phenol crystals (8g), glycerin(60mL), 
isopropanol (14mL), and distilled water (26mL). The slide was flooded with SYBR Gold solution 
on a heating block at 65֯ C for 5 min and allowed to cool for 5min at room temperature. Slides 
were washed in an acid alcohol (0.5% HCL, 70% isopropanol) bath 3 times for 3 min each followed 
by a water rinse. Samples were counterstained with Hematoxylin Quick stain and mounted using 
Prolong Gold antifade mounting medium [192]. Samples were imaged at 20x using both DAPI 
(Tissue) and FITC (SYBR+ bacteria) channels (See Chapter 2 imaging methods). The histology 
slides that had been processed for the INH+LK cohort were damaged, and no bacterial metrics 
were acquired using MIA as a result.  
 
4.2.3 MIA Algorithm Pipeline  
MIA was developed in the Python (version 3.6.7) language using Tkinter, PIL, Numpy, 
Pandas, and OpenCV libraries to perform the analysis. Along each major step of the image 
processing, representative images are created to help the user understand what objects were 
being gated and collected for each region of interest (ROI) (Figure 4.1). The ROI is the specific 
tissue section that is selected by the user.  Available microenvironment classifications to subdivide 
the populations include Type I Core, Type I Core Outside, Type I Rim, Type II, Type III, Healthy, 
and Unknown. The Type I Core is defined as the area in the center of the caseous necrotic lesion. 
The Type I Core Outside is the outer cellular edge of the core that is primarily composed of the 
foamy macrophages and neutrophils which are encapsulated within the fibrotic rim. The Type I 
Rim is the lesion tissue that starts on the outside of the collagen rim and the surrounding involved 





Figure 4.1. Visual representation of each of the steps performed in MIA’s pipeline analysis. The 
image is uploaded into MIA, and the user classifies the lesion area (A), the ROI is cropped (B), 
converted to an HSV image where the H channel is isolated and a mask is generated based upon 
the desired stain color channel (C), the image is further converted to a grayscale image (D), and 
the remaining image object edges are detected and outlined in red (E).  
 
4.2.3.1 Number Of Defined Bacterial Areas per µm2 
The various steps in the MIA pipeline are discussed below. In the initial step, the user 
identifies the classification for a particular ROI (Figure 4.1A), and a separate temporary cropped 
image is created for the analysis (Figure 4.1B). The temporary cropped RGB image is converted 
to an HSV, and the color is masked for the specified staining parameters on the H channel (Figure 
4.1C). For instance, the SYBR Gold will only accept pixel values between the minimum =[50,1,1] 
and maximum =[85,255,255]. The image which only contains the specified color of interest will be 
converted to a grayscale image (Figure 4.1D). Using OpenCV’s contour function the edges of 
detected objects (e.g., bacilli) are found. (Figure 4.1E). The area of each object is calculated, and 
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objects, or aggregates, that are too small or too large are removed from the detected object list. 
The remaining objects are highlighted in red as verification that the correct objects of interest had 
been detected. The number of remaining objects in the list is the number of objects (bacilli) that 
are found within the ROI. The total number of bacilli is divided by the total converted image area 
to provide the density of defined bacterial areas per unit2.  The default unit setting is µm2. 
 
4.2.3.2 Individual Bacterial Area Analysis 
 Each identified object of interest contoured edge coordinates are stored. Based upon each 
coordinate pairs, the sum total of the number of pixels located within the coordinates is the pixel 
area. Pixels are subjective, meaning that they need to be converted to standardized units to be 
able to make meaningful comparisons. The image size and individual objects of interest size in 
pixels are converted using the below formula:  
𝐼𝑚𝑎𝑔𝑒 𝑃𝑖𝑥𝑒𝑙 𝑆𝑖𝑧𝑒 =  (𝐶𝑎𝑚𝑒𝑟𝑎 𝑃𝑖𝑥𝑒𝑙 𝑆𝑖𝑧𝑒)(𝐵𝑖𝑛𝑛𝑖𝑛𝑔 𝑆𝑖𝑧𝑒)(𝑂𝑏𝑗𝑒𝑐𝑡𝑖𝑣𝑒 𝐿𝑒𝑛𝑠)(𝐿𝑒𝑛𝑠 𝑀𝑎𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛)(𝐶 𝑀𝑜𝑢𝑛𝑡) 
Each converted object of interest area is stored as a separate within the .csv, along with the 
identifying metadata for large data analysis.  
 
4.2.3.3 Percent of Image Composed of Bacteria 
The summed area of each object of interest is divided by the total image area to calculate 
the percentage of the image that is composed of the objects of interest.  
(% 𝐵𝑎𝑐𝑡𝑒𝑟𝑖𝑎 𝑖𝑛 𝐼𝑚𝑎𝑔𝑒) =  ∑(𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝐵𝑎𝑐𝑡𝑒𝑟𝑖𝑎𝑙 𝐴𝑟𝑒𝑎) 𝑇𝑜𝑡𝑎𝑙 𝐼𝑚𝑎𝑔𝑒 𝐴𝑟𝑒𝑎  
Additional metrics not used in this paper are also calculated and provided in a separate 





4.2.4 MIA Optimization and Validation 
Each of the three bacterial metrics (density, area, and percentage) are based on values 
incorrectly identifying the objects of interest and correctly identifying the edge coordinates. Object 
identification and edge detection were validated using Flow Cytometry Beads (Invitrogen 
CountBright beads lot# 1971889, cat_num: C36950) with a manufacturer value of 7.08 ± 0.478µm 
as the diameter. Beads were placed on a slide using a Shandon Cytospin 6 and mounted on 
microscopic slides using mm24 mounting medium. Slides were imaged at both 10x and 20x 
objectives and saved as .png files to prevent file compression and possible distortion of image 
objects. The accuracy of MIA object enumeration was calculated using values determined by 
manual observation and those processed by MIA. Pixel areas calculated by MIA were converted 
to µm, and the mean of all identified objects was used to compare to the bead values reported by 
the manufacturer. Accuracy of the analysis can vary based upon the objective of the microscope 
used to acquire the images. For example, an image taken at 100x will more accurately 
demonstrate the bead size than an image taken at 10x. The acceptable threshold of the calculated 
MIA value for the mean needed to be within the bead standard deviation of the mean provided by 
the manufacturer.  
 
4.3 - Results  
4.3.1 - Verification of the Software on Control Samples 
 
MIA was designed to measure three important bacterial metrics: 1) the number of bacteria 
per tissue area, which are defined further as “density”, 2) the individual bacterial area, and 3) the 
percentage of the image that is made up of the bacteria. All three metrics rely on two core 
algorithms that either enumerate the number of fluorescently labeled objects of interest (e.g., 
bacilli) or calculate the individual object of interest area. To validate the algorithms and the 
corresponding conversions, the fluorescent flow cytometry beads were placed on a microscopic 
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slide and scanned to create a digital image. Visual representations of each of the steps used in 
the analysis were collected for both visual and quantifiable verification. The essential steps 
included placing the beads on a slide, scanning to create a digital image, and passing the image 
through MIA’s core function for quantification. The function includes the creation of a mask to 
isolate the fluorescently labeled flow cytometry beads (Figure 4.2B) and calculates the object of 
interest edges by contouring (Figure 4.2C). MIAs object detection achieved 99.04% accuracy by 
identifying 208 out of 210 possible beads. The discrepancy was the result of two beads that had 
co-localized with another bead and appeared as one single object (Figure 4.2C, blue arrow). This 
means that it correctly identified all isolated objects, but cannot consistently discern objects that 








Figure 4.2. Visual representation of MIA’s ability to identify objects of interest, quantify the number 
of objects, and determine their area. Blue arrow indicates bead cluster that was identified as 1 
object but was actually three separate objects that had colocalized together.  
 
Next, we needed to evaluate MIA’s ability to correctly calculate the areas of objects of 
interest within an ROI. It was critical to have the results in a format that is easily interpreted and 
compared to images generated from other microscopes, cameras, and objectives. After the 
software has identified individual objects of interest and determined their location within the 
image, the number of pixels within each object are calculated. By knowing several variables about 
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the microscope used to generate the image (such as Pixel length, objective, binning), the pixels 
can be converted to metric units such as µm2. According to the manufacturer’s documentation, 
the flow cytometry beads have a diameter of 7.08 ± 0.478 µm and a mean bead area of 38.4845 
µm2. Measuring 200 beads using both 10x and 20x objectives, MIA calculated the mean bead 
diameter to be 6.66 ± 3.16 µm and the mean area to be 34.8563 µm2. Manufacturers will perform 
a more robust analysis than what was performed here, but the purpose here was to demonstrate 
that MIA’s calculated values were within an acceptable range to the values provided by the 
manufacturer. If accuracy is still a concern, images can  be scanned at a higher magnification, or 
a higher resolution camera can be employed.  In summary, the calculated values for both object 
of interest enumeration and object of interest area calculations were within acceptable ranges to 
be used for our analysis.  
 
4.3.2 – Verification Of The MIA Software On C3HeB/FeJ Histology Tissues 
 
MIA had demonstrated accuracy in correctly identifying flow cytometry beads within an 
image and calculating the area of each bead. We next wanted to evaluate LIRA’s ability to identify 
Mtb within a histology sample correctly. The first piece of data that was needed was to determine 
the minimum size of bacilli that could be visualized.  The average length of a bacilli is  2.71 ± 1.05 
μm in length, and the average diameter of the cell was 0.345 ± 0.029 μm [246].  This means the 
minimum visual area of an Mtb cell that is cut perpendicular would be 0.16 μm2 and is the minimum 
value used for MIA.  As demonstrated in Figure 4.3B, MIA was able to identify all possible 
individual and aggregated bacteria within an image, excluding those that are touching the edges 
of the image. In addition, the user can select specified sizes as demonstrated in Figure 4.3C. 
Correctly identifying the edges of the Mtb bacilli is the primary algorithm required of MIA, and as 
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demonstrated, it correctly identifies the coordinates for each bacillus and has the option to select 
area size as selected by the user.  
 
Figure 4.3. Visual representation of MIA’s ability to identify SYBR Gold stained bacilli within a 
histology tissue sample. Bacilli (Green) would be outlined in red if they were identified by MIA. A)  





4.3.3 – Analysis Of Drug-Treated Bacterial Populations In Vivo  
Figure 4.5. Difference in bacterial aggregation within the INH cohort Type I Core at 3 week and 
6 week treatment. A similar effect also observed in the Control Cohort.  
 
Within the prior study performed by a previous Ph.D. student in our laboratory (Emily 
Driver), it was concluded that there was no substantial visual bacterial burden difference between 
time points and cohorts [206]. When analyzing these same slides with MIA, there were differences 
in bacterial numbers and clustering observed between the various treatment groups. For instance, 
within the INH and Control mouse groups for the core of the caseous necrotic lesions (Type I 





Figure 4.6. Boxplots of log10 normalized individual bacilli and aggregate areas separated by lesion 
type and cohort. Red box indicates the specific cohort of interest for the analysis. 
 
For the measurement by MIA of bacterial areas for both the INH and Control cohort, the 
number of pixels was calculated for each object of interest by the enumeration algorithm, and 
each pixel was converted to µm2. Populations were log base 10 normalized and then visualized 
using boxplots. For the different treatment cohorts and lesion compartments, there were no 
substantive differences observed in the mean and interquartile range. What was of interest were 
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some of the outliers found in each cohort. For both the INH and Control groups, MIA showed that 
in the caseous necrotic lesions (Type I Lesion) a dramatic increase in large bacterial areas could 
be observed after 3 to 6 weeks treatment (Figure 4.6).  
 
 
Figure 4.7. Percentage of the image that is composed of visible bacteria. Red box indicates the 
specific cohort of interest for the analysis. NA indicates that no sample was measured for that 




 Another measurement by MIA calculates the percentage of the image composed of visible 
bacteria (Figure 4.7 Type I Core Lesion Tissue). This measurement showed an increase in the 
percent bacteria present for both Control and INH Cohort. Results were verified using a separate 
calculation by summing all green pixels within the image, which also resulted in a percentage of 
the image occupied by bacteria (results not shown). While this is a less accurate measurement, 
as it does not discriminate object size, it did achieve similar values thereby confirming the results 





Figure 4.8. Bacterial densities of each lesion type calculated in terms of (defined bacterial areas) 
/ µm2. The red box indicates the specific cohort of interest for the analysis. NA indicates that no 
sample was collected for that data point.   
 
 The next measurement by MIA was obtained by calculating bacterial density. By applying 
this on the same mouse study, we saw a decrease in bacterial density from 3 to 6 weeks for the 
INH cohort, but a weak increase in the Control cohort (Figure 4.8). The INH decrease was as 
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expected whereas the slight increase in density for the Control cohort was not. After closer visual 
inspection of the Control cohort, we noticed less bacterial burden at 3 weeks, which could account 
for the slight increase in defined bacterial areas density (Figure 4.8). Because the other two 
metrics behaved as predicted, the results suggest the achieved values for the bacterial density 
for the Control cohort are real.  
 Of note, these measurements by MIA described above were performed on this one pilot 
study only, and therefore should be seen as preliminary results. The reason for the quantification 
of the various measurements by MIA was to 1) test the MIA software for the first time on a 
C3HeB/FeJ mouse efficacy study to assess flaws in the software, and 2) see if there were any 
advantages of using MIA, such as finding discernible differences among treatment groups that 
were not seen in the past after manual histopathology analysis. These results showed that 
quantification by MIA was successful and that it was able to find differences in bacterial numbers 
and aggregation in the various treatment groups.  
 
4.3.4 - Mycobacterial Islands  
One observation that was made during our analysis and verified quantitatively using MIA 
was the development of consolidated Mtb super aggregates in the center of fully developed Type 
I lesions (Figure 4.9), hereby named mycobacterial islands in this Chapter. These mycobacterial 
islands developed 6 weeks post-treatment for both the INH and Control cohorts. In contrast, the 
LK cohort did not develop any islands and had an evenly distributed Mtb burden across the Type 
I Core. The mechanism of the formation of these super aggregates is unknown and will require 
more targeted analysis to discern. Even though these islands have been seen in previous studies 
within our laboratory, future studies will have to show the mycobacterial island phenomenon is 







Figure 4.9. Each drug treatment imaged with DAPi and SYBR GOLD at 20x for both 3 week (3wk) 
and 6 week (6wk) treatment time points. For the Control and INH cohorts, there is the 
development of mycobacterial islands (white arrows). 
 
4.4- Discussion 
TB disease is highly complex due to the lack of uniformity of responses for both host 
lesions and bacterial populations as the disease progresses. A TB-infected individual can develop 
a variety of different lesions with vastly different levels of carbon and energy availability, immune 
system response, environmental stresses, and physical barriers. LIRA was developed to quantify 
the complexities of the host pathology by quantifying various pulmonary lesions that develop 
throughout a TB infection, specifically in the C3HeB/FeJ mouse animal model. Within these host 
lesion compartments, recent studies have shown that multiple different bacterial phenotypes, 
such as variations in cell wall composition, metabolism, and replication properties, are present 
within a single lesion compartment. Previous limitations in collecting quantitative data on bacterial 
populations included the proprietary image format used during scanning, the memory 
requirements to store and process the images, bacterial enumeration in tissue, and the different 
lesion compartments. MIA was developed as a means to provide quantifiable data of bacterial 
110 
 
populations in different compartments by lowering the barrier for quantitative analysis for 
researchers not familiar with coding. In the C3HeB/FeJ animal model, MIA can more accurately 
measure the density of bacilli in the necrotic core (Type I Core compartment) between a treated 
and non-treated animal.  
One of the limitations of generating this value is that it cannot distinguish single bacteria 
from aggregated bacteria. This is not a new issue [247], and this could be addressed in future 
iterations of the software. A predicted number of bacilli can be determined within an aggregate by 
the user by calculating a frequency distribution of individual planktonic bacteria areas and 
applying it to each bacterial aggregate to predict a range of bacteria that are present. Calculating 
the mean distribution is important because the mean Mtb length is 2.71 ± 1.05 μm and the mean 
diameter is 0.345 ± 0.029 μm that could have even greater variability based upon strain used, 
location within the lesion, and the specific stress it is encountering. This would only provide an 
estimate of the bacterial number. The comparison of bacterial burden between cohorts or 
compartments is more accurately represented by the bacterial percentage of the image that is 
calculated by MIA.  
The use of MIA on the drug efficacy study performed by Emily Driver [206] was used as a 
preliminary test case to determine the validity of MIA as a new tool to quantify bacterial 
populations. In these preliminary observations with MIA, either anti-mycobacterial treatment with 
INH or no modulation of the immune system (Control cohort) resulted in the formation of 
mycobacterial islands within the necrotic lesion cores (Type I Core Lesion Tissue compartment). 
No mycobacterial island formations were formed within the treated LK cohort, even though there 
were some caseous necrotic lesions present. The opposite occurred where there was either no 
change or a substantial decrease in measuring bacterial aggregation. This test case showed that 
1) the MIA software was easy to use on a C3HeB/FeJ mouse efficacy study, and 2) was able to 
discern differences among treatment groups that were not seen in the past after manual 
111 
 
histopathology analysis. The next step will be to analyze more in vivo studies to assess the effect 
of treatment response on the bacterial populations in the various locations of the lung.  
Now that MIA has been optimized and validated on both control and in vivo samples, its 
capabilities can be expanded using additional staining methods to characterize and potentially 
identify different bacterial populations. This can include using immunofluorescence with 
antibodies against specific mycobacterial targets [248], stains that bind to mycobacterial cell wall 
components such as Auramine Rhodamine [249], and in situ hybridization probes [250]. The 
applications are numerous, and for drug development, these additional metrics can broaden the 
current understanding of how various drug treatments impact specific populations of Mtb within 
various tissue/lesion compartments. With the availability of large data and image analysis 
methodologies, it is possible not just to measure subsets of populations but to analyze on a single 
cell basis.  
In summary, MIA can accurately enumerate bacteria to calculate a bacterial density in an 
area on a microscopic slide, calculate the area of each object of interest, and determine how 
much of an ROI is composed of Mtb. By combining MIA, which quantifies bacterial properties, 
with LIRA, which quantifies host pathology response, the depth of information that can be gleaned 













CHAPTER 5 – FINAL DISCUSSION AND FUTURE DIRECTIONS 
 
5.1 - Final Discussion 
Throughout a TB infection, the human host shows progressive pulmonary pathology 
characterized by lesion heterogeneity, which can present itself from inflammatory up to 
destructive cavitary lesion types. A single patient can concurrently develop multiple different 
lesions with diverse microenvironments such as varying levels of pH, energy and carbon 
availability, vascularization, and immune cell interactions.  The best method for research purposes 
to recapitulate the complexities of human TB disease are animal models such as Guinea Pigs, 
non-human primates, and certain mouse species.  Animal modeling is essential in the 
development of new and more effective therapies but to maximize their potential, new tools are 
needed to quantify the disease presentations and bacterial locations. Artificial intelligence and 
computer vision represent a marked improvement in current manual measurement methodologies 
in terms of reproducibility and efficiency. These techniques also give additional insights and more 
detailed data that were not previously available and are helping to expand our knowledge on 
therapy efficacy and host-pathogen interactions. The results presented in this dissertation are the 
first steps in the development of digital tools to quantify the lesion involvement and bacterial 
locations in the C3HeB/FeJ TB animal model. This includes novel software tools using new code 
for the quantification of the different pulmonary lesion tissues in C3HeB/FeJ mice using Lesion 
Image Recognition Analysis (LIRA) and the quantification of bacterial metrics based upon the 
lesion compartment in which the population is located using Mycobacterial Image Analysis (MIA).  
Aim 1 (Chapter 2) details the process for writing and developing de novo software utilizing 
deep convolutional neural networks for the  identification and quantification of pulmonary lesions 
using digital microscopic images from the lungs of M. tuberculosis infected C3HeB/FeJ mice. 
Using the Lenaerts laboratories catalog of histopathology image scans from previous C3HeB/FeJ 
mouse studies, three neural networks were successfully trained to classify and quantify 
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pulmonary lesion tissues from mice between 6 to 10 weeks post aerosol infection.  The first neural 
network identifies the structural features that are found within the caseous necrotic Type I lesion, 
the second neural network identifies subcomponents of the Type I lesion, and the third neural 
network classifies neutrophilic Type II and cellular Type III lesions. Multiple advantages were 
discovered by using the LIRA software in identifying and quantifying pathology. The first 
advantage using LIRA was a remarkable reduction in analysis time by 82% when compared to 
the manual histopathology method used previously. The time-saving aspect is significant since 
analysis in the past used to take several weeks to months, depending on the size of the study. 
Analysis that takes an excessive amount of time to complete can lead the researcher to 
experience user fatigue. User fatigue increases the amount of bias or mistakes thus causing 
unintentional skewing or incorrect reporting of the data. While unintentional, it may lead to 
mistaken results or assumptions about the data that may impact final conclusions. The second 
advantage of LIRA over manual histopathology analysis became apparent by showing greater 
reproducibility between users. For this purpose, a single study was analyzed by different 
pathologists either by manual histopathology analysis or by using LIRA. Manual histopathology 
analysis showed a percent agreement among users of 87%, but with the assistance of LIRA, this 
increased to 94%. This is an important finding as reproducibility and unbiased analysis will enable 
us to compare multiple studies, time points, and analysis done by different individuals or 
laboratories. This will increase the accuracy of the data, which otherwise might be lost when 
higher variability is present. The third advantage of LIRA is the precision on a microscopic level 
that LIRA classifies the various lesions types. With the use of LIRA, there was a more accurate 
demarcation of lesion margins, as well as the detection of small isolated regions that may not be 
identifiable at a macroscopic level used by manual analysis. Both the pathologist and LIRA were 
able to classify the various lesion types correctly, but the added precision that LIRA provides 
increases the confidence of the final generated quantitative results. The purpose of LIRA was 
never to replace a human classifier but to work in tandem with each other. LIRA’s strength is its 
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performance for repetitive analysis, but LIRA performs poorly when given new information that 
was not included in its initial training set. Humans struggle to perform repetitive tasks consistently 
but are highly skilled in fluid intelligence problems that require new information or solutions. When 
paired together both LIRA and the human classifier complement each other to provide the most 
optimal and accurate analysis.  
Aim 2 (Chapter 3) detailed the use and performance of the LIRA software on 
histopathology images from a drug-treated test case mouse study. For this purpose, we analyzed 
the results of a previously conducted drug efficacy C3HeB/FeJ trial in comparison to the standard 
manual histopathology analysis performed by a certified pathologist. LIRA had originally been 
trained using tissue samples from untreated animals 6 to 10 weeks post initial aerosol infection. 
Machine learning algorithms can be very sensitive to changes in the input data, such as if the new 
input data differs significantly from the training data set that was used to generate the model. 
Because the TB C3HeB/FeJ animal model is often used in drug efficacy trials, it was important to 
determine if drug treatment would impact LIRA’s ability to classify pathology accurately. A 
previously conducted drug study using isoniazid (INH) and losartan (LK) was chosen to perform 
the validation of the LIRA software. It was especially advantageous because the study had been 
previously analyzed using standard methodology, allowing for a reduction in analysis bias when 
comparing old and new methodologies, and the study also included both antibiotic and 
immunotherapy cohorts to allow for more robust testing. In this chapter, for the validation of LIRA 
we had three goals; 1) we compared the results from the scores generated by a pathologist using 
standard methodology, 2) we analyzed the LIRA results in terms of the outcome of the therapies 
on pulmonary pathology, and 3) we determined if using a more targeted analysis approach such 
as LIRA would change or add to the initial interpretation of these results. Using Krippendorff’s 
alpha, a statistical method that is able to measure the agreement among different classifiers, we 
measured the agreement of classification scores of non-pathologist researchers to that of a board-
certified pathologist. The alpha score can range from 0 to 1 with 0 being “perfect disagreement”, 
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1 being “perfect agreement”, 0.99 to 0.80 being “good agreement”, and 0.79 to 0.667 being 
“tentative” (lowest acceptable limit).  The Krippendorff’s alpha value for each lesion type were all 
above the lowest acceptable values for agreement, and the overall score was 0.879 which is 
considered “good agreement”. This means that the scores generated by the non-pathologists 
were in agreement with the scores generated by the pathologist. Initial histopathology analysis of 
the drug efficacy trial had come to the conclusion that there were no significant changes in 
pathology between the different treatment groups; however, with LIRA substantial changes were 
observed. The first result was the striking increase in Type I lesion involvement for the INH cohort 
and the decrease in involvement for all the lesion types in the LK cohort. These LIRA findings 
were somewhat unexpected when they are compared to earlier CFU results and mortality data 
from similar mouse studies. Specifically, both treatment cohorts had comparable levels of 
bacterial reduction, but LK had the highest mortality (50%), while the INH cohort had the lowest 
mortality (0%). Taking the study results together, the LK cohort exhibited minimal lesion 
development, a reduction in the bacterial burden comparable to INH, and yet had a incredibly 
high mortality. Even though more investigation into the results is required, this implies that a 
reduction in both pathology and bacterial burdens may not always be a reliable indicator of drug 
efficacy.  
In Aim 3 (Chapter 4), we generated software for the enumeration of fluorescently stained 
bacteria in pulmonary tissues of C3HeB/FeJ mice infected with M. tuberculosis. Tuberculosis 
disease is the result of the interaction of the host immune system and the Mtb pathogen. LIRA is 
a quantitative tool that measures the response of the host; however, another quantitative tool was 
needed to measure the bacillary response, which is why MIA was developed. MIA relies on more 
traditional computer vision techniques to be applied to specific staining procedures to quantify 
bacterial metrics. The analysis creates a mask based upon the selected fluorophore stain color 
and acquires the x,y coordinates of the objects of interest that are present in the image. The edge 
coordinates of the objects within a selected region of interest (ROI) can be used to calculate the 
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object area (µm2), the object density within the ROI (defined bacterial areas / µm2), and the 
percentage of the image that is composed of the objects of interest (bacterial % of the image). 
The software was initially verified using flow cytometry beads as a control to verify the correct 
measurement of an object area and number of objects present. The mean of the calculated 
diameter of a flow cytometry beads was 6.66µm, which was well within the standard deviation of 
the mean provided by the manufacturer of 7.08 ± 0.478µm. The performance of the MIA software 
with the control beads showed a 99.04% accuracy in identifying the desired individual objects of 
interest that were present in a given image. We next tested the MIA software on an actual efficacy 
study using histology slides collected from the C3HeB/FeJ mice. The previous analysis, like in 
Aim 2, had determined that there were no significant differences between the visualized stained 
bacterial numbers. The lung sections from the same mouse study were used as described in Aim 
2 (Chapter 3) to measure the bacterial metrics within each lesion compartment. What these 
preliminary results showed was first of all that the MIA software was easy to use and highly time-
efficient. A few interesting preliminary observations showed some apparent changes in bacterial 
aggregation and density-dependent on the treatment groups. In both the Control and INH 
treatment groups, a general trend of increased Mtb aggregation was observed for most tissue 
compartments, especially in the cores of the necrotic Type I lesion tissue. In contrast, the LK 
group had a demonstrated decrease in the aggregation of bacteria within the tissue 
compartments, with an increase in bacterial density. Lastly, for the bacterial percentage (or overall 
visual burden of bacteria within an image) the untreated Control cohort remained the same, the 
INH treatment group had a reduction in most areas of the lung except for the lesion core, and the 
LK treatment cohort saw a general increase in all tissue compartments except in the Type I 
lesions.  
These initial results are preliminary at best and more studies will have to be analyzed; 
however, this test case using the losartan study in C3HeB/FeJ mice proved that the MIA software 
was easy to use and useful in determining differences between the various treatment groups 
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which could not be distinguished using previous manual methods. For future work, one could 
hypothesize that environmental stresses such as the immune system (Control) or anti-
mycobacterial therapy (INH) may promote the formation of mycobacterial aggregates and islands 
within the caseous necrotic cores in lungs. The formation of these aggregates may then negatively 
impact either the host or chemotherapy ability to eliminate the pathogen.  Future work is required 
to show these observations are reproducible and to prove this hypothesis further.  
  
5.2 – Future Directions 
The research presented in this dissertation is only the initial step for a larger image 
analysis pipeline, the purpose of which is to increase the efficiency of data collection during an 
Mtb infection. This section will serve as a road map for my successors on future directions and 
further refinements of this pipeline.  
Chapter 2 demonstrated that the LIRA software saves significant amounts of time and 
improves considerably on reproducibility on histopathology analysis of digital images while using 
this initial version of the LIRA software. However, several refinements could be implemented to 
improve the current workflow. First, LIRA’s pipeline analysis is currently a mixture of both 
command line and the general user interface (GUI). Because the majority of users will be non-
computer scientists, a large proportion of functions within the script will need to be called using 
graphical user interface (GUI) widgets. GUI widgets are the buttons you press in a piece of 
software that perform a specific task. Second, LIRA can only currently handle image file types 
that are non-proprietary (e.g., .jpg, .png, .tif). For this purpose, we wrote a script to convert the 
digital image scan files into a format that can be recognized by LIRA and the script still needs to 
be integrated into LIRA’s current workflow. Third, several functions (e.g., iterative looping) in LIRA 
could be further optimized using a faster programming language such as C or Cython. The new 
library of optimized code will need to be created to be callable in Python, and LIRA’s code will 
need to be updated. Lastly, it would be beneficial to implement an object detector to reduce the 
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amount of processing on empty slide window patches. This can be accomplished by performing 
the following stepwise approach: by uploading the original image, followed by creating a reduced 
image size copy (e.g. 10% of the original size), then determining the coordinates of the pulmonary 
tissue compartments in the image by creating a simple object detector, and only running CNN1, 
CNN2, and CNN3 on these specific window patches that are located within these coordinates. 
This will greatly reduce the large datasets that need to be processed and accelerate overall 
analysis time.  
TB is a complex disease with heterogeneity in lesion types present in the lungs. Lesion 
classification requires the identification of both the pathology features at a macroscopic level and 
cell type composition at a microscopic level. Therefore the LIRA software was specially designed 
to classify lesions using both macroscopic and microscopic classifications to address the 
complicated pulmonary pathology. While using the LIRA software on several C3heB/FeJ mouse 
studies over the last year, a realization occurred that two additional classifications could improve 
the current model. The first additional classification would include the detection of cavity formation 
in the Type I lesions at a macroscopic level. The second additional classification relates to the 
Type II lesions which often have pockets of DNA along the margin. These pockets of DNA 
resemble neutrophil extracellular traps (NETs), which seem to be consistently mislabeled by LIRA 
as Type III lesions. Creating a new classification, called NETs, and retraining the network should 
improve the overall model accuracy. The model architecture that the current LIRA software uses 
to make predictions on C3HeB/FeJ mouse models could, in the future, also be applied to 
additional TB animal models and disease types not currently integrated. New iterations of LIRA 
could include digital pathology analysis on the Guinea Pig, the rabbit model, on NHP, zebrafish 
models, and increased optimization for the BALB/c mice. These iterations will require the creation 
of new digital image data sets to create additional classifiers specific for these models.  
Chapter 3 demonstrated that LIRA is effective in correctly classifying data generated from 
a test case drug study using C3HeB/FeJ mice from 6 to 10 weeks post aerosol infection. At the 
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time of LIRA’s creation, the only available data for the training dataset was a larger number of 
tissue samples all collected within the six to ten week timeframe. Current studies are generating 
new data that extends past that timeframe. LIRA’s current iteration has noticeably poorer 
performance on more advanced pulmonary pathology past 12 weeks post aerosol infection, and 
therefore the model training dataset (CNN2 and CNN3) would benefit from updates with the 
current 12+ week data to improve accuracy. Chapter 4 demonstrated that the MIA software could 
effectively quantify bacterial singlets and aggregates, and separate bacterial populations based 
upon their lesion compartment location. Preliminary data showed that in vivo bacteria under stress 
might form larger aggregates or mycobacterial islands in cores of caseous lesions. To further 
investigate this hypothesis, we propose to implement both MIA and LIRA to more broadly study 
the effect on bacteria in more mouse efficacy studies, thereby using a wider range of current TB 
therapies, enhancing host immunity, or control agents designed to effect bacterial replication. An 
effective study will include therapies that target the bacteria and host therapies that either 
enhance or inhibit the host immune system. Treatments should include first-line drugs such as 
rifampin, ethambutol, and pyrazinamide as well as newly approved drugs for TB such as BDQ 
and linezolid. As a positive control and to assess the effect of the host on bacterial numbers and 
aggregation, mice could be vaccinated before initial infection to elicit a stronger immune response. 
A good candidate would be an intramuscular DNA vaccine containing Hsp65 and IL-12 genes 
that provided a 40% improvement of survival in Mtb infected primates [251]. As a negative control, 
additional therapies that change the integrity of granuloma formation can be used. This could 
include Enbrel [252], [253] which is a TNFα inhibitor, or Bevacizumab [254], [255]  which 
neutralizes vascular endothelial growth factor. Bevacizumab would be preferred, in the context of 
studying environmental stresses, since previous studies have shown that adjunct therapy of 
Bevacisumab increased the efficacy of first-line therapies by restoring the vascular architecture 
and consequently reducing hypoxia [21], [254].  Based on our initial results, we suspect that we 
will not observe the formation of the mycobacterial islands in the immune impaired cohorts. In 
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contrast, the cohorts that are receiving some form of therapy (e.g., antibiotics or vaccine) will 
develop moderate amounts of mycobacterial island formation. The Lenaerts laboratory is also 
investigating an experimental proprietary compound that appears to promote cavity formation 
within caseous necrotic lesions. The use of LIRA, in combination with MIA, will greatly enhance 
these studies by quantitatively monitoring both lesion development and the corresponding 
bacterial phenotype responses from initial infection to terminal cavity formation.   
The analysis of MIA might become even more impactful with the utilization of additional 
staining approaches that target other bacterial phenotypes or host cells. The MIA software in this 
dissertation was developed using the SYBR Gold staining method developed in our laboratory. 
However, the software was designed to gate for both Auromine Rhodamine (AR) and Ziehl 
Neelsen acid-fast staining. With minimal effort, the use of additional fluorophore channels can be 
integrated into the software by creating additional min and max HSV values specific to the 
wavelength color of the objects of interest. By using a wider diversity in fluorescent probes such 
as for detection of ribonucleic acid (RNA) by FISH, antibodies for use in immunohistochemistry, 
and other dyes will further the bacterial as well as host cell phenotypes and compositions. Of 
particular interest to our laboratory would be the further evaluation of the heterogeneity of bacterial 
populations within each lung compartment. We especially are interested in determining what 
proportion of bacilli are viable, metabolically active, are actively replicating, or show an altered 
cell wall. MIA can quantify an entire visual bacterial population within each lesion compartment, 
and in combination with the plethora of probes and staining approaches available more data and 
information can be generated. Of particular interest to me would be to study the number of Mtb 
phenotypes existing within each lesion compartment, and whether there is a predisposition for 
specific phenotypes for different environments. The end goal would be to be able to determine 
the effect of treatments on various bacterial phenotypes and in the different lung compartments.  
LIRA and MIA were designed as two separate software components which are intended 
in the future to be incorporated together as a single software. There are several steps that need 
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to happen before both software programs can be integrated to work in tandem. The first step will 
be the improvement of the current staining methodology in tissue samples. Because MIA relies 
on masking, the isolation of specific pixel values, the fluorescent signal needs to be pristine 
without background or false positive signals. Autofluorescence occurs with the use of aldehyde 
fixation (formaldehyde or glutaraldehyde), staining with H&E, and in tissues in the presence of 
high numbers of red blood cells. Attempts have been to reduce autofluorescence using 
counterstains such as potassium permanganate and Sudan Black with only limited success. What 
has proven successful was the implementation of a new perfusion technique reducing red blood 
cells that are naturally autofluorescent. The second area of improvement would be the image 
capturing devices. Current available microscopes on CSU campus and their software are not well 
suited for high image resolution throughput of large tissue datasets. This equipment shortcoming 
is probably the most limiting step in utilizing a high throughput analysis pipeline. Optimally, one 
would need a digital slide scanner to capture bright-field images of the H&E stained tissue, as 
well as taking corresponding scans of multiple fluorescent channels of a single area at the same 
time. At the moment, with the current equipment available, this process would be highly time-
consuming and is the reason that LIRA and MIA are still two separate entities to perform this type 
of analysis. The future vision is to overcome these obstacles and have a seamless analysis 
process that quantifies every relevant piece of data so that no important event is missed. Such a 
system is not feasible without utilizing the strengths of both AI and human analysis and 
understanding how they can be synergized together in a biological context. This approach will 
broaden our understanding of the interplay between the host and Mtb pathogen in the context of 
drug efficacy testing. With the continued optimization of analysis with new computational tools, 








[1] “WHO | Global tuberculosis report 2018,” WHO. [Online]. Available: 
http://www.who.int/tb/publications/global_report/en/. [Accessed: 20-May-2019]. 
[2] “WHO | 3. Tuberculosis control,” WHO. [Online]. Available: 
https://www.who.int/trade/distance_learning/gpgh/gpgh3/en/index7.html. [Accessed: 17-Oct-
2019]. 
[3] CDCMMWR, “World TB Day — March 24, 2019,” MMWR Morb. Mortal. Wkly. Rep., vol. 68, 2019. 
[4] “Tuberculosis (TB),” World Health Organization. [Online]. Available: http://www.who.int/news-
room/fact-sheets/detail/tuberculosis. [Accessed: 28-Jun-2018]. 
[5] “Treatment for TB Disease | Treatment | TB | CDC,” 09-May-2019. [Online]. Available: 
https://www.cdc.gov/tb/topic/treatment/tbdisease.htm. [Accessed: 21-May-2019]. 
[6] G. Elzinga, M. C. Raviglione, and D. Maher, “Scale up: meeting targets in global tuberculosis 
control,” The Lancet, vol. 363, no. 9411, pp. 814–819, Mar. 2004. 
[7] K. E. Dooley and R. E. Chaisson, “Tuberculosis and diabetes mellitus: convergence of two 
epidemics,” Lancet Infect. Dis., vol. 9, no. 12, pp. 737–746, Dec. 2009. 
[8] S.-H. Shieh, J. C. Probst, F.-C. Sung, W.-C. Tsai, Y.-S. Li, and C.-Y. Chen, “Decreased survival among 
lung cancer patients with co-morbid tuberculosis and diabetes,” BMC Cancer, vol. 12, p. 174, May 
2012. 
[9] “WHO | Surveillance of drug-resistant TB,” WHO. [Online]. Available: http://www.who.int/tb/areas-
of-work/monitoring-evaluation/mdr-tb-surveillance/en/. [Accessed: 21-May-2019]. 
[10] O. of the Commissioner, “FDA approves new drug for treatment-resistant forms of tuberculosis that 
affects the lungs,” FDA, 11-Sep-2019. [Online]. Available: http://www.fda.gov/news-events/press-
announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs. 
[Accessed: 15-Nov-2019]. 
[11] U. Manjunatha, H. I. Boshoff, and C. E. Barry, “The mechanism of action of PA-824,” Commun. 
Integr. Biol., vol. 2, no. 3, pp. 215–218, 2009. 
[12] A. M. Upton et al., “In Vitro and In Vivo Activities of the Nitroimidazole TBA-354 against 
Mycobacterium tuberculosis,” Antimicrob. Agents Chemother., vol. 59, no. 1, pp. 136–144, Jan. 
2015. 
[13] O. M. P. Jolobe, “Disseminated tuberculosis,” QJM Int. J. Med., vol. 110, no. 5, pp. 331–331, May 
2017. 
[14] R. L. Hunter, “PATHOLOGY of POST PRIMARY TUBERCULOSIS of the LUNG: AN ILLUSTRATED 
CRITICAL REVIEW,” Tuberc. Edinb. Scotl., vol. 91, no. 6, pp. 497–509, Nov. 2011. 
[15] R. J. Basaraba and R. L. Hunter, Pathology of Tuberculosis: How the Pathology of Human 
Tuberculosis Informs and Directs Animal Models, vol. 5. 2017. 
[16] W. C. Tobie, “The Tubercle Bacillus, in the Pulmonary Lesion of Man. Histobacteriology and Its 
Bearing on the Therapy of Pulmonary Tuberculosis. George Canetti,” Q. Rev. Biol., vol. 32, no. 2, pp. 
201–201, Jun. 1957. 
[17] G. Kaplan et al., “Mycobacterium tuberculosis growth at the cavity surface: a microenvironment 
with failed immunity,” Infect. Immun., vol. 71, no. 12, pp. 7099–7108, Dec. 2003. 
[18] A. Lenaerts, C. E. Barry, and V. Dartois, “Heterogeneity in tuberculosis pathology, 
microenvironments and therapeutic responses,” Immunol. Rev., vol. 264, no. 1, pp. 288–307, Mar. 
2015. 
[19] N. Dhar, J. McKinney, and G. Manina, “Phenotypic Heterogeneity in Mycobacterium tuberculosis,” 
Microbiol. Spectr., vol. 4, no. 6, Nov. 2016. 
123 
 
[20] “Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium 




[21] A. Kolloli and S. Subbian, “Host-Directed Therapeutic Strategies for Tuberculosis,” Front. Med., vol. 
4, Oct. 2017. 
[22] S. M. Irwin et al., “Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary 
Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice,” ACS Infect. Dis., vol. 
2, no. 4, pp. 251–267, Apr. 2016. 
[23] N. Strydom et al., “Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung 
lesions: A mechanistic model and tool for regimen and dose optimization,” PLOS Med., vol. 16, no. 
4, p. e1002773, Apr. 2019. 
[24] A. Williams and I. M. Orme, “Animal Models of Tuberculosis: An Overview,” Microbiol. Spectr., vol. 
4, no. 4, 2016. 
[25] A. Esteva et al., “Dermatologist-level classification of skin cancer with deep neural networks,” 
Nature, vol. 542, no. 7639, pp. 115–118, Feb. 2017. 
[26] D. C. Cireşan, A. Giusti, L. M. Gambardella, and J. Schmidhuber, “Mitosis Detection in Breast Cancer 
Histology Images with Deep Neural Networks,” in Medical Image Computing and Computer-Assisted 
Intervention – MICCAI 2013, vol. 8150, K. Mori, I. Sakuma, Y. Sato, C. Barillot, and N. Navab, Eds. 
Berlin, Heidelberg: Springer Berlin Heidelberg, 2013, pp. 411–418. 
[27] G. Litjens et al., “A Survey on Deep Learning in Medical Image Analysis,” Med. Image Anal., vol. 42, 
pp. 60–88, Dec. 2017. 
[28] J.-G. Lee et al., “Deep Learning in Medical Imaging: General Overview,” Korean J Radiol, vol. 18, no. 
4, pp. 570–584, Aug. 2017. 
[29] R. E. Butler et al., “The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis 
Infected Macrophages Is Not Dependent on Bacterial Virulence,” PLOS ONE, vol. 7, no. 10, p. 
e47573, Oct. 2012. 
[30] L. Huang, E. V. Nazarova, S. Tan, Y. Liu, and D. G. Russell, “Growth of Mycobacterium tuberculosis in 
vivo segregates with host macrophage metabolism and ontogeny,” J. Exp. Med., vol. 215, no. 4, pp. 
1135–1152, Apr. 2018. 
[31] Y. C. Manabe et al., “Different strains of Mycobacterium tuberculosis cause various spectrums of 
disease in the rabbit model of tuberculosis,” Infect. Immun., vol. 71, no. 10, pp. 6004–6011, Oct. 
2003. 
[32] K. Sakamoto, “The Pathology of Mycobacterium tuberculosis Infection,” Vet. Pathol., vol. 49, no. 3, 
pp. 423–439, Jan. 2012. 
[33] I. G. Sia and M. L. Wieland, “Current concepts in the management of tuberculosis,” Mayo Clin. Proc., 
vol. 86, no. 4, pp. 348–361, Apr. 2011. 
[34] G. W. Comstock, “Epidemiology of Tuberculosis,” Am. Rev. Respir. Dis., vol. 125, no. 3P2, pp. 8–15, 
Mar. 1982. 
[35] M. A. Behr, P. H. Edelstein, and L. Ramakrishnan, “Revisiting the timetable of tuberculosis,” BMJ, 
vol. 362, 2018. 
[36] V. Cornil and L. Ranvier, “Pathological histology of the respiratory apparatus,” in Manual of 
pathological histology, Philadelphia: Henry C Lea, 1880, pp. 407–445. 
[37] J. Andreu, J. Cáceres, E. Pallisa, and M. Martinez-Rodriguez, “Radiological manifestations of 
pulmonary tuberculosis,” Pulm. Infect., vol. 51, no. 2, pp. 139–149, Aug. 2004. 
124 
 
[38] A. A. Ordonez et al., “Radioiodinated DPA-713 Imaging Correlates with Bactericidal Activity of 
Tuberculosis Treatments in Mice,” Antimicrob. Agents Chemother., vol. 59, no. 1, pp. 642–649, Jan. 
2015. 
[39] R. L. Hunter, J. K. Actor, S.-A. Hwang, V. Karev, and C. Jagannath, “Pathogenesis of Post Primary 
Tuberculosis: Immunity and Hypersensitivity in the Development of Cavities,” Ann. Clin. Lab. Sci., 
vol. 44, no. 4, pp. 365–387, Sep. 2014. 
[40] R. L. Hunter, “Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary 
tuberculosis,” Tuberc. Edinb. Scotl., vol. 97, pp. 8–17, Mar. 2016. 
[41] G. Canetti, “Biology of the mycobacterioses. Pathogenesis of tuberculosis in man,” Ann. N. Y. Acad. 
Sci., vol. 154, no. 1, pp. 13–18, Sep. 1968. 
[42] K. Chatterjee, B. Colaco, C. Colaco, M. Hellman, and N. Meena, “Rasmussen’s aneurysm: A forgotten 
scourge,” Respir. Med. Case Rep., vol. 16, pp. 74–76, Jan. 2015. 
[43] A. O. Ankrah, T. S. van der Werf, E. F. J. de Vries, R. A. J. O. Dierckx, M. M. Sathekge, and A. W. J. M. 
Glaudemans, “PET/CT imaging of Mycobacterium tuberculosis infection,” Clin. Transl. Imaging, vol. 
4, pp. 131–144, 2016. 
[44] D. C. Perlman et al., “Variation of Chest Radiographic Patterns in Pulmonary Tuberculosis by Degree 
of Human Immunodeficiency Virus-Related Immunosuppression,” Clin. Infect. Dis., vol. 25, no. 2, pp. 
242–246, Aug. 1997. 
[45] R. Y. Chen et al., “PET/CT imaging correlates with treatment outcome in patients with multidrug-
resistant tuberculosis,” Sci. Transl. Med., vol. 6, no. 265, pp. 265ra166-265ra166, Dec. 2014. 
[46] M. T. Coleman et al., “PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques 
and humans with tuberculosis,” Sci. Transl. Med., vol. 6, no. 265, pp. 265ra167-265ra167, Dec. 2014. 
[47] “Historical Perspectives Centennial: Koch’s Discovery of the Tubercle Bacillus.” [Online]. Available: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/00000222.htm. [Accessed: 16-Nov-2019]. 
[48] A. K. Singh and U. D. Gupta, “Animal models of tuberculosis: Lesson learnt,” Indian J. Med. Res., vol. 
147, no. 5, pp. 456–463, May 2018. 
[49] K. Patel, S. S. Jhamb, and P. P. Singh, “Models of Latent Tuberculosis: Their Salient Features, 
Limitations, and Development,” J. Lab. Physicians, vol. 3, no. 2, pp. 75–79, 2011. 
[50] P. L. Lin et al., “Sterilization of granulomas is common in active and latent tuberculosis despite 
within-host variability in bacterial killing,” Nat. Med., vol. 20, no. 1, pp. 75–79, Jan. 2014. 
[51] P. L. Lin et al., “Early events in Mycobacterium tuberculosis infection in cynomolgus macaques,” 
Infect. Immun., vol. 74, no. 7, pp. 3790–3803, Jul. 2006. 
[52] E. L. Rayner et al., “Early lesions following aerosol infection of rhesus macaques (Macaca mulatta) 
with Mycobacterium tuberculosis strain H37RV,” J. Comp. Pathol., vol. 149, no. 4, pp. 475–485, Nov. 
2013. 
[53] L. E. Via et al., “Differential Virulence and Disease Progression following Mycobacterium 
tuberculosis Complex Infection of the Common Marmoset (Callithrix jacchus),” Infect. Immun., vol. 
81, no. 8, pp. 2909–2919, Aug. 2013. 
[54] G. Kaplan and L. Tsenova, “Pulmonary Tuberculosis in the Rabbit,” in A color atlas of comparative 
pathology of pulmonary tuberculosis, 2010, pp. 107–130. 
[55] M. E. Visser et al., “Baseline Predictors of Sputum Culture Conversion in Pulmonary Tuberculosis: 
Importance of Cavities, Smoking, Time to Detection and W-Beijing Genotype,” PLoS ONE, vol. 7, no. 
1, Jan. 2012. 
[56] S. Clark, Y. Hall, and A. Williams, “Animal models of tuberculosis: Guinea pigs,” Cold Spring Harb. 
Perspect. Med., vol. 5, no. 5, pp. a018572–a018572, Dec. 2014. 
[57] C. C. Dascher et al., “Immunization with a mycobacterial lipid vaccine improves pulmonary 




[58] S. S. Kashino, D. R. Napolitano, Z. Skobe, and A. Campos-Neto, “Guinea pig model of Mycobacterium 
tuberculosis latent/dormant infection,” Microbes Infect., vol. 10, no. 14, pp. 1469–1476, Nov. 2008. 
[59] T. F. Vandamme, “Use of rodents as models of human diseases,” J. Pharm. Bioallied Sci., vol. 6, no. 
1, pp. 2–9, Jan. 2014. 
[60] S. Major, J. Turner, and G. Beamer, “Tuberculosis in CBA/J Mice,” Vet. Pathol., vol. 50, no. 6, pp. 
1016–1021, Mar. 2013. 
[61] G. L. Beamer et al., “Interleukin-10 promotes Mycobacterium tuberculosis disease progression in 
CBA/J mice,” J. Immunol. Baltim. Md 1950, vol. 181, no. 8, pp. 5545–5550, Oct. 2008. 
[62] T. A. Skvortsov, D. V. Ignatov, K. B. Majorov, A. S. Apt, and T. L. Azhikina, “Mycobacterium 
tuberculosis Transcriptome Profiling in Mice with Genetically Different Susceptibility to 
Tuberculosis,” Acta Naturae, vol. 5, no. 2, pp. 62–69, 2013. 
[63] T. K. Kondratieva et al., “A new model for chronic and reactivation tuberculosis: Infection with 
genetically attenuated Mycobacterium tuberculosis in mice with polar susceptibility,” Tuberculosis, 
vol. 113, pp. 130–138, Dec. 2018. 
[64] F. Sánchez et al., “Multigenic Control of Disease Severity after Virulent <em>Mycobacterium 
tuberculosis</em> Infection in Mice,” Infect. Immun., vol. 71, no. 1, p. 126, Jan. 2003. 
[65] L. Heitmann et al., “The IL-13/IL-4Rα axis is involved in tuberculosis-associated pathology,” J. 
Pathol., vol. 234, no. 3, pp. 338–350, Nov. 2014. 
[66] C. L. Emson, S. E. Bell, A. Jones, W. Wisden, and A. N. J. McKenzie, “Interleukin (IL)-4–independent 
Induction of Immunoglobulin (Ig)E, and Perturbation of  T Cell Development in Transgenic Mice 
Expressing IL-13,” J. Exp. Med., vol. 188, no. 2, pp. 399–404, Jul. 1998. 
[67] Y.-J. Jung, R. LaCourse, L. Ryan, and R. J. North, “Evidence inconsistent with a negative influence of T 
helper 2 cells on protection afforded by a dominant T helper 1 response against Mycobacterium 
tuberculosis lung infection in mice,” Infect. Immun., vol. 70, no. 11, pp. 6436–6443, Nov. 2002. 
[68] I. Kramnik, W. F. Dietrich, P. Demant, and B. R. Bloom, “Genetic control of resistance to 
experimental infection with virulent Mycobacterium tuberculosis,” Proc. Natl. Acad. Sci., vol. 97, no. 
15, pp. 8560–8565, Jul. 2000. 
[69] H. Pan et al., “Ipr1 gene mediates innate immunity to tuberculosis,” Nature, vol. 434, no. 7034, pp. 
767–772, Apr. 2005. 
[70] B.-S. Yan et al., “Progression of Pulmonary Tuberculosis and Efficiency of Bacillus Calmette-Guérin 
Vaccination Are Genetically Controlled via a Common <em>sst1</em>-Mediated Mechanism of 
Innate Immunity,” J. Immunol., vol. 179, no. 10, p. 6919, Nov. 2007. 
[71] E. R. Driver et al., “Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ 
Mice for Testing of Drugs against Mycobacterium tuberculosis,” Antimicrob. Agents Chemother., vol. 
56, no. 6, pp. 3181–3195, Jun. 2012. 
[72] S. D. Chakravarty, J. Xu, B. Lu, C. Gerard, J. Flynn, and J. Chan, “The Chemokine Receptor CXCR3 
Attenuates the Control of Chronic Mycobacterium tuberculosis Infection in BALB/c Mice,” J. 
Immunol., vol. 178, no. 3, pp. 1723–1735, Feb. 2007. 
[73] G. J. Ryan et al., “Multiple M. tuberculosis Phenotypes in Mouse and Guinea Pig Lung Tissue 
Revealed by a Dual-Staining Approach,” PLOS ONE, vol. 5, no. 6, p. e11108, Jun. 2010. 
[74] S. M. Irwin et al., “Presence of multiple lesion types with vastly different microenvironments in 
C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis,” Dis. Model. Mech., 
vol. 8, no. 6, pp. 591–602, Jun. 2015. 
[75] J.-P. Lanoix et al., “Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is 
Best Explained by Neutral pH of Caseum,” Antimicrob. Agents Chemother., vol. 60, no. 2, pp. 735–
743, Feb. 2016. 
[76] A. A. Ordonez et al., “Mouse model of pulmonary cavitary tuberculosis and expression of matrix 
metalloproteinase-9,” Dis. Model. Mech., vol. 9, no. 7, pp. 779–788, 01 2016. 
126 
 
[77] S. S. Cross, “Grading and scoring in histopathology,” Histopathology, vol. 33, no. 2, pp. 99–106, 
1998. 
[78] J. W. Crissman et al., “Best Practices Guideline: Toxicologic Histopathology,” Toxicol. Pathol., vol. 32, 
no. 1, pp. 126–131, Jan. 2004. 
[79] K. N. Gibson-Corley, A. K. Olivier, and D. K. Meyerholz, “Principles for valid histopathologic scoring in 
research,” Vet. Pathol., vol. 50, no. 6, Nov. 2013. 
[80] G. T. Sica, “Bias in Research Studies,” Radiology, vol. 238, no. 3, pp. 780–789, Mar. 2006. 
[81] “Qualitative and Quantitative Analysis of Nonneoplastic Lesions in Toxicology Studies - Cynthia 
Shackelford, Gerald Long, Jeffrey Wolf, Carlin Okerberg, Ronald Herbert, 2002.” [Online]. Available: 
https://journals.sagepub.com/doi/abs/10.1080/01926230252824761. [Accessed: 30-Jul-2019]. 
[82] B. Thoolen et al., “Proliferative and Nonproliferative Lesions of the Rat and Mouse Hepatobiliary 
System,” Toxicol. Pathol., vol. 38, no. 7_suppl, pp. 5S-81S, Dec. 2010. 
[83] C. G. Begley and L. M. Ellis, “Drug development: Raise standards for preclinical cancer research,” 
Nature, vol. 483, pp. 531–533, Mar. 2012. 
[84] “Checklists work to improve science,” Nature, vol. 556, p. 273, Apr. 2018. 
[85] P. B. Stark, “Before reproducibility must come preproducibility,” Nature, vol. 557, p. 613, May 2018. 
[86] J. L. Hecht, J. Kotsopoulos, M. A. Gates, S. E. Hankinson, and S. S. Tworoger, “Validation of Tissue 
Microarray Technology in Ovarian Cancer: Results from the Nurses’ Health Study,” Cancer 
Epidemiol. Prev. Biomark., vol. 17, no. 11, pp. 3043–3050, Nov. 2008. 
[87] P. L. Lin et al., “Quantitative Comparison of Active and Latent Tuberculosis in the Cynomolgus 
Macaque Model,” Infect. Immun., vol. 77, no. 10, pp. 4631–4642, Oct. 2009. 
[88] M. S. Jassal, G. G. Nedeltchev, J. Osborne, and W. R. Bishai, “A modified scoring system to describe 
gross pathology in the rabbit model of tuberculosis,” BMC Microbiol., vol. 11, no. 1, p. 49, Mar. 
2011. 
[89] J. DORMANS et al., “Correlation of virulence, lung pathology, bacterial load and delayed type 
hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a 
BALB/c mouse model,” Clin. Exp. Immunol., vol. 137, no. 3, pp. 460–468, Sep. 2004. 
[90] P. W. Snook, “Comparison between Digital and Manual Interpretation of High Altitude Aerial,” p. 4. 
[91] J. McFadyen, M. Mermillod, J. B. Mattingley, V. Halász, and M. I. Garrido, “A Rapid Subcortical 
Amygdala Route for Faces Irrespective of Spatial Frequency and Emotion,” J. Neurosci., vol. 37, no. 
14, p. 3864, Apr. 2017. 
[92] B. V. Ehinger, K. Häusser, J. P. Ossandón, and P. König, “Humans treat unreliable filled-in percepts as 
more real than veridical ones,” eLife, vol. 6, p. e21761, May 2017. 
[93] “Visual perception,” 11-Oct-2017. [Online]. Available: https://qbi.uq.edu.au/brain/brain-
functions/visual-perception. [Accessed: 02-Aug-2019]. 
[94] E. Samei and E. A. Krupinski, The Handbook of Medical Image Perception and Techniques. Cambridge 
University Press, 2018. 
[95] D. Memmert, “The effects of eye movements, age, and expertise on inattentional blindness,” 
Conscious. Cogn., vol. 15, no. 3, pp. 620–627, Sep. 2006. 
[96] A. K. Barbey, “Network Neuroscience Theory of Human Intelligence,” Trends Cogn. Sci., vol. 22, no. 
1, pp. 8–20, Jan. 2018. 
[97] “IBM pitched Watson as a revolution in cancer care. It’s nowhere close,” STAT, 05-Sep-2017. . 
[98] H. L. Semigran, D. M. Levine, S. Nundy, and A. Mehrotra, “Comparison of Physician and Computer 
Diagnostic AccuracyComparison of Physician and Computer Diagnostic AccuracyLetters,” JAMA 
Intern. Med., vol. 176, no. 12, pp. 1860–1861, Dec. 2016. 
[99] D. Mery, F. Pedreschi, and A. Soto, “Automated Design of a Computer Vision System for Visual Food 
Quality Evaluation,” Food Bioprocess Technol., vol. 6, no. 8, pp. 2093–2108, Aug. 2013. 
127 
 
[100] M. Sonka, V. Hlavac, and R. Boyle, “Image pre-processing,” in Image Processing, Analysis and 
Machine Vision, M. Sonka, V. Hlavac, and R. Boyle, Eds. Boston, MA: Springer US, 1993, pp. 56–111. 
[101] J. G. Moik, Digital processing of remotely sensed images. 1980. 
[102] Y.-R. Van Eycke, J. Allard, I. Salmon, O. Debeir, and C. Decaestecker, “Image processing in digital 
pathology: an opportunity to solve inter-batch variability of immunohistochemical staining,” Sci. 
Rep., vol. 7, no. 1, pp. 1–15, Feb. 2017. 
[103] Y. Alginahi, “Preprocessing Techniques in Character Recognition,” in Character Recognition, M. 
Mori, Ed. Sciyo, 2010. 
[104] NIAID, Mycobacterium tuberculosis Bacteria. 2015. 
[105] “Pedestrian Detection Database.” [Online]. Available: 
https://www.cis.upenn.edu/~jshi/ped_html/. [Accessed: 15-Oct-2019]. 
[106] S. S. Haykin and S. S. Haykin, Neural networks and learning machines, 3rd ed. New York: Prentice 
Hall, 2009. 
[107] H. Larochelle, Y. Bengio, J. Louradour, and P. Lamblin, “Exploring Strategies for Training Deep 
Neural Networks,” J Mach Learn Res, vol. 10, pp. 1–40, Jun. 2009. 
[108] D. H. Hubel and T. N. Wiesel, “Receptive fields, binocular interaction and functional architecture 
in the cat’s visual cortex,” J. Physiol., vol. 160, no. 1, pp. 106-154.2, Jan. 1962. 
[109] J. Bruna, S. Chintala, Y. LeCun, S. Piantino, A. Szlam, and M. Tygert, “A mathematical motivation 
for complex-valued convolutional networks,” ArXiv150303438 Cs Stat, Mar. 2015. 
[110] Y. Lecun, L. Bottou, Y. Bengio, and P. Haffner, “Gradient-based learning applied to document 
recognition,” Proc. IEEE, vol. 86, no. 11, pp. 2278–2324, Nov. 1998. 
[111] K. Fukushima and S. Miyake, “Neocognitron: A Self-Organizing Neural Network Model for a 
Mechanism of Visual Pattern Recognition,” in Competition and Cooperation in Neural Nets, 1982, 
pp. 267–285. 
[112] Ç. Kaymak and A. Uçar, A Brief Survey and an Application of Semantic Image Segmentation for 
Autonomous Driving. 2018. 
[113] D. Hutchison et al., “Evaluation of Pooling Operations in Convolutional Architectures for Object 
Recognition,” in Artificial Neural Networks – ICANN 2010, vol. 6354, K. Diamantaras, W. Duch, and L. 
S. Iliadis, Eds. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010, pp. 92–101. 
[114] A. Krizhevsky, I. Sutskever, and G. E. Hinton, “ImageNet Classification with Deep Convolutional 
Neural Networks,” in Advances in Neural Information Processing Systems 25, F. Pereira, C. J. C. 
Burges, L. Bottou, and K. Q. Weinberger, Eds. Curran Associates, Inc., 2012, pp. 1097–1105. 
[115] P. Whiting, A. W. S. Rutjes, J. B. Reitsma, A. S. Glas, P. M. M. Bossuyt, and J. Kleijnen, “Sources of 
Variation and Bias in Studies of Diagnostic Accuracy: A Systematic Review,” Ann. Intern. Med., vol. 
140, no. 3, p. 189, Feb. 2004. 
[116] M.-C. Rousselet et al., “Sources of variability in histological scoring of chronic viral hepatitis,” 
Hepatology, vol. 41, no. 2, pp. 257–264, Feb. 2005. 
[117] F. Aeffner et al., “The Gold Standard Paradox in Digital Image Analysis: Manual Versus 
Automated Scoring as Ground Truth,” Arch. Pathol. Lab. Med., vol. 141, no. 9, pp. 1267–1275, Sep. 
2017. 
[118] A. E. Rey, G. T. Vallet, B. Riou, M. Lesourd, and R. Versace, “Memory plays tricks on me: 
perceptual bias induced by memory reactivated size in Ebbinghaus illusion,” Acta Psychol. (Amst.), 
vol. 161, pp. 104–109, Oct. 2015. 
[119] S. Coren and J. T. Enns, “Size contrast as a function of conceptual similarity between test and 
inducers,” Percept. Psychophys., vol. 54, no. 5, pp. 579–588, Nov. 1993. 
[120] M. K. Albert, “Occlusion, transparency, and lightness,” Vision Res., vol. 47, no. 24, pp. 3061–
3069, Nov. 2007. 
128 
 
[121] “Adelson E. Lightness perception and lightness illusions. In: Gazzaniga M, ed. The New Cognitive 







qs=chrome..69i57&sourceid=chrome&ie=UTF-8. [Accessed: 04-Aug-2019]. 
[122] “OSA | Number of discernible object colors is a conundrum.” [Online]. Available: 
https://www.osapublishing.org/josaa/abstract.cfm?uri=josaa-30-2-264. [Accessed: 04-Aug-2019]. 
[123] A. Valberg, “Color induction: Dependence on luminance, purity, and dominant or 
complementary wavelength of inducing stimuli,” JOSA, vol. 64, no. 11, pp. 1531–1540, Nov. 1974. 
[124] R. B. Lotto and D. Purves, “An empirical explanation of color contrast,” Proc. Natl. Acad. Sci., vol. 
97, no. 23, pp. 12834–12839, Nov. 2000. 
[125] “14-bit vs 12-bit RAW - Can You Tell The Difference?” [Online]. Available: 
https://photographylife.com/14-bit-vs-12-bit-raw. [Accessed: 04-Aug-2019]. 
[126] R. S. Nickerson, “Confirmation Bias: A Ubiquitous Phenomenon in Many Guises,” p. 46. 
[127] H. Ditrich, “Cognitive fallacies and criminal investigations,” Sci. Justice J. Forensic Sci. Soc., vol. 
55, no. 2, pp. 155–159, Mar. 2015. 
[128] I. B. Anderson, T. I. Sørensen, and A. Prener, “Increase in incidence of disease due to diagnostic 
drift: primary liver cancer in Denmark, 1943-85,” BMJ, vol. 302, no. 6774, pp. 437–440, Feb. 1991. 
[129] E. F. McInnes and C. L. Scudamore, “Review of approaches to the recording of background 
lesions in toxicologic pathology studies in rats,” Toxicol. Lett., vol. 229, no. 1, pp. 134–143, Aug. 
2014. 
[130] T. J. Fuchs, P. J. Wild, H. Moch, and J. M. Buhmann, “Computational Pathology Analysis of Tissue 
Microarrays Predicts Survival of Renal Clear Cell Carcinoma Patients,” in Proceedings of the 
international conference on Medical Image Computing and Computer-Assisted Intervention MICCAI, 
Berlin, Heidelberg, 2008, vol. 5242, pp. 1–8. 
[131] D. Cireşan, U. Meier, and J. Schmidhuber, “Multi-column Deep Neural Networks for Image 
Classification,” ArXiv12022745 Cs, Feb. 2012. 
[132] I. J. Goodfellow et al., “Generative Adversarial Networks,” ArXiv14062661 Cs Stat, Jun. 2014. 
[133] “Artificial intelligence in healthcare | Nature Biomedical Engineering.” [Online]. Available: 
https://www.nature.com/articles/s41551-018-0305-z. [Accessed: 05-Aug-2019]. 
[134] S. Kouchaki et al., “Application of machine learning techniques to tuberculosis drug resistance 
analysis,” Bioinforma. Oxf. Engl., Nov. 2018. 
[135] “Efficient Deep Network Architectures for Fast Chest X-Ray Tuberculosis Screening and 
Visualization | Scientific Reports.” [Online]. Available: https://www.nature.com/articles/s41598-
019-42557-4. [Accessed: 05-Aug-2019]. 
[136] S. Lopez-Garnier, P. Sheen, and M. Zimic, “Automatic diagnostics of tuberculosis using 
convolutional neural networks analysis of MODS digital images,” PLOS ONE, vol. 14, no. 2, p. 
e0212094, Feb. 2019. 
[137] “The top 10 causes of death,” World Health Organization. [Online]. Available: 
http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. [Accessed: 28-Jun-
2018]. 
[138] David S. Barnes, The making of a social disease tuberculosis in nineteenth-century France. 
Berkeley, Place of publication not identified, Berkeley, Calif.: University of California Press, 1995. 
129 
 
[139] J. L. Cook, “Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model By 
Arthur M. Dannenberg, Jr. Washington, D.C.: ASM Press, 2006. 468 pp., illustrated. $149.95 (cloth),” 
Clin. Infect. Dis., vol. 44, no. 9, pp. 1257–1257, May 2007. 
[140] G. Manina, N. Dhar, and J. D. McKinney, “Stress and Host Immunity Amplify Mycobacterium 
tuberculosis Phenotypic Heterogeneity and Induce Nongrowing Metabolically Active Forms,” Cell 
Host Microbe, vol. 17, no. 1, pp. 32–46, Jan. 2015. 
[141] S. Gagneux, “Host–pathogen coevolution in human tuberculosis,” Philos. Trans. R. Soc. B Biol. 
Sci., vol. 367, no. 1590, pp. 850–859, Mar. 2012. 
[142] D. F. Warner and V. Mizrahi, “Tuberculosis Chemotherapy: the Influence of Bacillary Stress and 
Damage Response Pathways on Drug Efficacy,” Clin. Microbiol. Rev., vol. 19, no. 3, pp. 558–570, Jul. 
2006. 
[143] R. S. Wallis, M. Palaci, and K. Eisenach, “Persistence, Not Resistance, Is the Cause of Loss of 
Isoniazid Effect,” J. Infect. Dis., vol. 195, no. 12, pp. 1870–1871, Jun. 2007. 
[144] R. R. Kempker, M. Kipiani, V. Mirtskhulava, N. Tukvadze, M. J. Magee, and H. M. Blumberg, 
“Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with 
Multidrug-Resistant Tuberculosis,” Emerg. Infect. Dis., vol. 21, no. 6, pp. 992–1001, Jun. 2015. 
[145] C. D. Hamilton et al., “The value of end-of-treatment chest radiograph in predicting pulmonary 
tuberculosis relapse,” Sep-2008. [Online]. Available: 
https://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000009/art00014. 
[Accessed: 01-Aug-2018]. 
[146] H.-R. Kim et al., “Impact of Extensive Drug Resistance on Treatment Outcomes in Non-HIV-
Infected Patients with Multidrug-Resistant Tuberculosis,” Clin. Infect. Dis., vol. 45, no. 10, pp. 1290–
1295, Nov. 2007. 
[147] B. Prideaux et al., “The association between sterilizing activity and drug distribution into 
tuberculosis lesions,” Nat. Med., vol. 21, no. 10, pp. 1223–1227, Oct. 2015. 
[148] E. J. Muñoz-Elías, J. Timm, T. Botha, W.-T. Chan, J. E. Gomez, and J. D. McKinney, “Replication 
Dynamics of Mycobacterium tuberculosis in Chronically Infected Mice,” Infect. Immun., vol. 73, no. 
1, pp. 546–551, Jan. 2005. 
[149] S. M. Irwin et al., “Limited Activity of Clofazimine as a Single Drug in a Mouse Model of 
Tuberculosis Exhibiting Caseous Necrotic Granulomas,” Antimicrob. Agents Chemother., vol. 58, no. 
7, pp. 4026–4034, Jul. 2014. 
[150] A. A. Ordonez et al., “Mouse model of pulmonary cavitary tuberculosis and expression of matrix 
metalloproteinase-9,” Dis. Model. Mech., vol. 9, no. 7, pp. 779–788, 01 2016. 
[151] I. M. Orme, “Tuberculosis Vaccine Types and Timings,” Clin Vaccine Immunol, vol. 22, no. 3, pp. 
249–257, Mar. 2015. 
[152] V. K. Sambandamurthy et al., “Long-Term Protection against Tuberculosis following Vaccination 
with a Severely Attenuated Double Lysine and Pantothenate Auxotroph of Mycobacterium 
tuberculosis,” Infect. Immun., vol. 73, no. 2, pp. 1196–1203, Feb. 2005. 
[153] L. E. Via et al., “A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance 
of Bacteria in Cavitary Lesions in Marmosets,” Antimicrob. Agents Chemother., vol. 59, no. 7, pp. 
4181–4189, Jul. 2015. 
[154] A. G. White et al., “Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium 
tuberculosis Infection and Treatment in Non-human Primates,” JoVE J. Vis. Exp., no. 127, pp. 
e56375–e56375, Sep. 2017. 
[155] L. Via et al., “Infection Dynamics and Response to Chemotherapy in a Rabbit Model of 
Tuberculosis using [F-18]2-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed 
Tomography,” Antimicrob. Agents Chemother., vol. 56, pp. 4391–402, Jun. 2012. 
130 
 
[156] M. Lee et al., “Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis,” N. 
Engl. J. Med., vol. 367, no. 16, pp. 1508–1518, Oct. 2012. 
[157] S. T. Malherbe et al., “Persisting PET-CT lesion activity and M. tuberculosis mRNA after 
pulmonary tuberculosis cure,” Nat. Med., vol. 22, no. 10, pp. 1094–1100, Oct. 2016. 
[158] P. L. Lin et al., “Radiologic Responses in Cynomolgus Macaques for Assessing Tuberculosis 
Chemotherapy Regimens,” Antimicrob. Agents Chemother., vol. 57, no. 9, pp. 4237–4244, Sep. 
2013. 
[159] R. J. Basaraba et al., “Lymphadenitis as a major element of disease in the guinea pig model of 
tuberculosis,” Tuberculosis, vol. 86, no. 5, pp. 386–394, Sep. 2006. 
[160] Z. Han, B. Wei, Y. Zheng, Y. Yin, K. Li, and S. Li, “Breast Cancer Multi-classification from 
Histopathological Images with Structured Deep Learning Model,” Sci. Rep., vol. 7, no. 1, p. 4172, Jun. 
2017. 
[161] Z. Yan et al., “Multi-Instance Deep Learning: Discover Discriminative Local Anatomies for 
Bodypart Recognition,” IEEE Trans. Med. Imaging, vol. 35, no. 5, pp. 1332–1343, May 2016. 
[162] G. Wu, M. Kim, Q. Wang, Y. Gao, S. Liao, and D. Shen, “Unsupervised Deep Feature Learning for 
Deformable Registration of MR Brain Images,” in Medical image computing and computer-assisted 
intervention : MICCAI ... International Conference on Medical Image Computing and Computer-
Assisted Intervention, 2013, vol. 16, pp. 649–56. 
[163] Y. Xu et al., “Large scale tissue histopathology image classification, segmentation, and 
visualization via deep convolutional activation features,” BMC Bioinformatics, vol. 18, May 2017. 
[164] “Machine Learning Methods for Histopathological Image Analysis.” [Online]. Available: 
https://reader.elsevier.com/reader/sd/24A2E9B94F1FBA96FAF83C82BEAB7F6D62B6160BEB3D2BA
E2E8D14DB52DA2639EA3E0031E6FEB1853F99A9A97720D6AD. [Accessed: 28-Jun-2018]. 
[165] B. Kieffer, M. Babaie, S. Kalra, and H. R. Tizhoosh, “Convolutional Neural Networks for 
Histopathology Image Classification: Training vs. Using Pre-Trained Networks,” ArXiv171005726 Cs, 
Oct. 2017. 
[166] L. Hou et al., “Automatic histopathology image analysis with CNNs,” in 2016 New York Scientific 
Data Summit (NYSDS), 2016, pp. 1–6. 
[167] N. Hatipoglu and G. Bilgin, “Classification of histopathological images using convolutional neural 
network,” in 2014 4th International Conference on Image Processing Theory, Tools and Applications 
(IPTA), 2014, pp. 1–6. 
[168] P. Mobadersany et al., “Predicting cancer outcomes from histology and genomics using 
convolutional networks,” Proc. Natl. Acad. Sci., p. 201717139, Mar. 2018. 
[169] M. K. S. Varma, N. K. K. Rao, K. K. Raju, and G. P. S. Varma, “Pixel-Based Classification Using 
Support Vector Machine Classifier,” in 2016 IEEE 6th International Conference on Advanced 
Computing (IACC), 2016, pp. 51–55. 
[170] A. Tzotsos, A Support Vector Machine Approach for Object Based Image Analysis. . 
[171] Y. Lecun and Y. Bengio, “Convolutional networks for images, speech, and time-series,” Handb. 
Brain Theory Neural Netw., 1995. 
[172] Y. LeCun, Y. Bengio, and G. Hinton, “Deep learning,” Nature, vol. 521, no. 7553, pp. 436–444, 
May 2015. 
[173] Y. Ding, Q. Feng, T. Wang, and X. Fu, “A modular neural network architecture with concept,” 
Neurocomputing, vol. 125, pp. 3–6, Feb. 2014. 
[174] B. L. M. Happel and J. M. J. Murre, “Design and evolution of modular neural network 
architectures,” Neural Netw., vol. 7, no. 6, pp. 985–1004, Jan. 1994. 
[175] “Deep and Modular Neural Networks | SpringerLink.” [Online]. Available: 
https://link.springer.com/chapter/10.1007/978-3-662-43505-2_28. [Accessed: 18-Jul-2018]. 
131 
 
[176] C. S. Pattichis, F. Schnorrenberg, C. N. Schizas, M. S. Pattichis, and K. Kyriacou, “A Modular 
Neural Network System for the Analysis of Nuclei in Histopathological Sections,” in Computational 
Intelligence Processing in Medical Diagnosis, Physica, Heidelberg, 2002, pp. 291–322. 
[177] P. L. Dunn and R. J. North, “Virulence ranking of some Mycobacterium tuberculosis and 
Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung 
pathology, and cause mortality in mice,” Infect. Immun., vol. 63, no. 9, pp. 3428–3437, Sep. 1995. 
[178] B. P. Kelly, S. K. Furney, M. T. Jessen, and I. M. Orme, “Low-dose aerosol infection model for 
testing drugs for efficacy against Mycobacterium tuberculosis.,” Antimicrob. Agents Chemother., vol. 
40, no. 12, pp. 2809–2812, Dec. 1996. 
[179] M. A. De Groote et al., “Comparative Studies Evaluating Mouse Models Used for Efficacy Testing 
of Experimental Drugs against Mycobacterium tuberculosis,” Antimicrob. Agents Chemother., vol. 
55, no. 3, pp. 1237–1247, Mar. 2011. 
[180] J. C. Cyktor, B. Carruthers, R. A. Kominsky, G. L. Beamer, P. Stromberg, and J. Turner, “IL-10 
Inhibits Mature Fibrotic Granuloma Formation during Mycobacterium tuberculosis Infection,” J. 
Immunol., p. 1202722, Feb. 2013. 
[181] “Labeling Nodes Using Three Degrees of Propagation.” [Online]. Available: 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0051947. [Accessed: 19-Jul-2018]. 
[182] M. Gamer, J. Lemon, and I. F. P. Singh, irr: Various Coefficients of Interrater Reliability and 
Agreement. 2019. 
[183] J. L. Fleiss, “Measuring nominal scale agreement among many raters.,” Psychol. Bull., vol. 76, no. 
5, pp. 378–382, 1971. 
[184] K. A. Hallgren, “Computing Inter-Rater Reliability for Observational Data: An Overview and 
Tutorial,” Tutor. Quant. Methods Psychol., vol. 8, no. 1, pp. 23–34, 2012. 
[185] M. L. McHugh, “Interrater reliability: the kappa statistic,” Biochem. Medica, vol. 22, no. 3, pp. 
276–282, Oct. 2012. 
[186] K. Krippendorff, “Computing Krippendorff’s Alpha-Reliability,” p. 12. 
[187] K. Krippendorff, Content analysis an introduction to its methodology, Fourth Edition. Los 
Angeles: SAGE, 2019. 
[188] R. Klopfleisch, “Multiparametric and semiquantitative scoring systems for the evaluation of 
mouse model histopathology - a systematic review,” BMC Vet. Res., vol. 9, no. 1, p. 123, Jun. 2013. 
[189] M. A. Gavrielides, B. D. Gallas, P. Lenz, A. Badano, and S. M. Hewitt, “Observer Variability in the 
Interpretation of HER2/neu Immunohistochemical Expression With Unaided and Computer-Aided 
Digital Microscopy,” Arch. Pathol. Lab. Med., vol. 135, no. 2, pp. 233–242, Feb. 2011. 
[190] D. D. Miller and E. W. Brown, “Artificial Intelligence in Medical Practice: The Question to the 
Answer?,” Am. J. Med., vol. 131, no. 2, pp. 129–133, Feb. 2018. 
[191] J. Yosinski, J. Clune, Y. Bengio, and H. Lipson, “How transferable are features in deep neural 
networks?,” in Advances in Neural Information Processing Systems 27, Z. Ghahramani, M. Welling, 
C. Cortes, N. D. Lawrence, and K. Q. Weinberger, Eds. Curran Associates, Inc., 2014, pp. 3320–3328. 
[192] G. J Ryan, H. Shapiro, and A. J Lenaerts, Improving acid-fast fluorescent staining for the detection 
of mycobacteria using a new nucleic acid staining approach, vol. 94. 2014. 
[193] L. Blanc, A. Lenaerts, V. Dartois, and B. Prideaux, “Visualization of Mycobacterial Biomarkers and 
Tuberculosis Drugs in Infected Tissue by MALDI-MS Imaging,” Anal. Chem., vol. 90, no. 10, pp. 6275–
6282, May 2018. 
[194] “Treatment Regimens for Latent TB Infection | Treatment | TB | CDC,” 18-Jul-2019. [Online]. 
Available: https://www.cdc.gov/tb/topic/treatment/ltbi.htm. [Accessed: 24-Oct-2019]. 
[195] World Health Organization and Stop TB Initiative (World Health Organization), Eds., Treatment 
of tuberculosis: guidelines, 4th ed. Geneva: World Health Organization, 2010. 
132 
 
[196] G. S. Timmins and V. Deretic, “Mechanisms of action of isoniazid,” Mol. Microbiol., vol. 62, no. 5, 
pp. 1220–1227, Dec. 2006. 
[197] “Dynamic Persistence of Antibiotic-Stressed Mycobacteria | Science.” [Online]. Available: 
https://science.sciencemag.org/content/339/6115/91. [Accessed: 29-Aug-2019]. 
[198] “Tuberculosis Drugs and Mechanisms of Action | NIH: National Institute of Allergy and Infectious 
Diseases.” [Online]. Available: https://www.niaid.nih.gov/diseases-conditions/tbdrugs. [Accessed: 
24-Oct-2019]. 
[199] Y. Tang et al., “Non-adherence to anti-tuberculosis treatment among internal migrants with 
pulmonary tuberculosis in Shenzhen, China: a cross-sectional study,” BMC Public Health, vol. 15, 
May 2015. 
[200] C. Lange, D. Chesov, J. Heyckendorf, C. C. Leung, Z. Udwadia, and K. Dheda, “Drug-resistant 
tuberculosis: An update on disease burden, diagnosis and treatment,” Respirol. Carlton Vic, vol. 23, 
no. 7, pp. 656–673, Jul. 2018. 
[201] “Tuberculosis surveillance and monitoring in Europe 2015,” European Centre for Disease 
Prevention and Control, 17-Mar-2015. [Online]. Available: 
https://www.ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-
europe-2015. [Accessed: 24-Oct-2019]. 
[202] “WHO | Global tuberculosis report 2019,” WHO. [Online]. Available: 
http://www.who.int/tb/publications/global_report/en/. [Accessed: 24-Oct-2019]. 
[203] C. H. Wong, K. W. Siah, and A. W. Lo, “Estimation of clinical trial success rates and related 
parameters,” Biostatistics, vol. 20, no. 2, pp. 273–286, Apr. 2019. 
[204] O. of the Commissioner, “Step 1: Discovery and Development,” FDA, Apr. 2019. 
[205] J. L. Davis, “Chapter 2 - Pharmacologic Principles,” in Equine Internal Medicine (Fourth Edition), 
S. M. Reed, W. M. Bayly, and D. C. Sellon, Eds. W.B. Saunders, 2018, pp. 79–137. 
[206] E. R. Driver, “C3HeB/FeJ mice as a novel preclinical mouse model for Mycobacterium 
tuberculosis : an analysis of the host pathogenesis and the in vivo environment of the necrotic 
granuloma, The,” Thesis, Colorado State University. Libraries, 2015. 
[207] J. Harper et al., “Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions,” 
J. Infect. Dis., vol. 205, no. 4, pp. 595–602, Feb. 2012. 
[208] A. J. Lenaerts et al., “Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis 
Revealed by R207910,” Antimicrob. Agents Chemother., vol. 51, no. 9, pp. 3338–3345, Sep. 2007. 
[209] S. J. Sasindran and J. B. Torrelles, “Mycobacterium Tuberculosis Infection and Inflammation: 
what is Beneficial for the Host and for the Bacterium?,” Front. Microbiol., vol. 2, Jan. 2011. 
[210] V. Dartois and C. E. Barry, “Clinical pharmacology and lesion penetrating properties of second- 
and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and 
extensively-drug resistant (XDR) tuberculosis.,” Curr. Clin. Pharmacol., vol. 5, no. 2, pp. 96–114, May 
2010. 
[211] J. P. Sarathy et al., “Prediction of Drug Penetration in Tuberculosis Lesions,” ACS Infect. Dis., vol. 
2, no. 8, pp. 552–563, Aug. 2016. 
[212] G. V. Rayasam and T. S. Balganesh, “Exploring the potential of adjunct therapy in tuberculosis,” 
Trends Pharmacol. Sci., vol. 36, no. 8, pp. 506–513, Aug. 2015. 
[213] E. Hennessy, C. Adams, F. J. Reen, and F. O’Gara, “Is There Potential for Repurposing Statins as 
Novel Antimicrobials?,” Antimicrob. Agents Chemother., vol. 60, no. 9, pp. 5111–5121, Sep. 2016. 
[214] J.-W. C. Alffenaar, O. W. Akkerman, and R. van Hest, “Statin Adjunctive Therapy for Tuberculosis 
Treatment,” Antimicrob. Agents Chemother., vol. 60, no. 11, pp. 7004–7004, Nov. 2016. 
[215] D. A. Jolliffe et al., “Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual 
participant data,” Eur. Respir. J., vol. 53, no. 3, Mar. 2019. 
133 
 
[216] “Losartan: MedlinePlus Drug Information.” [Online]. Available: 
https://medlineplus.gov/druginfo/meds/a695008.html. [Accessed: 29-Aug-2019]. 
[217] R. D. Cohn et al., “Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure 
of muscle regeneration in multiple myopathic states,” Nat. Med., vol. 13, no. 2, pp. 204–210, Feb. 
2007. 
[218] K. Garg, B. T. Corona, and T. J. Walters, “Losartan administration reduces fibrosis but hinders 
functional recovery after volumetric muscle loss injury,” J. Appl. Physiol., vol. 117, no. 10, pp. 1120–
1131, Sep. 2014. 
[219] M. Molina-Molina et al., “Losartan attenuates bleomycin induced lung fibrosis by increasing 
prostaglandin E2 synthesis,” Thorax, vol. 61, no. 7, p. 604, Jul. 2006. 
[220] M. Robinson et al., “Quality assurance guidance for scoring and reporting for pathologists and 
laboratories undertaking clinical trial work,” J. Pathol. Clin. Res., vol. 5, no. 2, pp. 91–99, 2019. 
[221] A. J. Lenaerts et al., “Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against 
Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models,” Antimicrob. Agents 
Chemother., vol. 49, no. 6, pp. 2294–2301, Jun. 2005. 
[222] I. M. Orme, “Immune Responses in Animal Models,” in Tuberculosis, T. M. Shinnick, Ed. Berlin, 
Heidelberg: Springer Berlin Heidelberg, 1996, pp. 181–196. 
[223] D. J. Ordway et al., “Evaluation of Standard Chemotherapy in the Guinea Pig Model of 
Tuberculosis,” Antimicrob. Agents Chemother., vol. 54, no. 5, pp. 1820–1833, May 2010. 
[224] Y. Zhang, M. M. Wade, A. Scorpio, H. Zhang, and Z. Sun, “Mode of action of pyrazinamide: 
disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid,” 
J. Antimicrob. Chemother., vol. 52, no. 5, pp. 790–795, Nov. 2003. 
[225] K. Kurthkoti et al., “The Capacity of Mycobacterium tuberculosis To Survive Iron Starvation 
Might Enable It To Persist in Iron-Deprived Microenvironments of Human Granulomas,” mBio, vol. 8, 
no. 4, pp. e01092-17, Sep. 2017. 
[226] H. Polena et al., “Mycobacterium tuberculosis exploits the formation of new blood vessels for its 
dissemination,” Sci. Rep., vol. 6, Sep. 2016. 
[227] M. C. Tsai et al., “Characterization of the tuberculous granuloma in murine and human lungs: 
cellular composition and relative tissue oxygen tension,” Cell. Microbiol., vol. 8, no. 2, pp. 218–232, 
2006. 
[228] M.-J. Kim et al., “Caseation of human tuberculosis granulomas correlates with elevated host lipid 
metabolism,” EMBO Mol. Med., vol. 2, no. 7, pp. 258–274, Jul. 2010. 
[229] S. K. Ward, B. Abomoelak, S. A. Marcus, and A. M. Talaat, “Transcriptional Profiling of 
Mycobacterium Tuberculosis During Infection: Lessons Learned,” Front. Microbiol., vol. 1, Nov. 
2010. 
[230] W. Lee, B. C. VanderVen, R. J. Fahey, and D. G. Russell, “Intracellular Mycobacterium 
tuberculosis Exploits Host-derived Fatty Acids to Limit Metabolic Stress,” J. Biol. Chem., vol. 288, no. 
10, pp. 6788–6800, Mar. 2013. 
[231] “Mycobacterial survival strategies in the phagosome: defence against host stresses. - PubMed - 
NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/19438516. [Accessed: 31-Oct-
2019]. 
[232] “Targeting phenotypically tolerant Mycobacterium tuberculosis.” [Online]. Available: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367488/. [Accessed: 31-Oct-2019]. 
[233] L. G. Wayne, “Synchronized replication of Mycobacterium tuberculosis.,” Infect. Immun., vol. 17, 
no. 3, p. 528, Sep. 1977. 
[234] L. G. Wayne, “Dormancy of Mycobacterium tuberculosis and latency of disease,” Eur. J. Clin. 
Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol., vol. 13, no. 11, pp. 908–914, Nov. 1994. 
134 
 
[235] M. Gengenbacher and S. H. E. Kaufmann, “Mycobacterium tuberculosis: Success through 
dormancy,” Fems Microbiol. Rev., vol. 36, no. 3, pp. 514–532, May 2012. 
[236] N. D. Walter et al., “Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis 
During Treatment of Human Tuberculosis,” J. Infect. Dis., vol. 212, no. 6, pp. 990–998, Sep. 2015. 
[237] G. L. Hobby, K. Meyer, and E. Chaffee, “Observations on the Mechanism of Action of Penicillin.,” 
Proc. Soc. Exp. Biol. Med., vol. 50, no. 2, pp. 281–285, Jun. 1942. 
[238] “Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. - PubMed - 
NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/15207493. [Accessed: 05-Nov-
2019]. 
[239] H. L. Torrey, I. Keren, L. E. Via, J. S. Lee, and K. Lewis, “High Persister Mutants in Mycobacterium 
tuberculosis,” PLoS ONE, vol. 11, no. 5, May 2016. 
[240] Z. Ahmad et al., “Biphasic Kill Curve of Isoniazid Reveals the Presence of Drug-Tolerant, Not 
Drug-Resistant, Mycobacterium tuberculosis in the Guinea Pig,” J. Infect. Dis., vol. 200, no. 7, pp. 
1136–1143, Oct. 2009. 
[241] E. C. Hett and E. J. Rubin, “Bacterial Growth and Cell Division: a Mycobacterial Perspective,” 
Microbiol. Mol. Biol. Rev. MMBR, vol. 72, no. 1, pp. 126–156, Mar. 2008. 
[242] C. Deb et al., “A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis 
generates a lipid-loaded, drug-tolerant, dormant pathogen,” PloS One, vol. 4, no. 6, p. e6077, Jun. 
2009. 
[243] A. Bhatt et al., “Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and 
subclinical latent tuberculosis in immunocompetent mice,” Proc. Natl. Acad. Sci. U. S. A., vol. 104, 
no. 12, pp. 5157–5162, Mar. 2007. 
[244] Y. Yuan, Y. Zhu, D. D. Crane, and C. E. Barry, “The effect of oxygenated mycolic acid composition 
on cell wall function and macrophage growth in Mycobacterium tuberculosis,” Mol. Microbiol., vol. 
29, no. 6, pp. 1449–1458, Sep. 1998. 
[245] P. Seiler et al., “Cell-Wall Alterations as an Attribute of Mycobacterium tuberculosis in Latent 
Infection,” J. Infect. Dis., vol. 188, no. 9, pp. 1326–1331, Nov. 2003. 
[246] H. Yamada, M. Yamaguchi, K. Chikamatsu, A. Aono, and S. Mitarai, “Structome Analysis of 
Virulent Mycobacterium tuberculosis, Which Survives with Only 700 Ribosomes per 0.1 fl of 
Cytoplasm,” PLoS ONE, vol. 10, no. 1, Jan. 2015. 
[247] R. Hazan, Y.-A. Que, D. Maura, and L. G. Rahme, “A method for high throughput determination 
of viable bacteria cell counts in 96-well plates,” BMC Microbiol., vol. 12, p. 259, Nov. 2012. 
[248] D. Qin, X. He, K. Wang, X. J. Zhao, W. Tan, and J. Chen, “Fluorescent Nanoparticle-Based Indirect 
Immunofluorescence Microscopy for Detection of Mycobacterium tuberculosis,” J. Biomed. 
Biotechnol., vol. 2007, 2007. 
[249] G. Tarhan, L. Ordulu, F. Gümüşlü, I. Ceyhan, and S. Cesur, “[Comparison of auramine-rhodamine 
and Erlich-Ziehl-Neelsen staining methods for the diagnosis of tuberculosis],” Mikrobiyol. Bul., vol. 
37, no. 2–3, pp. 131–136, Jun. 2003. 
[250] J. Shah et al., “Dual color fluorescence in situ hybridization (FISH) assays for detecting 
Mycobacterium tuberculosis and Mycobacterium avium complexes and related pathogens in 
cultures,” PLoS ONE, vol. 12, no. 4, Apr. 2017. 
[251] M. Okada et al., “Novel therapeutic vaccine: Granulysin and new DNA vaccine against 
Tuberculosis,” Hum. Vaccin., vol. 7, no. sup1, pp. 60–67, Jan. 2011. 
[252] S. Mezouar, I. Diarra, J. Roudier, B. Desnues, and J.-L. Mege, “Tumor Necrosis Factor-Alpha 
Antagonist Interferes With the Formation of Granulomatous Multinucleated Giant Cells: New 
Insights Into Mycobacterium tuberculosis Infection,” Front. Immunol., vol. 10, 2019. 
135 
 
[253] S. D. Chakravarty et al., “Tumor necrosis factor blockade in chronic murine tuberculosis 
enhances granulomatous inflammation and disorganizes granulomas in the lungs,” Infect. Immun., 
vol. 76, no. 3, pp. 916–926, Mar. 2008. 
[254] M. Datta et al., “Anti-vascular endothelial growth factor treatment normalizes tuberculosis 
granuloma vasculature and improves small molecule delivery,” Proc. Natl. Acad. Sci. U. S. A., vol. 
112, no. 6, pp. 1827–1832, Feb. 2015. 
[255] N. P. Kumar, V. V. Banurekha, D. Nair, and S. Babu, “Circulating Angiogenic Factors as 
Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis,” PloS One, vol. 11, 
no. 1, p. e0146318, 2016. 
[256] G. Middlebrook, R. J. Dubos, and C. Pierce, “VIRULENCE AND MORPHOLOGICAL 
CHARACTERISTICS OF MAMMALIAN TUBERCLE BACILLI,” J. Exp. Med., vol. 86, no. 2, pp. 175–184, 
Jul. 1947. 
[257] H. Bloch, “Studies on the virulence of tubercle bacilli; isolation and biological properties of a 


























HETEROGENEITY OF PULMONARY LESION TYPES IN C3HEB/FEJ MICE IS MODULATED 
BY SPECIFIC CHARACTERISTICS OF THE M. TUBERCULOSIS STRAIN USED 
 
A1. Introduction 
C3HeB/FeJ mice are a TB animal model that develops caseous necrotic pulmonary 
granulomas resembling the human granuloma that develops during a TB infection. These 
granulomas form into three morphologically distinct types that have been classified as 
encapsulated granulomas with central necrosis (Type I), fulminant neutrophilic alveolitis (Type II), 
and cellular inflammatory lesions (Type III). It is not fully understood how external factors, such 
as the bacterial strain used during infection, will influence the host response of determining the 
lesion type that will be developed. In our laboratory, a culture batch of Mycobacterium tuberculosis 
Erdman unexpectedly exhibited heightened levels of virulence, which included a substantially 
increased mortality rate, high levels of bacterial cording, and substantial levels of pulmonary 
lesion involvement. This event was not isolated to our laboratory but was also observed in a 
collaborator's culture that found similar events.  Taking advantage of these hypervirulent cultures, 
we investigated how variables such as the virulence of the TB strain, method of propagation, 
infectious dose, time within storage, and the level of bacterial aggregation influence lesion 
development after an aerosol infection. 
This is especially relevant for the C3HeB/FeJ animal model because it has been reported 
among laboratories that use this animal model that they observe different results than what our 
laboratory has been reporting. It is especially perplexing since our laboratory can consistently 
achieve reproducible outcomes of desired lesion development, particularly for the development 
and selection of the Type I lesion.  By investigating the variables that can impact lesion 
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development, it is our ultimate goal to eventually standardize the model to develop consistent 
pathology regardless of the laboratory that is performing the study. 
 
A.2 – Materials And Methods 
A.2.1 - Bacterial Strains And Culture Methods 
There were two different culturing methods that were employed throughout the study. The 
first is the general culturing methodology used (See Chapter 2 for more information) for all strains 
except for the CSU hypervirulent Mtb culture. The second is the slight deviation that occurred 
from the normal standard culturing protocol. The steps are:  1) loop full of Lenaerts seed stock, 
was streaked on a 7H11/ ADC agar plate to create a bacterial lawn. 2) 22 days later, 1 loop full 
of the Mtb lawn is used to inoculate 20mL of 7H9/ADC liquid culture for 14 days. 3) 5mL of the 
7H9/ADC culture is then transferred into 45mL of PB liquid culture with 0.05% Tween 80 for 7 
days. 4) 5mL of the culture is transferred to a fresh 45mL of PB liquid culture with Tween 80 
0.05% Tween 80 for 7 days. 5) The culture is upscaled to 500mL of PB media with 0.05% Tween 
80 for 6 days. 6) An additional 0.02% Tween is added before being harvested the next day. 
 
A.2.2 - Mouse Infection 
 C3HeB/FeJ mice were aerosol infected using the strain specified in the study. More 
detailed information can be found in Chapter 2.  
 
A.2.3 - Staining And Imaging  
  Bacteria cultures were heat-fixed for 5 minutes on a hot plate and additionally with 4%PFA 
for 48 hours. After the fixation step, the bacteria were stained using the standard SYBR Gold 
protocol found within Chapter 2.  Tissue preparation, staining, and all microscopy imaging were 




A.2.4 – LC/MS  
10mL of bacterial stock was centrifuged at 2000g to obtain a pellet. The supernatant was 
discarded and 4mL of 2:1 chloroform:methanol solution was added. The pellet was re-suspended 
and allowed to sit overnight. The suspended solution was centrifuged again at 2000g to obtain a 
pellet, and the organic layer is removed. The organic layer was treated with 100µl of 0.2 M NaOH 
in methanol for 30 minutes at 37 ֯ C֯. After the allotted time, the solution is neutralized with glacial 
acetic acid until the pH reaches about 7. 200µl of chloroform-methanol 2:1 and 100µl of H2O were 
added, and the organic phase was removed. The samples were analyzed on an Agilent 6224 
LCMS-TOF using the Sartain method in negative mode. Data was analyzed using Mass Hunter, 
XCMS, and Excel software. Relative abundance for molecular features of interest were 
normalized using global normalization. 
 
A.3 – Results 
A.3.1 – Initial Observations Of The Hypervirulent Strain 
Figure A.1. Graphs of both the standard working stock (Erdman Working Stock) and the culture 
batch that exhibited hypervirulent characteristics (Erdman Hyper Virulent).   
 
During a routine Mtb aerosol infection with the C3HeB/FeJ mouse model, a new batch of 
Mtb (hypervirulent Mtb) exhibited an unprecedented amount of mortality (75%) in comparison to 
the previous culture batch (26%) (working stock Mtb) (Figure A.1). What was more surprising was 
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that this was also observed in the more Mtb resistant BALB/c strain (100%) (data not shown). 
This increase in virulence is not explainable by differing levels of infectious doses because the 
hypervirulent Mtb had an infectious dose of 70 CFU, and the working stock Mtb had an infectious 
dose of 69 CFU. These results were verified in three independent studies confirming that between 
batches, our working stock had a substantial increase in virulence. 
 
Figure A.2. Microscopy (40x) images of the Mtb Erdman culture batches of both the Standard 
Working Stock (Top Panel Left), the Hyper Virulent Stock (Top Panel Middle), and a digitally 
enhanced Mtb aggregate (Top Panel Right). The Hyper Virulent Stock showed an increase in 
bacterial aggregation when compared to the Standard Working Stock.  In the bottom panel is the 
TLC of both the TMM and TDM for both culture batches, which showed no significant differences. 
 
 
To investigate the cause of virulence further, a batch of our working stock Mtb and our 
hypervirulent Mtb were stained using SYBR Gold and digitally imaged. The hypervirulent Mtb 
culture had a substantial increase in visual cording than the working stock (Figure A.2A). Mtb 
cording is the aggregation of bacteria in a bundle like structure via a parallel arrangement. It is 
one of many indicators used to predict the virulence of Mtb strains. The degree of cording is 





monomycolate (TMM), and its modifications [256], [257]. Due to the contrasting levels of cording 
that was present between the two culture batches, the levels of TDM and TMM were measured 
by both thin layer chromatography (TLC) and liquid chromatography-mass spectrometry (LC-MS). 
It was initially predicted that because of the increased level of cording present in the hypervirulent 
Mtb culture that there would be increased levels of both TDM and TMM.  The TLC had no 
significant differences in either TMM or TDM between the two culture batches (Figure A.2B). This 
was an unexpected finding that was verified using LC-MS, but the LC-MS did identify a substantial 
increase in an unidentified molecular feature that was present (Figure A.3). 
 
 
Figure A.3. Graph of the FFA molecular features obtained by the LC/MS. An uncharacterized 
class of molecular features (red box) is present in the Highly Virulent (Bottom) culture batch but 
is greatly reduced in the standard Working Stock (Top). The 601.59 m/z is of particular interest, 
and the proposed molecular formula is listed above.  
  
 
When performing a global analysis of free fatty acids (FFA) in the negative mode, there 
was a group of uncharacterized molecular features that had elevated levels of relative abundance 
in the virulent Mtb culture (Figure A.3). The uncharacterized late series molecular features had 
141 
 
an m/z values of 657.6528, 643.6371, 629.6214, 615.6057, 601.59, 587.5743, 573.5586, 
657.6528, and 629.6214. The 615.6057 m/z and 601.59 m/z peaks stood out among these 
features because they had a fold increase of 12.1 and 9.6 respectively between the two samples. 
Because of the lack of significant difference in TDM / TMM levels, and there was such a 
substantial increase in these uncharacterized FFA, it was prudent to investigate these findings 
further. While the chemical structure of these uncharacterized molecules is unknown, it is 
suspected that they are part of the mycolic acid biosynthesis pathway. Using GC/MS, it was 
determined that there is at least one double bond present, and it is highly likely that it contains 
two. 
 
A.3.2 – Observation Of Increased Virulence In Other Mtb Strains 
Figure A.4. Mtb strains (left column) are organized by the level of virulence observed in vivo with 
the corresponding normalized relative abundance of the 601.59 m/z molecular feature (right 
column). Strains highlighted in green are the Mtb Erdman strain, blue are the Mtb H37Rv strain, 
and pink is Mtb clinical isolate.    
 
 
Building upon our previous findings, we expanded our analysis to include additional 
laboratory strains with varying degrees of tested virulence within the C3HeB/FeJ mouse model.   
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Using LC/MS to obtain the relative abundance values, the strains were rank-ordered from the 
most virulent strain to the least virulent strain (Figure A.4). A general trend emerged of the most 
virulent strains exhibiting the highest levels of relative abundance of the 601.59 m/z peak except 
for the clinical HN878 strain. Under a typical infection, the HN878 strain induces high levels of 
mortality, lesion development, and bacterial burden. However, a successive mouse experiment 
that used the specific culture batch of HN878 had exhibited low levels of lesion development, 
bacterial burden, and almost no mortality. This suggests that there is a correlation between the 
presence of the 601.59 m/z peak and the level of virulence that is detected. 
 
Figure A.5. SYBR Gold stained Mtb strains digital image (1st row), corresponding lesion H&E 
histology (2nd row), and the mortality over time (3rd row). The most virulent strain of Mtb is placed 
on the 1st column, while the least virulent strain is on the last column.   
 
We next investigated if there was a correlation between virulence and the level of Mtb 
aggregation observed at the tie of infection. 6 to 8 week female C3HeB/FeJ mice were infected 
143 
 
with either a batch of hypervirulent Mtb Erdman from the University of Texas (Shenan Strain), a 
CSU working Mtb Erdman culture, an Mtb H37Rv mouse passaged culture from John Hopkins 
University, and an Mtb H37Rv strain that was grown as a pellicle from University of Colorado. 
Data for the CSU hypervirulent culture was used from the previous infections. When comparing 
the pathology and mortality of the infected mice, a trend emerges that more aggregated bacteria 
exhibit higher levels of lesion involvement and mortality (Figure A.5). 
 
A.3.3 Loss Of Virulence In Long Term Storage 
 
Figure A.6. The same batch of Hyper Virulent Erdman Mtb with decreased levels of virulence 
over time. Mortality graphs (top row) and the infection details (bottom row) show a demonstrated 
loss of virulence over a 5 year period within a -80֯C freezer. 
 
 
After the identification of trends in both bacterial aggregation and the presence of the 
601.59 m/z molecular feature being correlated with various levels of virulence, an additional 
mouse infection was performed. Despite previous results from three different studies, using the 
exact strain, the hypervirulent Mtb culture appeared to lose its virulence (Figure A.6). No studies 
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have been published on this effect before, but it has been previously observed in our laboratory 
that Mtb cultures stored long term in cold storage (-80֯C) will lose their virulence. Taking this 
information into account, we investigated both the level of aggregation and the presence of the 
601.59 m/z peak. No visual phenotypic changes were observed in the levels of aggregation 
between the two Mtb cultures, but there was a unique decrease in the relative abundance of the 
601.59 m/z peak over time. This is further confirmation of a possible correlation between using 
the 601.59 m/z as an indicator of virulence but ultimately meant that there were no more samples 
in which to continue our testing. 
 
 
Figure A.7. The globally normalized 601.59 m/z molecular with relative abundance on the y-axis 
and the time in months over the x-axis. A decline in relative abundance is observed over a three 





A.3.4 – Attempt To Induce Hyper Virulence  
 
Figure A.8. Phenotypic variations in the biological replicates were observed during sample 
culturing. Phenotypes include (A) a highly clumped pellicle, (B) corded like pellicles, (C) standard 
pellicle formation, (D), and cells that were entirely planktonic with no visible aggregation. After 
furthering passaging, all phenotypes converged to the standard pellicle formation. 
 
 
Due to the loss of virulence during long term storage to continue our research, we needed 
to induce hypervirulence again in our working stock of Mtb. Several deviations from the normal 
culturing protocol had been identified that might have contributed to the increase in virulence from 
the working stock. This included the initial streaking of bacilli on a 7H11/ADC plate before being 
transferred to a liquid 7H9/ADC culture tube and a substantial increase in Tween 80 at the final 
step. It was hypothesized that Mycobacterium tuberculosis switched between different media 
types will display higher levels of mortality and Type II lesion involvement than bacteria kept in 
PB media. During culturing, we had further unexpected results that required further investigation. 
To help capture the increase in virulence, three biological replicates were kept at each stage of 
culture propagation. Instead of a single phenotype that was comparable to the other replicates, 
there was instead four different phenotypes that were observed (Figure A.8). The first was a 
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densely clumped culture that had a thick film on the surface (originally labeled 'extra clumpy'). 
The second was the development of large filamentous rafts that had comparable macroscopic 
features similar to what is observed microscopically with cording (originally labeled 'clumpy'). The 
third was the development of individual rafts that were of moderate size and is what is expected 
during normal culture propagation (originally labeled 'normal'). The fourth was a completely 
planktonic culture that exhibited a refractive sheen similar to what is observed in an oil spill 
(originally labeled 'planktonic'). By the third passage within the PB culture flask, all three cultures 
had converted over to the third phenotype (normal).  
 
Figure A.9. Globally normalized relative abundance of the 601.59 m/z molecular feature in three 
of the different cultured phenotypes. In contrast to what was initially observed with the 
hypervirulent strain, it does not seem that the molecular features of interest are correlated with 
Mtb aggregation or cording.   
 
LC/MS analysis of three observed phenotypes indicates that there are observable differences in 
the relative abundance of the 601.59 m/z peak, but it is the opposite of what had been previously 
observed (Figure A.9). More research is needed to investigate the correlation of virulence to 





Our laboratory can generate consistent disease presentation within the C3HeB/FeJ 
mouse model. Because the mouse strain develops lesions similar to human pathology, it is 
increasingly being used as a means to score the virulence of various Mtb strains. This may be an 
issue because, through personal communications with other laboratories, they are observing 
results that vary from what is generated in our laboratory. The aim of this project was to determine 
what variables influence the virulence of the Mtb strain used and the host response during an 
infection. Even though we consistently get reproducible results with our Mtb Erdman strain, we 
did have a cultured batch that became extremely virulent, not only the C3HeB/FeJ mouse model 
but also the more resistant BALB/C mice. This provided us an opportunity to help standardize the 
TB C3HeB/FeJ murine animal modal for use in other laboratories. 
Under initial investigation, it was observed that mycobacterial strains that exhibited higher 
levels of virulence had increased quantities of cording/aggregation and levels of the molecular 
feature 601.59 m/z. This virulence phenotype is unstable and can be modulated by varying the 
propagation methods, route of infection, and as discovered recently, even the amount of time in 
being in cold storage. With the loss of the hypervirulent Mtb culture, further work is needed to 
move forward. The first project will be to more stringently investigate how propagation methods 
impact the level of virulence within a specific strain. A proposed experiment would be to use three 
strains of Mtb (Erdman, H37Rv, HN878) and measure how culturing bacteria through mouse 
passaging, pellicle passaging, and under stress impacts the virulence within the C3HeB/FeJ mice 
model. The second would be to determine the molecular structure of the 601.59m/z molecular 
feature and determine if the correlation is causative, indirect, or coincidental. The third would be 
to investigate further the four phenotypes that were observed during our attempt to recreate the 
virulent strain of Mtb that was created previously. This includes performing an aerosol infection to 
observe how even under identical culturing methodologies, how phenotypic variations that 
emerge can influence the host response. In conclusion, knowing about how even under identical 
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culturing methods multiple different Mtb phenotypes can form, virulence decreases with time, and 
how a possible new class of FFA can be used as an indicator for virulence are just the first 





























LIST OF ABBREVIATIONS 
 
TB - Tuberculosis 
LIRA – Lesion Image Recognition and Analysis 
MIA – Mycobacterial Image Analysis 
CFU - Colony Forming Units  
WHO - World Health Organization  
SDG - Sustainable Development Goals 
HIV - Human Immunodeficiency Virus 
INH - Isoniazid 
RIF- Rifampicin 
EMB - Ethambutol 
PZA – Pyrazinamide 
BDQ – Bedaquilline 
Mtb – Mycobacterium tuberculosis  
XDR TB – Extensively Drug-Resistant Tuberculosis 
MIC - Minimum Inhibitory Concentration 
MBC - Minimum Bactericidal Concentration 
AI – Artificial Intelligence  
LTBI - Latent Tuberculosis Infection 
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18F-FDG - 2-[18F]fluoro-2-deoxyglucose 
NHP - Non-Human Primate Model 
CM - Cynomolgus macaques 
I/St - I/StSnEgYCit Mouse Strain 
IPR1 - Intracellular Pathogen Resistance 1 
Ifi75 - Interferon-Inducible-75 
LDA - Low-Dose Aerosol 
CV – Computer Vision 
ROI – Region of Interest 
ML – Machine Learning 
CNN – Convolutional Neural Networks 
GPU - Graphical Processing Units 
CPU - Central Processing Units 
SST1 - Super Susceptibility To Tuberculosis -1 Locus 
PET - Positron Emission Tomography 
CT - Computed Tomography 
SVM - Support Vector Machines 
PB - Proskauer-Beck Medium 
PBS - Phosphate Buffered Saline Solution 
MIP - Microbiology,  Immunology, and Pathology 
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H&E - Haemotoxylin and Eosin 
Misc. – Miscellaneous 
CNN1 – LIRAs Type I Macro-Classifier 
RIPC - Raw Image Patch Counts 
CNN2 – LIRAs Type I Micro-Classifier 
CNN3 – LIRAs Non-Type I Micro-Classifier 
GANs - Generative Adversarial Networks  
MALDI - Matrix Assisted Laser Desorption Ionization 
RPT - Rifapentine 
MDR TB - Multidrug-Resistant TB 
ECDC - European Centre for Disease Prevention and Control 
LK – Losartan 
GRA - Graduate Research Assistant 
RA – Research Associate 
Fe – Iron 
AR - Auramine-Rhodamine 
IF - in situ Hybridization 
GUI - General User Interface 
NETs - Neutrophil Extracellular Traps 
RNA - Ribonucleic Acid 
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TDM - trehalose-6,6′-dimycolate 
TMM - trehalose-6,6′-monomycolate 
TLC - Thin Layer Chromatography 
LC-MS - Liquid Chromatography–Mass Spectrometry 
FFA - Free Fatty Acids 
 
